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SUMMARY
The effectiveness of cancer treatment is compromised by the need to reduce
the uncertainties originating from a variety of factors including tumor volume delin-
eation, patient setup, and irregular physiologic motion. In particular, effective yet
practical tumor motion management remains a major challenge in current external
beam radiation therapy. Many strategies such as motion encompassment, breath-
hold techniques, and respiratory gating have been proposed in the literature and
implemented clinically. These methods have shown success in certain situations with
different limitations. With the advent of image guided radiation therapy, real-time
tumor tracking methods have become popular in clinics to proactively address the
challenge with on-board tumor localization. Nevertheless, such techniques rely on
surrogate signals and have been reported vulnerable to errors. In this dissertation,
emission guided radiation therapy (EGRT) is proposed as a new modality for effective
and practical management of cancer treatment uncertainties. One implementation of
EGRT is to use positron emission tomography (PET) emissions in real-time for direct
tumor tracking during radiation delivery. Radiation beamlets are delivered along PET
lines of response by a fast rotating ring therapy unit consisting of a linear accelerator
and PET detectors. A complete treatment scheme with capabilities of accurate tumor
tracking and dose planning is proposed to implement this EGRT concept. Simula-
tion studies with a physical phantom, 4D digital patient model, and clinical patient
data are carefully designed to evaluate the feasibility and performance of EGRT. We
show that with the capabilities of achieving both tumor tracking and sophisticated
intensity modulation, EGRT has the potential to enable an effective implementation





This work focuses on proposing and demonstrating the concept of emission guided
radiation therapy (EGRT) [30, 67, 68, 28] for potential personalized cancer treat-
ment. EGRT is proposed as a new modality of radiation therapy (RT), or specifically
external beam radiation therapy (EBRT) for the scope of this dissertation. This sec-
tion first gives an introduction to the general background of cancer treatment using
radiation and then describes modern therapy techniques as well as radiation delivery
machines which are widely used in current clinical practice.
1.1.1 General Background
The three most common cancer treatment techniques are: surgery, chemotherapy,
and RT. About half of cancer patients receive RT during their treatment course [2].
RT uses high-energy radiation (e.g. x-rays, gamma rays, and charged particles) to
damage the DNA of malignant cancer cells so as to kill them. This is achieved directly
or indirectly with charged particles or free radicals within the cells [38]. RT can be
used alone or in combination with other treatment methods such as surgery and/or
chemotherapy. Depending on the stage of a tumor, RT can be given with curative
intent of eliminating it, or palliative intent of preventing the patient from suffering
caused by the tumor. For example, it is often used to shrink a tumor that is pressing
on the spine which causes pain or near the esophagus which prevents the patient from
eating [2].
Since RT may also damage normal cells based on the same principle, the delivery
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of the radiation needs to be properly planned to achieve the best outcome with min-
imal side effects. A basic RT chain includes the sequential procedures of simulation,
treatment planning, and radiation delivery, as illustrated in Figure 1.1.
Figure 1.1: A typical radiation therapy chain.
In the simulation step, patients are imaged with diagnostic scans including com-
puted tomography (CT), which is most commonly used, magnetic resonance imaging
(MRI), PET, and ultrasound to identify useful information such as tumor location,
size, and shape. The image scans are then used for treatment planning where tumors
and organs at risk (OARs) are contoured, the dose prescription is determined, and the
delivery plan of the radiation beams is optimized. The prescribed radiation can vary
depending on many factors such as the type of cancer, the proximity of radiosensitive
normal tissues, and the patient’s age as well as medical conditions. The resultant
treatment plan is finally used for daily radiation delivery after proper patient setup
which aims to ensure that patients can be treated exactly as planned.
Radiation can be delivered outside the patient body by a linear accelerator (Linac),
inside the patient by placing a radiation source near the tumor, or by administration
via mouth/vein, referred to as EBRT, brachytherapy, and systemic radiation therapy,




Brachytherapy or internal radiation therapy is defined as a short-distance treatment
of malignant disease with radiation emanating from small sealed sources, referred to
as seeds [79]. The seeds are placed directly into or near the treatment volume using
specialized delivery devices including needles, catheters, or other carriers that are
specific to certain tumor sites. Figure 1.2 illustrates an example of source placement
into a prostate tumor using needles under the image guidance of ultrasound.
Figure 1.2: Seed implant into prostate with ultrasound guidance [1].
Brachytherapy can be implemented as a low dose rate (LDR) or high dose rate
(HDR) treatment. In LDR treatment, low-dose radiation emitted from the source
continuously irradiates the cancer cells over a period of several days or even longer.
In HDR treatment, radiation sources are loaded into or near the cancer sites typically
by a robotic machine at the beginning of each treatment session and removed once
the session is finished.
The radiation source placement in brachytherapy is either temporary or perma-
nent. Permanent placement techniques surgically seal the seeds within the patient
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body without removing them even after the radiation has completely decayed. Due
to this fact, permanent placement is only applied in LDR brachytherapy. Temporary
placement techniques use specific carriers to load the sources, which are removed at
the end of the treatment in the reverse order of source loading. Temporary placement
can be applied in either LDR or HDR treatment.
Brachytherapy can be used alone or in addition to EBRT to boost radiation within
a tumor [103]. As compared to EBRT, the advantage of brachytherapy is that it
may deliver higher doses of radiation to certain types of cancers while causing less
healthy tissue damage. However, it is only good for well localized small lesions and
the procedure is very labor intensive. Brachytherapy is rarely used for tumors with
significant motion such as those in the lung.
1.1.3 External Beam Radiation Therapy
EBRT is the most common form of RT. It can be delivered with beams of electrons,
photons (e.g. x-rays, gamma rays), and protons/heavy particles. Among these, a
photon beam is the most widely used clinically. Proton beam deposits much of its
energy at the end of the beam path (called the Bragg peak) while a photon beam
deposits energy in small packets all along the way through human tissue. Electron
beams have much less penetration ability into tissue and therefore are often used to
irradiate superficial tumors (e.g. skin cancer).
Cancer patients usually receive EBRT over a period of several weeks, divided into
many daily treatment fractions [63], referred to as fractionated radiation therapy.
Many factors will affect the total number of treatment fractions. For example, the
total target prescription dose to be delivered is one of the most important factors.
Such fractionated treatment schemes minimize the damage to normal tissue and in-
creases the likelihood of irradiating cancer cells at their most radiosensitive periods
of the cell cycle. Other fractionation schemes including accelerated fractionation,
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hyperfractionation, and hypofractionation are being investigated and may be used
toward applicable patient cases [22].
1.1.4 Modern Therapy Techniques
In the early days of RT, a tumor was targeted based on the bony structures in the
2D transmission images of the patient. Radiation delivery was planned using the
planar radiographs by collimating rectangular fields that circumscribe the inferred
tumor location [110]. RT advanced into the era of 3D with the advent of CT in the
1970s which allowed physicians to use x-ray projection data to build a 3D patient
model for more accurate tumor targeting. Since then, the frontier of RT has been
pushed forward again and again due to the fast development of many technologies
such as the invention of advanced computers and the multileaf collimator (MLC). In
particular, the following modern therapy techniques are being widely used in daily
radiation treatments: 3D conformal radiation therapy (3DCRT), intensity modulated
radiation therapy (IMRT), image guided radiation therapy (IGRT), and stereotactic
treatments.
• 3DCRT
3DCRT shapes the profile of each radiation beam/field using a MLC to fit that of
the target from a beam’s eye view (BEV) (see Figure 1.3). The MLC is typically
made of lead or tungsten which highly attenuate the photon beam. When
the resultant treatment volume conforms to the tumor shape, the radiation
toxicity to the surrounding healthy tissue is significantly reduced as compared
to the previous generations of RT. The target prescription dose can therefore
be increased.
• IMRT
In addition to the shaping of each radiation field, IMRT further modulates the
beam intensity within each field to allow increased flexibility to control the dose
5
Figure 1.3: The treatment beam passes through the primary collimator and is shaped
by a device called a MLC so that it conforms to the tumor profile. Adapted from
Varian Medical website.
distribution. This is usually accomplished by the movement of MLC leaves.
IMRT can be delivered in a step-and-shoot mode or a rotational mode which is
often independently referred to as volumetric modulated arc therapy (VMAT).
Figure 1.4 shows an illustration of a step-and-shoot IMRT treatment with nine
fields.
To calculate the beam intensities across all fields so as to achieve a desired dose
prescription, inverse treatment planning is commonly used. Inverse planning is
a process of finding the optimal beam intensity distribution given certain dose
constraints for both the target and OARs. This is different from the traditional
forward treatment planning where the radiation oncologists select the number
and angles of the treat beams in advance and computers then calculate how
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Figure 1.4: Illustration of a nine-field IMRT treatment for a head and neck case. 3D
view of nine IMRT beams are shown with the gray levels representing the intensity
values to be applied. Adapted from [3].
much dose will be delivered from those beams. Compared with 3DCRT, IMRT
possesses more flexibility for delivering highly conformal treatments and per-
forms better in cases where OARs that are close to the target need sparing. For
example, IMRT is commonly used in head and neck cancer cases to control the
risk of some side effects by minimizing the damage to the salivary glands.
• IGRT
IGRT aims to provide image guidance to eliminate the cancer treatment un-
certainties for better RT treatment outcomes. This is achieved by integrating
cutting-edge image guidance into each step of the RT treatment. It includes
image-based tumor definition during the treatment planning stage, image-based
patient positioning devices for patient setup, and image-guided tumor targeting
tools during radiation delivery. Guidance provided by different types of imaging
scans including fluoroscopy, cone beam computed tomography (CBCT), MRI,
or PET has been proposed in the literature. Radiation treatment can benefit
significantly from such treatment guidance. For example, the on-board imager
could identify tumor size and location changes due to irradiation. It allows the
corresponding repositioning of the patient or the adjustment of the radiation
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beam during treatment. IGRT may also address the problem of tumor mo-
tion and shorten the duration of treatment due to improved targeting accuracy.
Therefore, IGRT plays an increasingly important role in modern RT.
• Stereotactic Treatments
Stereotactic treatments here refer to stereotactic radiosurgery (SRS) and stereo-
tactic body radiation therapy (SBRT). SRS gives a relatively large single ra-
diation dose to a small target area. It thus requires great targeting accuracy
which is achieved by using an external head frame for 3D target localization and
immobilization. SRS can be performed with charged particles, Gamma Knife,
CyberKnife, or modified Linac. These systems can give a high dose of radiation
without excess damage to healthy tissue. However, SRS is typically limited to
the treatment of small tumors with well-defined contours. For example, it is
most commonly used in the treatment of brain tumors, spinal tumors, and brain
metastases from other cancer types.
Different from either SRS or 3DCRT, SBRT delivers radiation therapy in several
sessions to tumors which are outside the brain and spinal cord. Compared with
3DCRT, SBRT usually uses smaller radiation fields and higher fraction doses.
One of the major reasons for more than one fraction in SBRT is that the above
tumors can move with the patient body and cannot be targeted as accurately
as tumors within the brain or spine. SBRT is also limited to treat only small
and isolated tumors (e.g. cancers in the lung and liver).
1.1.5 Radiation Delivery Machines
EBRT is typically delivered using a machine called a Linac. Back in 1953 when
the first cancer patient was treated with a Linac, the radiation delivery machine
was very bulky preventing its widespread use. With the development of radiation
therapy technologies over the past several decades, the Linac has become more and
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more compact, advanced, and readily available to the public. It is now capable of
delivering highly conformal radiation to the target with great accuracy, precision, and
efficiency given the exact tumor location.
The essential component of a medical Linac is the linear accelerator that acceler-
ates electrons to kinetic energies from 4 to 25 MeV using microwave radiofrequency
fields of 103 MHz (L band), 2856 MHz (S band), or 9350 MHz (X band). Treatment
photon beams are produced when the accelerated electrons strike the x-ray target.
Currently there are three major types of medical Linacs in the clinic. They are typ-
ically categorized based on the dose delivery geometry: conventional, helical, and
robotic. Although different in radiation delivery geometry, these Linacs follow the
same principle of photon beam generation and the corresponding treatment follows
the same basic therapy chain as discussed above.
• Conventional
The modern conventional Linac is usually built on a C-arm gantry that rotates
precisely around a treatment couch with the mechanical isocenter maintained
to within a sphere of 1 mm radius. The Linac head on the gantry’s C-arm
can deliver the radiation beam with 360 degrees of rotation around the patient.
The photon beam is shaped before irradiating the patient with a combination
of several collimating structures. High-density field blocks and additional edge
blocks first produce beams of square fields with a size up to 40 cm by 40 cm
at the patient. The computer controlled MLC is then used to further shape
the beam to fit the profile of the specific target from the BEV at the selected
treatment angles.
• Helical
A helical Linac delivers the radiation slice-by-slice rather than irradiating the
entire tumor volume at one time as in a conventional Linac. The accelerator,
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photon-producing target, and collimation systems are mounted on a ring gantry.
The part of the machine that delivers radiation can thus rotate completely
around the patient in the same manner like a typical diagnostic CT scanner.
As the gantry rotates, the patient simultaneously slides through the system
bore to achieve the full coverage of the target. The primary collimator of the
helical Linac produces a fan beam of photons, which can be further collimated
by a binary multileaf collimator (bMLC). CT-guided IMRT can therefore be
implemented in such a helical delivery geometry.
• Robotic
A robotic Linac delivers radiation by making use of an industrial robot to hold
a compact accelerator. There is no isocentric rotation of the compact Linac.
Rather, the Linac is controlled by the computer to irradiate the tumors from
many angles in 3D space (except from below the patient). To fully exploit this
flexibility, field sizes are kept very small to reduce the bulk of the system. Such
robotic delivery schemes allow the selection and use of many noncoplanar beam
angles to build up dose within the tumor volume.
1.2 Treatment Uncertainties
Despite the different geometries in radiation delivery, all types of Linac machines face
the same challenge of reducing the treatment uncertainties in RT. Treatment uncer-
tainties can originate from a variety of factors which exist in each step of the RT
workflow. For example, the uncertainty of tumor volume delineation during simula-
tion, patient setup uncertainty prior to treatment, irregular physiologic tumor motion
during treatment, interfraction tumor motion between treatment sessions, and unpre-
dictable tumor response to radiation such as tumor volume shrinkage over the course
of treatment [70]. Moreover, there are even more treatment uncertainties when the
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patient has two or more moving tumors. As an example, Figure 1.5 illustrates the se-
vere uncertainty in delineation of lung target volumes using only CT versus PET/CT
among radiation oncologists.
Figure 1.5: Comparison of tumor volume delineation using (a) CT only and (b)
matched PET/CT by the same 11 radiation oncologists (Figure from [92]).
As a result, even though advances in image-based radiation treatment planning
and delivery have greatly improved the ability to conform the radiation dose to the
tumor, the effectiveness of cancer treatment is significantly compromised by the need
to reduce the above treatment uncertainties. For example, IMRT is capable of gen-
erating highly conformal dose distributions to the target while sparing healthy tissue
[27, 56]. However, IMRT treatment performance is heavily determined by the accu-
racy of tumor tracking, which cannot be guaranteed in the presence of intrafractional
organ motion [37, 11, 45] and interfractional patient setup errors [11, 25, 58]. Also, in
the treatment of thoracic or abdominal tumors using SBRT, extremely precise local-
ization of the tumor is required to avoid irradiating nearby critical structures. This
precise localization is challenged by the need to account for the movement of tumors
in the body caused by respiration.
Among all treatment uncertainties, intrafractional tumor motion is one of the
biggest challenges. It has cast significant limitations on radiation treatment outcomes
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at each step of the RT chain: image acquisition, treatment planning, and radiation
delivery (see sections below). Motion amplitude can be as high as 5 cm in the lung
region [49]. Frequency variations, amplitude changes, and baseline shifts occur on
a regular basis both interfractionally and intrafractionally [80, 86, 78, 89], and are
difficult to predict [93]. Figure 1.6 illustrates such an example. The tumor trajectory
can be highly irregular across different patients and hysteresis (different inhale and
exhale paths) can occur. Plus, motion is independent of size, location, and pulmonary
function [93]. Therefore, accurate tumor tracking and effective yet practical tumor
motion management remain major challenges in current RT practice.
Figure 1.6: Variations in respiratory patterns from the same patient based on data
measured 3 minutes apart (Figure from [49]). Motion is measured using infrared
reflectors placed on the patient surface. Three color curves correspond to motion in
the superior-inferior (SI), anterior-posterior (AP), and medial-lateral (ML) directions,
respectively.
• Image acquisition
When target motion is not accounted for, severe artifacts may appear in the
images acquired during simulation or the on-board imaging process. These ar-
tifacts typically present themselves as distortions of the tumor volume and/or
incorrect positional and volumetric information. This is commonly observed
for thoracic and abdominal tumors. The resultant artifacts will generate tar-
get/normal tissue delineation errors and adversely affect the dose calculation




Treatment planning can be greatly influenced by tumor motion, setup error,
and other uncertainties since it naturally requires accurate knowledge of tu-
mor location. A common solution is to define a planning target volume (PTV)
that covers the full motion extent. This is suboptimal since it increases the
volume of healthy tissue to be irradiated and consequently the likelihood of
treatment-related complications. However, if motion is not taken care of, the
target will not receive adequate dose coverage which may significantly deterio-
rate the treatment benefits. Furthermore, the image artifacts in the simulation
step will generate additional errors for the planning process.
• Radiation delivery
Without an effective method to account for organ motion and setup error, the
actual delivered dose distribution may severely deviate from the planned one. As
a result, either the target may receive inadequate dose coverage or the sensitive
OARs may not be successfully spared, or both. As compared to conventional
3DCRT treatments, dose performance can be even more severely impacted in
IMRT treatments since dose gradients within the treatment fields are very sen-
sitive to tumor location uncertainty.
1.3 Motion Management Strategies
With more and more advanced techniques applied in clinics to tackle the non-motion
related issues, the challenges brought by motion have therefore become the bottle-
neck of radiation cancer treatments. As the fatality of lung cancer is still the highest
among all cancer types in the U.S., and as many non-lung cancers metastasize to the
lung and liver where motion is a significant problem, this has spurred a flood of re-
search activities over the past decade for each step of a complete motion management
scheme including imaging, planning and delivery, well documented in AAPM TG-76
report [49]. Four main categories of strategies can be summarized as breath-hold,
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gating, tracking, and motion encompassment.
1.3.1 Breath-hold
Breath-hold methods aim to reduce the respiration motion effect via active or passive
breath-holding which may freeze the tumor motion to the maximum possible extent.
This is typically achieved with the following techniques:
1. Deep-inspiration breah-hold (DIBH): In a DIBH technique, the patient is ver-
bally coached to breath through a mouthpiece connected to a spirometer that
measures air flow [39]. The volume of air breathed in and out is calculated
and displayed as a function of time. The therapist can then help the patient
to maintain a reproducible state of maximum breath-hold for 10 to 20 seconds
during which radiation is delivered.
2. Active-breathing control (ABC): ABC apparatus can suspend breathing at any
predetermined position and is often used at 75% of deep inhale for best balance
between reproducibility of the breathing trace and patient comfort [107]. The
device is mainly composed of a digital spirometer connected to a balloon valve.
Real-time lung volume is monitored during the entire respiratory trace. Once
a specified lung volume value is reached, the valve is inflated with an air com-
pressor for a predefined duration of 15 to 30 seconds. During this period, the
patient’s breath is being actively held.
3. Self-held breath-hold: In this technique, the patient is given a hand-held switch
that is connected to a Linac interlock circuit. When the patient holds his/her
breath, he depresses the switch to clear the interlock allowing the therapist to
activate the beam for radiation delivery. When the patient needs breath, he
can release the switch which will turn the beam off through the interlock.
4. Forced shallow breathing (FSB): FSB employs a stereotactic body frame with an
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attached plate for abdominal compression. The respiratory/diaphragm motion
is reduced due to the applied pressure and the patient can have limited normal
respiration throughout the whole treatment.
1.3.2 Gating
The essential principle of motion gating is to irradiate the moving tumor within only
a small portion of the motion path. In other words, gating techniques turn the beam
on only when the target is determined to be traveling within a pre-planned area,
referred to as the gating window. Some gating techniques can be applied in both
simulation and delivery steps to treat the tumor as if there were no motion.
Gating techniques rely on a surrogate signal of the motion, either external or
internal, to determine whether the tumor is within the desired gating window [53, 17].
Such determination can be based on the displacement of the measured surrogate
signal. The radiation beam is activated whenever the surrogate signal is within a
pre-set window of relative displacement. If the motion can be assumed periodic, the
determination can also be based on the phase of the surrogate signal. The radiation
beam is turned on when the phase of the respiration signal is within a pre-set phase
window. In either case, respiratory gating typically relies on an indirect tracking
method where the correlation between the tumor and the surrogate motion is not
guaranteed [42, 97].
1. External respiration signal: The commercially available and most widely
discussed gating system is the Varian real-time position management system
(RPM) (Varian Medical Systems, Palo Alto, CA) [102]. It is mainly for respira-
tory motion and is based on an external respiration signal. During treatment,
an infrared reflective plastic box serving as the external fiducial marker is placed
on the patient’s anterior abdominal surface. The inroom camera is able to accu-
rately detect the reflective markers and display the corresponding motion signal
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as a function of time. Once a stable respiration trace has been established, gated
simulation and radiation delivery can be initiated.
2. Internal respiration signal: The major principle of gating using an internal
respiration signal is to obtain the surrogate signal of tumor motion by implant-
ing internal fiducial markers into the patient and then tracking the positions
of these markers based on their radiopaque properties with x-ray [34]. The
fiducials (e.g. 2-mm-diameter gold spheres) can be implanted in or near the
tumor using a percutaneous or bronchoscopic implanting technique. A pair of
stereotactic kilovoltage x-ray imaging systems is typically in place to monitor
the positions of fiducials in all three dimensions several times a minute. The
beam is turned on when each fiducial is found to be within the pre-defined
gating window. Such procedures can also be applied to set up the patient.
1.3.3 Real-time Tracking
Real-time tumor tracking addresses the motion problem more proactively by reposi-
tioning the radiation beam or the patient dynamically to ensure that the beam and
the target are matched as planned all the time. Continuous real-time tracking ideally
can eliminate the need of a tumor-motion margin, while maintaining a 100% duty
cycle for efficient dose delivery. To succeed, the following major challenges need to
be properly tackled.
1.3.3.1 Determine The Tumor Position
Localizing the tumor during treatment is the most important and challenging task in
real-time tracking. The most direct way is to image the tumor itself in real time with
a sufficiently high frequency using fluoroscopes (typically a pair of fluoroscopes are
mounted in the treatment room) [88]. For example, lung tumors sometimes can be
visualized directly in fluoroscopic images at a certain exposure level depending on their
location. More often though, tumors in the body will not have well-defined contours
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and sufficient contrast for image segmentation and therefore the use of fiducial markers
as surrogates for localization is necessary. These markers can be the same as those
used in the gating technique. They are usually high-Z materials implanted in or
near the mobile tumors, which can be readily identified in x-ray images to determine
their 3D coordinates. These coordinates are finally used for the calculation of tumor
translation, rotation, and marker migration.
Due to motion irregularity, the tumor needs to be imaged many times a second
in the above tracking methods, which is a major limitation with x-ray imaging that
can result in excessive imaging dose to the patient [87]. Non-radiographic tumor
tracking methods have been developed to avoid this issue [105, 54]. In this type of
method, miniature radiofrequency coils are implanted into the patient and tracked
electromagnetically in three dimensions from outside the patient. The real-time tumor
position can then be monitored at a sufficiently high frequency.
However, the above methods are invasive procedures and they are not only costly,
but also sacrifice patient comfort and may cause severe side effects such as pneu-
mothorax [33]. Moreover, implanted internal markers cannot accurately depict the
whole tumor volume and shape by showing only several points on the tumor, and
marker migration is also an issue [66]. Some researchers have proposed direct tumor
targeting methods using fluoroscopic images without implanting markers [20, 8]. In
these studies, tumor motion phase or position is determined by matching the real-
time acquired fluoroscopic images with the pre-built templates, which may fail when
the tumor boundary is unclear in fluoroscopic images [57].
1.3.3.2 Treatment System Response
With the tumor position properly monitored in real time, a further challenge of high
performance radiation therapy is to accurately deliver the dose to a fast moving tar-
get based on the tumor location information. Typical methods of dynamic motion
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compensation include gating [43], couch shifting [104, 7], dynamic multileaf collima-
tor (DMLC) tracking [69, 48, 81], and robotic tracking [15]. Gating delivery has been
discussed in the previous section 1.3.2. Couch correction repositions the patient to
align with the beam by an amount of translation determined from the difference of the
planned and actual tumor position. The disadvantage is that it may introduce con-
tinuous back-and-forth patient motion, which leads to problems of patient discomfort
and low treatment tolerance [70].
A more popular approach is DMLC repositioning. Rather than reposition the
patient, DMLC tracking repositions the beam so as to follow the real-time tumor
position by correspondingly moving the MLC leaves. The new spatial distribution of
MLC leaves is calculated based on the deviation of the actual tumor position from the
planned one. DMLC tracking may require leaf speeds that may at times exceed the
MLC speed limit [70]. It also involves non-trivial adjustments to the base treatment
plan for satisfactory performance [50].
Another advanced method of tumor tracking uses the robotic Linac to flexibly
reposition the beam to follow the tumor’s motion (e.g. CyberKnife system by Ac-
curay). With the robotic Linac controlled to move in six degrees of freedom, this
approach has the advantage of adapting to the full 3D motion of the tumor. How-
ever, it usually requires the implantation of fiducial markers for image guidance.
No matter which method to use, they all face the same issue: system latency.
That is, after the detection of the tumor position, there is a significant time delay
before the system can make any response. This can be due to many factors such as
the processing of tracking images, the calculation of actual translation, movement of
the couch to a new position, or repositioning of the MLC aperture. For example, it is
reported that a delay of 90 ms between identification of fiducial marker coordinates
and radiation response is observed in a gating system [49].
Therefore, without an effective method that is able to tolerate the system latency,
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the tumor position needs to be predicted in advance so that the synchronization of
the beam with the tumor’s varying position is possible. This is necessary regardless
of the method used and it applies to both gating and real-time tracking systems.
However, as discussed earlier, the human breathing cycle can have significant cycle-
to-cycle and long-term fluctuations in both displacement and frequency. This makes
the tumor position very difficult to predict and thus leaves the latency challenge not
fully tackled. Another concern with the dynamic motion compensation method is
that the beam may pass through a sensitive critical structure that is to be avoided
in the original treatment plan.
1.3.4 Motion Encompassment
Although the motion problem has caused a series of issues that may degrade the ben-
efits of RT, many radiotherapy facilities are not equipped with sophisticated therapy
machines or other resources to explicitly account for tumor motion according to the
above strategies. In this case, motion encompassment is another option to proceed
without enormous resources and personnel requirements. The principle of motion
encompassment makes it feasible to be implemented similarly as the therapy of a
static tumor. Motion encompassment mainly involves imaging the moving tumors
properly to obtain the internal target volume (ITV) that covers the full extent of the
tumor motion, subsequent definition of PTV as the expansion of the ITV, and final
treatment planning and dose delivery based on a static PTV.
1.3.4.1 Imaging
To image a moving tumor, various types of CT scanning including slow CT, breath-
hold CT, and four dimensional computed tomography (4DCT) can be used. Slow CT
is generally the method most available to obtain the motion-encompassing volume and
commonly used for lung tumors in the high-contrast area. In slow CT, the scanner
is operated very slowly and multiple CT scans can be averaged such that multiple
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respiration phases are recorded per slice. Hence, the reconstructed image of the tumor
should show the full extent of motion that has occurred during the scan.
Acquiring separate inhale and exhale gated/breath-hold CT scans is another com-
mon solution to obtain the ITV volume. The method requires a step of image fusion
on both scans and consequent contouring to delineate the desired ITV [99]. As com-
pared to slow CT, this method needs longer imaging time and relies on the patient’s
ability to hold his/her breath reproducibly. To save time, one can apply this method
only within the tumor travel region while for other patient areas a free-breathing CT
can be used.
The most advanced solution for obtaining high-quality CT data in the presence
of tumor motion is 4DCT or respiration-correlated CT [91, 24]. Four dimensional
data can be analyzed to accurately determine the tumor trajectory and ITV volume.
Retrospectively correlated CT is closest to an ideal 4D imaging modality as it captures
the whole breathing cycle and provides reconstructed images for all motion phases of
the period. This is achieved by sorting all acquired projections to each phase of the
motion with the help of a surrogate signal. A limitation of 4DCT is that it assumes
the motion is periodic and it can be divided into certain phases. However, this is not
guaranteed due to common variations in respiratory patterns.
1.3.4.2 Planning and Delivery
After the ITV volume is determined using the proper type of CT scan, the subsequent
process of treatment planning and delivery will be similar as that for static tumors.
Specifically, adequate margins are added to the ITV to account for patient setup
uncertainty, the motion changes between imaging and treatment, etc. The amount
of margin added depends on the specific patient case. With the motion and other
treatment uncertainties taken care of by the ITV volume and the additional PTV
margin, IMRT planning and delivery can be implemented without major modification
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from the therapy of static tumors as in current clinical practice.
As discussed previously, one of the major disadvantages of the gating concept is
that it results in a treatment with low duty cycle, and even frequent interruptions due
to the irregularity of tumor motion. As for 4D tracking methods, the complexities
of 4D planning, the invasiveness of necessary internal fiducial marker implantation,
and additional uncertainties of coordinating 4D planning with 4D delivery prevent
their widespread use clinically. As a result, the motion-encompassing methods still
have vast popularity due to their high efficiency, ease of implementation (requires
least amount of resources), and compliance with current 3D therapy protocols and
guidelines. It fits very well the needs of those RT facilities in which advanced tracking
or gating systems are not readily available.
As a sacrifice, as pointed out in section 1.2, due to the usage of the ITV rather
than the clinical target volume (CTV) for planning, more normal tissues are exposed
to radiation as compared to gating and tracking methods. This limits the highest dose
that can be prescribed to the PTV and GTV, resulting in lower tumor control [64].
Figure 1.7 illustrates that the toxicity may be increased significantly with increased
mean lung dose. Thus, to improve upon the ITV approach, it is crucial to lower the
mean lung dose.
Figure 1.7: Pulmonary toxicity as a function of mean lung dose (Figure from [64]).
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1.4 Emission Computed Tomography
Emission computed tomography (ECT) is a type of tomography based on radioactive
emissions within the image subjects. ECT includes PET and single photon emission
computed tomography (SPECT) based on how emissions are generated. PET and
SPECT images are both representations of a patient’s biological state. In this section,
we will take PET as an example to introduce ECT imaging principles.
Although CT can provide good anatomic information about the patient, very often
one has to rely on PET imaging to delineate the gross tumor volume (GTV) extent
and provide other useful biological information of the tumor. This is because a tumor
can have low contrast in CT images, which make it barely distinguishable from other
surrounding normal tissues. Figure 1.8 shows an example of locating a tumor using
commercially available PET/CT technology.
(a) CT scan (b) PET scan
(c) PET/CT scan
Figure 1.8: (a) CT scan provides good anatomic details about patient. (b) PET
scan delineates tumor metabolic activity distribution. (c) PET/CT fusion indicates
metabolic tumor volume with respect to surrounding normal tissues.
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1.4.1 Principle
PET is extensively involved with cancer detection, staging, treatment decision-making,
and assessment of therapeutic response in radiation oncology. It uses positron emis-
sions as a signaling mechanism. Positrons are generated from radioactive decay of
atoms in the molecular probe transported into the patient usually via injection. The
following isotopes are typically used in PET imaging because of suitable decay times:
11C, 13N, 15O, 18F, 64Cu, 82Rb, and 124I. The molecular probe that contains these
atoms interacts with a living subject in the same way as a chemically identical
molecule made of the corresponding stable isotopes. In addition, extremely small
concentrations of the probe are used to generate an adequate PET signal. PET can
therefore track cancer cells without affecting their behavior.
One of the most successful and widely used PET probes has been 2-[18F]fluoro-
2-deoxy-D-glucose (FDG). It consists of a modified molecule of glucose in which a
radioactive fluorine isotope (18F) substitutes for a hydroxyl group. After injection into
the patient through a vein, FDG is transported from the blood stream into the cells
by glucose transporters. In the cell, phosphorylation prevents the glucose from being
released, resulting in FDG accumulation within the cell. Since FDG does not have
the hydroxyl group as in normal glucose for further glycolysis, it cannot be further
metabolized before radioactive decay. Hence, the FDG concentration can indicate
the local rate at which the cells consume glucose. Higher concentration means higher
intensity in reconstructed PET images. Since tumor cells typically have abnormally
high metabolism, the tumor lesions usually appear brighter than background tissue
on PET scans.
When trapped in cells, 18F decays to emit a positron which annihilates with an
electron within tens of microns to a few millimeters of the decay location. The
annihilation results in the simultaneous emission of two back-to-back 511 keV photons,
called annihilation photons. The major process can be represented using the following
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formulas:
18F →18 O + e+ + υ (1)
e+ + e− → γ + γ (2)
When two annihilation photons are recorded by the detectors around the object,
it can be inferred that a positron was emitted along the line that connects the two
detectors involved, called the line of response (LOR), see Figure 1.9. The LOR also
forms the basic unit of information for reconstructing PET images, often referred to
as a coincidence event or coincidence count. Note that without advanced techniques
such as time-of-flight PET, the exact location of emission on the line cannot be
determined.
Figure 1.9: Illustration of LOR for detection.
There are two physical limitations that degrade the spatial resolution of PET
imaging even if the scanner is perfect. The first one is that the positron travels a
small distance (e.g. 0.22 mm full width at half maximum for 18F) before it annihilates
with an electron. Thus, the emission location may not be exactly on the line but
rather in its proximity. The other major factor is the residual momentum carried by
the positron when annihilation occurs. Due to this fact, the two annihilation photons
are not emitted exactly 180◦ apart. There is a 0.3◦ uncertainty which translates to a
spatial resolution loss of a few mm for clinical scanners.
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1.4.2 Detection and Reconstruction
Annihilation photons are detected using radiation detectors that surround the subject,
which are typically arranged in a ring structure. Since the photons must travel along
the LOR or equivalently, the photon source must locate on the LOR, no additional
transverse collimation is needed in a PET imaging system. 511 keV photons are very
penetrating as compared to photons in the diagnostic energy range (60-140 keV). This
is an advantage for PET imaging because they can easily escape from the patient body
and hence yield a high photon count rate for detection. However, annihilation photons
are hard to stop and detect for the same reason. Hence, PET radiation detectors are
usually made from dense materials with high atomic number.
Most PET radiation detectors are composed of scintillation crystals, which con-
vert the annihilation photon energy into light, and photodetectors. The most com-
monly used scintillation crystals are Lu2SiO5 (LSO), Gd2SiO5 (GSO), and Bi4Ge3O12
(BGO). These crystals are cut in small, discrete elements and put together to form
2D arrays. Crystals are then linked through a light guide to a sensitive photodetector
such as a photomultiplier tube to amplify the signal for processing.
During detection, there will be thousands of annihilations ongoing at the same
time and hence lots of LORs can be formed. Incorrect pairing of photons that come
from different annihilation events can occur, called false coincidence. This includes
scattered coincidences and random coincidences. It is then crucial to determine the
true LORs so that the correct information can be used for image reconstruction.
Current PET imaging systems rely on an energy window and a time window to
discriminate photon counts. An energy window of 511±30% keV is typically enforced
to reject scattered photons, which typically lose significant amount of energy, from
being recorded. A time window is then used to select two single counts to form a
coincidence event. Only two photons that are detected within the same time window
can be used to form a LOR. The width of the time window is typically 6 or 12 ns for
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current commercial systems. Figure 1.10 illustrates the essential components of PET
imaging.
Figure 1.10: Essential components of PET imaging [75]. Anticollinear 511 keV
photons are first generated and then detected by a combination of scintillation crystals
(yellow) and photomultiplier tube. When the electronics records two photons in near
coincidence, a coincidence event is generated forming the corresponding LOR (red
line), which is stored in a computer for image reconstruction.
After the list of LORs which pass both the energy and time window is obtained,
there are still corrections needed to be made before final image reconstruction. For
example, attenuation correction is necessary to correct for the effect that photon
pairs experience non-uniform attenuation when traveling within the patient (see Fig-
ure 1.11).
With necessary corrections done, there are mainly two types of algorithms avail-
able to reconstruct the desired PET images for diagnostic purposes: filtered back-
projection and iterative reconstruction. The first one is faster since it is an analytic
algorithm but has poorer noise characteristics while the latter is slower but typically
yields better image quality.
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Figure 1.11: PET images before (top row) and after (bottom row) attenuation cor-
rection. Adapted from [98].
1.5 Motivation and Organization
1.5.1 Motivation
Tumor location uncertainties are common in radiation therapy due to treatment setup
errors, tumor motion, and many other factors (see section 1.2). To alleviate this
problem, many motion management strategies have been proposed, as described in
section 1.3. Image guidance techniques, such as respiratory gating, are commonly
used in the presence of large target motion. Fiducial markers are also frequently
implanted into the disease sites to further improve the treatment guidance accuracy.
Despite the demonstrated success under certain circumstances, these methods are still
sub-optimal with respect to tumor tracking accuracy, treatment efficiency, patient
comfort, complexity and cost effectiveness.
The ITV approach uses a very large margin to compensate for tumor motion and
patient setup error to ensure dose coverage of the tumor. It has been widely used
despite its limited ability to prescribe high dose to the GTV for better tumor control.
Such limitation is due to the fact that the motion-encompassing methods do not ex-
plicitly incorporate any form of tumor tracking. A natural thought to improve upon
the popular ITV approach is to develop a method that combines the strategies of
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motion encompassment and tumor tracking. In addition, the tumor tracking method
needs to be accurate, non-invasive, simple, and efficient. The current tumor track-
ing methods, which relies on external or internal surrogates, are essentially indirect
approaches and therefore the tracking accuracy cannot be guaranteed all the time.
Internal fiducial-based tracking are reported less vulnerable to errors however they are
invasive and can cause significant patient discomfort as well as severe complications.
In search of an alternative method for real-time tumor tracking, ECT imaging
becomes a viable approach. As indicated in section 1.4, ECT imaging is an effective
method for cancer detection and tumor delineation. The tumor can be easily dis-
tinguished from background tissues using direct biological signals. Due to the fact
that these signals are coming from the tumor itself, the ECT imaging makes itself an
excellent candidate for direct and accurate tumor tracking. In addition, since the tu-
mor tracking is based on the emission signals and no fiducial markers will be needed,
ECT-based tumor tracking is non-invasive. The signals are emitted continuously and
no gating techniques are necessary so that such tumor tracking can be very efficient
as well. Unfortunately, there are currently no methods which are able to integrate
ECT imaging for real-time tumor tracking purposes. This is because it usually takes
minutes to collect enough emissions for image reconstruction. However, although
ECT image-based guidance is slow, individual emissions can instantaneously reflect
tumor location information.
In this dissertation, we propose, for the first time, a new RT modality which inte-
grates direct emission guidance into radiation delivery for accurate and personalized
RT treatment. We refer to it as emission guided radiation therapy or EGRT. This
dissertation presents a comprehensive summary of our investigations on EGRT.
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1.5.2 Organization
This dissertation is divided into six chapters. Chapter 1 gives background information
on radiation therapy, RT treatment uncertainties, current major motion management
strategies, ECT imaging in oncology, and the main motivation of this work.
Chapter 2 illustrates the proposal of the general EGRT concept, system design,
and treatment planning approach. The implementation of the EGRT concept based
on PET emission guidance is explained in detail. This includes a proposed EGRT
system geometry, the basic EGRT algorithm to ensure tumor tracking, and a primitive
dose modulation method.
Chapter 3 presents three EGRT applications to demonstrate the feasibility of
EGRT for improved radiation therapy outcomes. This includes the application of
tumor tracking, simultaneous tracking of multiple tumors, and treatment of a non-
PET-avid target. Detailed simulation workflow and evaluation studies are presented.
Chapter 4 investigates the impact of major treatment parameters on EGRT treat-
ment performance. Parameters including the number of firing points, PTV margin
size, treatment time, EGRT spatial and time window size, and rotation period are
discussed.
Chapter 5 proposes a treatment planning scheme that enables EGRT’s capability
of incorporating sophisticated planning modulation. This planning scheme is demon-
strated with detailed simulation studies involving clinically acquired patient imaging
data.
Chapter 6 further discusses the image-based implementation of the EGRT concept





EGRT is a new concept for radiation treatment. Unlike conventional RT treatments
where the tumor is not targeted or targeted based on a surrogate signal or anatomic
structure, EGRT utilizes the biological signal emitted from the tumor itself to guide
the delivery of radiation. Such emission guidance makes the often invisible tumor
light up during radiation delivery and help deliver the radiation to the right position
at the right time, especially in the presence of tumor motion or setup error.
This chapter mainly discusses the proposed EGRT system and treatment scheme
and answers the following questions: What essentially is EGRT? How is radiation
delivered based on emission guidance? What kind of treatment system is used? What




EGRT broadly refers to any radiation treatment that directly uses emission guidance
to facilitate dose delivery. It can be in the form of internal or external beam radiation
therapy, depending on the specific design of EGRT. It is not limited to any specific
type of radiation delivery geometry. The EGRT system can be based on a conven-
tional C-arm, helical or robotic gantry geometry. In addition, EGRT does not conflict
with any type of modern therapy techniques. IGRT and IMRT can be incorporated
into EGRT after necessary modifications. The emission guidance can be from single
photon emissions or positron emissions. The essential mechanism in an EGRT treat-
ment is the use of emission signals as the guidance for dose delivery. This guidance
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needs to be involved in a real-time fashion during actual radiation delivery. However,
this does not mean that the possibility of utilizing emission guidance before or after
RT treatment for other useful purposes should be eliminated.
Two types of EGRT treatments can be conceived based on how emission guidance
is utilized: image-based EGRT [28, 112] and LOR-based EGRT. Image-based EGRT
aims to reconstruct an image using collected LOR counts within subsecond time
scales and then apply a tumor localization algorithm to identify the tumor location
for conventional on-board treatment guidance. Promising results have been obtained
for image-based EGRT, however, there are still challenges to tackle. This will be
further discussed in Chapter 6.
LOR-based EGRT is instead a new treatment paradigm based on positron emis-
sions (for the concept of positron emission, please see section 1.4). In PET, each
detected LOR gives an approximate line-of-sight to the emission source almost in-
stantaneously due to the intrinsic collimation effect of coincidence detection [18].
Instead of waiting minutes for enough LORs to form PET images, an LOR-based
EGRT system delivers beamlets of therapeutic radiation along LOR paths individu-
ally as they are detected to achieve a helical dose delivery. The nearly real-time LOR
response is made possible with a fast rotating Linac and collimation system to align
the beam along the LOR path with a minimal lag time. The feasibility of rotating
a Linac and a bMLC has been previously demonstrated, as well as a rotating PET
system [60, 61, 13, 59, 9].
With the integration of real-time emission detection and radiotherapy, tumor lo-
calization and dose delivery are more naturally unified. Tumor tracking is inherent,
automatic, and direct. This work is specifically on the feasibility demonstration of
LOR-based EGRT, which will be referred to simply as EGRT for the remainder of
this dissertation. The emission guidance of EGRT stems from the physical principle
of positron annihilations in PET imaging. Therefore, EGRT can be classified as a
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new type of broadly defined IGRT method. It should be noted that the treatment
guidance in EGRT is not provided by PET images, but rather by individual emissions.
2.1.2 Positron Emission Based EGRT
One major application of EGRT is to achieve accurate tumor tracking in current RT
to significantly reduce or eliminate the treatment uncertainties. Positron emission
based EGRT or LOR-based EGRT integrates PET imaging for near real-time tumor
tracking and thus is a perfect fit for this application. It can also be implemented as
a feasible and novel solution to solve the dilemma of the ITV approach discussed in
Chapter 1.
Other groups have investigated emission based tracking methods where positron
sources are implanted as fiducial markers [111, 14]. EGRT is unique in that it involves
administration of positron emitting radiotracers into the patient and uses the signals
from the radiotracer that is concentrated in the target for true biological tracking.
Such signals are able to locate the tumor accurately in a non-invasive way with a high
temporal resolution. The LOR detected for one positron event naturally defines the
line of sight which passes through the uptake site. Enlightened by this physical prin-
ciple, we mount a positron imaging system on a radiation therapy machine (compact
Linac) and perform radiation therapy and real-time tumor tracking simultaneously
(to be discussed in detail in the following sections). The schematic diagram of this
EGRT concept is shown in Figure 2.1.
The gamma-ray detectors as used in a PET scanner detect the LORs generated
from positron events. Once the positron event is determined to be likely coming
out of the treatment target, the corresponding LOR will be enqueued into a list of
beamlets waiting for dose delivery. At the first time when the rotating Linac aligns
with the enqueued LOR, radiation will be delivered along the LOR passing through
the target.
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(a) LOR Detection (b) Dose delivery
Figure 2.1: The schematic diagram of the proposed EGRT treatment. (a) LOR
detection using PET detectors, (b) Dose delivery along the detected LOR path.
As can be appreciated from the above scheme, there are two major difficulties
in the implementation of EGRT. The first is how to design a delivery algorithm
to ensure tumor tracking given the system latency. The second is how to invent a
planning scheme to incorporate desired intensity modulation as in IMRT treatments.
A major contribution of this work is to provide and demonstrate viable solutions to
the above two challenges.
2.2 System Design
2.2.1 General Considerations
As mentioned in section 2.1.1, the design of EGRT system depends on how the emis-
sion guidance is used. For example, an EGRT system that uses single photon emis-
sions (e.g. SPECT) will require gamma-camera-type detectors and that which uses
positron emissions will need PET detectors. Regardless of the type of emission used,
the EGRT system should be properly designed to fully exploit the provided guidance
mechanism and achieve tumor tracking. At the same time, the design needs to be
practical for system manufacturing purposes. For example, for image-based EGRT,
the system should at least have two components: PET detectors and a Linac. The
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PET detectors are used to collect LORs for image reconstruction and the Linac is
used to deliver dose based on the real-time acquired tumor location estimated from
reconstructed PET images. Since 3D location is needed, the PET detectors should
be able to cover the entire moving tumor at all times during RT and thus the longi-
tudinal extent should be more than several centimeters. Such a system can be based
on a conventional Linac geometry where rotation speed is limited.
For LOR-based EGRT, the system also needs to have both PET detectors and a
Linac. However, since radiation is delivered beamlet-by-beamlet along each individual
LOR, a helical dose delivery geometry is more suitable. To achieve tumor tracking
with a high temporal resolution, the system needs to rotate fast enough to effectively
freeze tumor motion. This can be made possible with a small longitudinal extent of
PET detectors and a compact Linac mounted on a closed ring gantry. The following
section presents such a detailed EGRT system design for the LOR-based concept,
which is used throughout the following chapters.
2.2.2 Proposed EGRT System
Figure 2.2 shows the proposed LOR-based EGRT treatment system design.
The system is composed of two major components: two arcs of symmetrically
opposed PET detectors and a compact Linac equipped with both a primary collimator
and a rapidly switching bMLC. The Linac design is based on current technology [55],
with a photon beam energy of 6 MV and a maximum dose rate delivery capability of
800 MU/min. The bMLC system is also based on a current pneumatic-driven system
with 64 binary leaves made of 10-cm-thick tungsten. The Linac, collimation system,
and PET detectors are mounted together on a fast rotating slip-ring gantry in the
same transverse plane. The primary collimator defines the slice-width of the fan beam
of radiation and the bMLC selects among individual beamlets within this fan beam
in order to direct radiation along the detected LOR paths.
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Figure 2.2: Cross-sectional diagram of the proposed treatment system geometry for
EGRT. The PET detector arcs are symmetrically opposed, with a span of 2 cm in
the longitudinal direction. During treatment, the PET detectors, Linac system and
MV x-ray detectors rotate together around the system isocenter on a slip-ring gantry.
The patient table moves so that the treatment is delivered helically.
In EGRT, only LORs that meet pre-defined criteria may be responded to, noted
as qualified LORs. Pre-defined criteria are specified by the EGRT algorithm and
designed to ensure accurate tumor tracking. The Linac responds to the qualified
LORs at designated points referred to as firing positions, which are equally spaced
around the circle. During treatment, the system rotates around the system isocenter
with a constant rotation period while the patient is translated slowly through the
system bore with a fixed translation speed, resulting in a helical dose delivery scheme.
In order to compensate for tumor motion, the rotation period should be small relative
to the respiratory cycle or the motion period of the tumor in consideration. In this
work, we model a constant rotation period of 1 second. For the proposed system, if
the PET activity distribution is relatively uniform and if the PET detector arrays
are symmetrically opposed, then the average angular separation between a detected
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LOR and the Linac position at any given time is a quarter of a rotation or 90◦. With
a 1 second rotation period, the expected average lag time is 250 ms. This inherent
latency in the system is modeled in simulations to assess the ability of EGRT to
compensate for tumor motion.
In this work, we model 256 firing positions around the circle, which is similar to the
number of angular bins assigned to LOR data in conventional clinical PET imaging.
At a 1 second revolution period, there is a travel time of about 4 ms between firing
positions and we assume the bMLC can switch to a new configuration within this
travel time to prepare for dose delivery at the next firing position. Current high
speed pneumatically driven tungsten leaves can switch as fast as 10-20 ms [106]. If 4
ms cannot be achieved for our proposed system, either a slower rotation rate or fewer
firing positions or a combination of both would be employed to ensure the feasibility
of the designed bMLC configurations. In this work, bMLC configurations refer to the
set of information that defines beamlet responses, including the spatial coordinates
of the firing points, the leaf numbers that are opened, and the phase number of the
phantom when a leaf is opened (for evaluation purposes). Current medical Linacs
operate in a pulsed mode, with a very low duty cycle. Each pulse is on for a few
microseconds, with a few milliseconds between pulses, yielding duty cycles on the
order of 0.1%. Thus the bMLC will most likely be the main limiting component with
respect to timing in the system design.
Figure 2.3 shows a simplified 3D rendering of the treatment geometry, with Fig-
ures 2.3 (a) and (b) showing LOR detection and radiation response, respectively.
2.3 Treatment Preparation
Treatment preparation is an important component in any type of RT treatment. For




Figure 2.3: Snapshot of a LOR being detected and radiation response in a simplified
3D rendering of the EGRT system.
patient setup before delivery. CT simulation collects CT data for imaging and treat-
ment planning. Patient setup aims to set up the patient exactly as in the simulation
so that the patient receives radiation as planned to the maximum extent.
Due to the introduction of positron emission guidance into RT, simulation needs
to be modified accordingly in EGRT. Take the LOR-based EGRT as an example, a
PET/CT scan instead of a single CT scan is needed. The standard PET/CT scan
protocol applies. Since not every cancer patient receives PET scan during conven-
tional RT treatment, the PET scan may introduce additional cost. However, the
PET/CT scan provides more accurate information for the radiation oncologist to
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diagnose and stage cancer and monitor radiation therapy, which may dramatically
improve the treatment outcome. In addition, a PET scan can also provide essential
information for treatment planning.
Patient preparation and setup on the treatment day will also be different from
conventional treatments. Since an EGRT treatment depends on the guidance from
the distribution of the emission radiopharmaceutical throughout the patient’s body,
correct preparation is more important than that for conventional therapy. Again take
the LOR-based EGRT as an example. On the treatment day, intravenous injection
of the positron tracer (e.g. FDG) is required for EGRT treatment. The amount of
activity injected will be determined as in the standard PET imaging protocol. After
the injection of the radioactive glucose, the patient will be asked to rest quietly for
approximately an hour. This allows the glucose to circulate throughout the body and
concentrate within the tumor volumes. For a diabetic patient, a nurse may need to
check his/her blood sugar level before injecting the radioactive glucose. After the
resting period the patient will empty his/her bladder and the radiation therapist will
escort the patient into the treatment room to lie down on the treatment couch. The
patient will need to lie as still and comfortably as possible for the entire treatment,
which may take up to 20 min. Before dose delivery, a PET scan can be done to update
the initial treatment plan and a megavoltage computed tomography (MVCT) scan




Radiation delivery in EGRT treatment should fully make use of the emission guidance
to ensure that tumor motion is accounted for. For example, in image-based EGRT,
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when tumor translation is determined, the radiation beam should be re-aligned ac-
cordingly so that it can follow the target motion or alternatively the treatment plan
should be transformed to reflect the tumor location change. The beam alignment can
be achieved via couch correction or alternatively repositioning of the MLC.
For LOR-based EGRT, as long as the radiation beamlet is backprojected along
the detected LORs, basic emission guidance is achieved. However, such a scheme
of radiation delivery is not sufficient on its own due to, for example, the existence
of background emission signal. Algorithms need to be designed to filter out such
background interference. In addition, many other practical issues need to be addressed
for the implementation of the radiation backprojection concept such as the rotation
speed of the gantry, spatial error tolerance level for backprojection, and the scheme
to ensure near real-time tracking. The EGRT basic algorithm, described in the next
section, answers the above questions and is used to implement the LOR-based EGRT
concept.
2.4.2 Basic EGRT Algorithm
The EGRT algorithm is based on the concept of backprojecting beamlets of radiation
along detected LOR paths. An illustration of the proposed algorithm is shown in
Figure 2.4. Figure 2.4 (a) shows two distinct events during EGRT treatment: the
moment when one LOR is detected (Linac and PET detector arcs are displayed with
solid lines) and the moment when this LOR is responded to (Linac and PET detector
arcs are displayed with dotted lines).
The sequence of events of the treatment scheme depicted by Figure 2.4 (a) is: (1)
PTV is defined, at the tumor contouring stage, to contain the GTV motion, with
additional margins as in the case of conventional radiation therapy. The patient
is administered with a PET radiotracer and undergoes setup and registration using
MVCT images after the patient is positioned on the table to align the PTV. MVCT
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can provide sufficient image quality for tumor identification and patient setup [31].
(MVCT x-ray detectors and patient table are shown in Figure 2.2 but not in Figure 2.4
for simplicity). (2) The EGRT system performs in-plane rotation continuously with
a constant period on the slip-ring gantry while the patient bench undergoes through-
plane translation for a helical treatment. (3) LORs are detected. (4) Assuming this
shown LOR meets certain criteria specified below, when the Linac arrives at the
firing position for this LOR, the corresponding collimator leaf is opened, resulting in
a radiation beamlet delivered along this particular LOR path. LOR detection and
selective LOR response (steps (3) and (4)) are repeated to achieve the full helical
treatment covering the PTV.
Figure 2.4: (a) shows the process of LOR detection and response by the bMLC
selected beamlets of radiation. (b) and (c) are enlarged views of the corresponding
blocks as labeled in (a). (b) shows the EGRT spatial window, one of the LOR
response criteria of the basic EGRT treatment scheme. The LOR (red solid line) that
intersects with the source trajectory at a point that falls within the EGRT spatial
window (blue arc) is qualified for radiation response. (b) and (c) together show the
collimator leaf (shaded) closest to the line that connects the source and the midpoint
of the LOR-PTV intersection (yellow point in Figure 2.4 (c)).
The margins added to the CTV to define the PTV account for tumor location
uncertainties including intrafractional/interfractional motion and setup errors, such
that the tumor is always inside the PTV during treatment. The PTV is assumed
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to be static throughout the treatment and provides an approximate region in which
the GTV is contained. Only the LORs intersecting the PTV are used for treatment
guidance, so that the EGRT system can track and locate the GTV for dose delivery
with minimal interference from background emissions.
Besides the PTV criterion, other pre-defined criteria are also used in EGRT to
optimally use the LORs in guiding radiation beamlets, which include: the EGRT
time window and the EGRT spatial window. To ensure nearly real-time tracking,
the Linac only responds to LORs that are detected within a short period of time
relative to the current firing time, referred to as the EGRT time window. In this
work, the EGRT time window is fixed to be 500 ms. In addition, the LORs whose
intersection with the source trajectory is more than a pre-determined distance away
from the closest firing position are also excluded to minimize azimuthal error. This
small tolerance is referred to as the EGRT spatial window, specified using angular
separation along the source/firing trajectory (see Figure 2.4 (b)).
It should be noted that due to this spatial tolerance, beamlets may not be back-
projected exactly along the corresponding LOR paths. Figure 2.4 (b) shows, in an
enlarged view, the deviation of the actual delivery path (blue dotted line) from the
detected LOR path (red solid/dashed line). The actual path of delivery is selected
along the line that passes through the source point and the midpoint of the LOR-PTV
intersection, as illustrated together by Figures 2.4 (b) and (c). Figure 2.4 (b) also
illustrates the LOR passing the EGRT spatial window criterion (blue arc), as well as
the shaded leaf that will be opened. Note that at each firing position, a set of leaves
may be opened for a set of qualified LORs. In all simulations presented in Chapter 3,
the EGRT spatial window is fixed at ±0.5 degrees. We find that the average leaf
openings for each of the 256 firing positions, accumulated over all rotations within a
2 mm slice, is within a range of 2-6 for the PTV sizes used in the 4D patient model




Treatment planning extends the capability of achieving a desired dose distribution
and is crucial to any treatment modality. In current RT practice, treatment planning
is mainly CT based and it typically does not take into account any tumor biology
information or tumor response to radiation. However, biological information can sig-
nificantly help with the treatment planning process. For example, PET imaging can
improve the accuracy and consistency of tumor volume delineation. Also, the cur-
rent most widely used IMRT inverse planning techniques typically try to produce a
homogeneous target dose under the assumption of uniform biology within the target
volume. However in reality, the spatial biological distribution (e.g. radiosensitivity,
tumor proliferation rate, functional importance) in most tumors is heterogeneous.
Such information should be taken into account to produce more effective and per-
sonalized treatment plans for better treatment outcomes. Fortunately, incorporating
emission imaging into treatment planning has been reported possible.
The development of a treatment planning system that fully incorporates biological
information is beyond the scope of this dissertation and will be a major focus in the
future development of EGRT. Instead, this work mainly focuses on development of
a scheme to incorporate a conventional planning technique into this new type of
emission guided treatment. For image-based EGRT, since the emission guidance
is used for tumor tracking purposes and not integrated with radiation delivery, the
same conventional IMRT treatment planning can be directly applied. For LOR-based
EGRT, the emission guidance links together tumor tracking and dose delivery in a
non-conventional way. Conventional IMRT planning cannot be directly incorporated
and needs to be modified based on the characteristics of LOR-based radiation delivery.
Chapter 5 discusses a complete treatment planning scheme based on the current IMRT
planning technique. In the next section, we discuss the method of modulating dose
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delivery in LOR-based EGRT, which reveals the basic principle for the full planning
scheme.
2.5.2 EGRT Modulation
The basic EGRT algorithm enables dynamic tumor tracking but has limited ability to
optimize the dose distribution given the treatment planning dose constraints. How-
ever, the ability to modulate the dose distribution according to specific treatment
goals is highly desirable. We propose here EGRT modulation methods in addition
to the basic EGRT treatment scheme to demonstrate the potential of dose planning.
Since the basic EGRT algorithm translates all detected LORs into a set of bMLC con-
figurations, i.e. a sequence of leaf openings, we use modulation of actual leaf opening
probabilities to achieve EGRT modulation. In the future, the beam intensity and/or
duration for each leaf opening could also be modulated to provide more flexibility for
dose control.
Although the LOR data is randomly generated so that the beamlet radiation
response is inherently stochastic, modulation of the response probabilities is based on
deterministic weights from the planning process. In the proposed helical geometry,
with fast rotation, slow translation and small PET detector extent in the longitudinal
direction, the LORs are approximately detected and responded to in a series of 2D
slices. This particular 3D parallel geometry samples the delivery space into a stack
of 2D fan-beam sinograms, referred to as sinogram space. Each bin in sinogram
space corresponds to a spatial orientation of a beamlet response path for a specific
slice. Every detected LOR path can then be mapped into one of the sinogram bins
according to a nearest neighbor approximation.
Under such geometric approximation, the traditional inverse planning formulation
can be adapted for EGRT as
43
minimize ‖D ·Σ ·Ψ(bwoa)− d‖ (3)
subject to 0 < Σ < 1 (4)
where d is the prescribed 3D dose distribution in vectorized form, and bwoa is the
expected distribution of the number of LORs that will be detected in sinogram space
given the tracer activity distribution and EGRT treatment settings (i.e. treatment
time and table speed) in the absence of attenuation. Ψ, the attenuation operator,
represents the change made to bwoa by the attenuation effect. Ψ(bwoa) is in the di-
agonal matrix form whose diagonal elements are the number of LORs in sinogram
space after attenuation while Σ is the modulation matrix, of the same size, whose
diagonal elements specify the probability of opening a leaf for a particular sinogram
bin. Σ is analogous to the intensity modulation parameter in conventional IMRT,
and is what must be determined to solve the inverse optimization problem. Each
column of matrix D is a beamlet kernel, corresponding to the 3D dose distribution
imparted by one unit beamlet. Based on this formalism, we develop attenuation cor-
rection and integrated boost schemes as two specific EGRT modulation applications
to demonstrate its feasibility.
2.5.2.1 Attenuation Correction
In PET imaging, attenuation of the annihilation photons within the subject leads to
lower signal along highly attenuating paths. If not accounted for, the reconstructed
image will reflect this attenuation bias with lower activity estimates within the atten-
uating regions, as illustrated in Figure 1.11. Attenuation correction is now routine
in PET/CT imaging by using the CT scan to estimate the attenuation map of the
subject at photon energies in the PET range1, followed by using this estimate to
weight LORs according to the attenuation along their individual paths.
1i.e. 511 keV
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In EGRT, the same issue arises where the LOR detection rate is inversely propor-
tional to the attenuation of the two annihilation photons. Attenuation can be highly
non-uniform across all directions, resulting in non-uniform LOR detection rates and
therefore a non-uniform radiation response distribution. To correct for this effect,
the analytic solution could be approximated from Eqn. 3 as Σ ≈ Ψ−1. That is,
the attenuation effect can be removed by applying a modulation probability vector
in sinogram space that is inversely proportional to resultant LORs detection rate.
Specifically, the attenuation, i.e. line integral, is first pre-calculated using Siddon’s
algorithm [90] from the planning patient CT images for all sinogram bins. The leaf
opening probability is a value between 0 and 1, calculated from the attenuation of the
associated bin. Let us denote the maximum attenuation across all bins as amax and
jth bin as aj. Since the maximum attenuation would yield the smallest number of
leaf openings, the opening probability should be preserved as 1. The jth bin should
have an opening probability of,
pj = e
−amax+aj (5)
Depending on the strength of the attenuation, the leaf open probability for each
bin will range from 0 to 1 to compensate for that bin’s LOR detection rate. Figure 2.5
illustrates how the response to an individual LOR is adjusted when attenuation cor-
rection modulation is enabled.
2.5.2.2 Integrated Boost
Target dose boosting is often utilized in current radiation therapy to ensure that the
target receives adequate dose [108]. In an integrated boost scheme, a sub-volume
within the PTV is prescribed a higher dose than the remaining PTV. Note that the
sub-volume is defined at the tumor contouring stage and is assumed static during
the treatment as it is defined relative to the PTV. To achieve a target dose boost
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Figure 2.5: An example illustration of EGRT modulation in the case of attenuation
correction. The workflow starts with the shaded module. When one LOR is qualified
for response, i.e. it passes the three criteria of the basic EGRT algorithm, the leaf
will be opened if the attenuation correction algorithm is not enabled. However, if
the modulation algorithm is enabled, the open probability will not be 1. Rather,
this LOR will first find its corresponding bin in terms of its spatial orientation in
the pre-calculated attenuation map and the response probability of this LOR, pj, is
determined as shown. Note that since only LORs that intersect the PTV may be
responded to, the attenuation map is only calculated for the PTV region.
in EGRT, the same boost region is constructed within the PTV. Using Eqn. 3, we
can construct a modulation matrix Σ whose diagonal elements corresponding to the
boost region (i.e. in the beamlet directions which intersect the boost sub-volume) are
larger than those which correspond to the non-boost PTV region. In this work, the
ratio of the boost and non-boost modulation values (diagonal elements of Σ ) is the
ratio of the prescription dose to these two regions and the modulation matrix is scaled
to a range of [0 1]. In the case where both modulation methods are applied, the final
modulation matrix is obtained by component-wise multiplication of the individual




Due to the novel approach of delivering radiation based on biological guidance, EGRT
can have many applications. For example, EGRT is a good option to implement
stereotactic treatments (or ablative radiotherapy). Ablative radiotherapy is a concept
to improve tumor control by delivering small numbers of large doses over shorter
periods [73], as mentioned in section 1.1.4. In early-stage cancers such as lung and
prostate, current ablative radiotherapy has shown excellent local control rates [96, 6,
51]. Control rates achieved in the lung with ablative radiotherapy are rivaling those
that can be obtained with surgery [35, 72]. However, ablative radiotherapy requires
precise localization of the tumor to avoid irradiating nearby critical structures. As
previously mentioned, this precise localization is challenged by the need to account
for the movement of tumors in the body caused by factors such as respiration. EGRT
can therefore provide a feasible solution in this particular case.
In this chapter, we mainly discuss three major EGRT applications: tumor track-
ing, tracking of multiple targets, and treatment of non-PET-avid volumes.
3.1 Tumor Tracking
As introduced in section 1.2, treatment uncertainties especially those due to tumor
motion and patient setup error significantly limit the effectiveness of RT treatment.
Hence, one of the most important applications of EGRT is to effectively and practi-
cally tackle the tumor tracking problem. This is also the major motivation that has
inspired the EGRT concept.
In this section, we aim to demonstrate EGRT’s superior capability of tumor track-
ing using carefully designed simulation studies. Typical intrafractional lung tumor
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motion and interfractional setup errors are simulated in various situations. They are
major sources of tumor location uncertainty and also the most commonly observed
cancer treatment uncertainties in current clinical practice. A simple water phantom,
physical phantom experiments, and a 4D digital patient model have been used for
demonstration. The simulation workflow will first be discussed, followed by evalua-
tion details pertaining to specific simulation studies and associated results. Note that
the simulation workflow with related simulation parameters presented below (i.e. sec-
tion 3.1.1) takes the study of the digital patient model as an example for illustration.
The workflow for the studies of water phantom and physical phantom experiments is
similar. Their simulation details including simulation parameters are listed in their
own sections.
3.1.1 Simulation Workflow
An anthropomorphic digital patient model, the 4D XCAT phantom [85], is used in
our studies for demonstration. Both cardiac and respiratory motion are simulated.
The phantom consists of an attenuation distribution and an activity distribution with
the same anatomical geometry, and it is constructed based on real patient anatomy
and typical radiotracer uptake distributions measured in nuclear medicine imaging.
The activity distribution specifies how the radioactive tracers are distributed inside
the phantom, and the attenuation distribution is used in the calculation of radiation
dose distributions. The XCAT phantom used has a voxel resolution of 2 mm for
all simulation studies included in this work. Scenarios of lung and prostate cancers
are simulated. Other major XCAT phantom simulation parameters can be found in
Table 3.1.
To simulate a dynamic EGRT treatment and examine the feasibility of EGRT, the
following simulation workflow that completely simulates the proposed EGRT dynamic
treatment has been designed and is shown in Figure 3.1.
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Table 3.1: Major XCAT phantom simulation parameters
Scenario Parameter Value Parameter Value
Lung Respiration period 4.2 s Phantom size 256× 256× 35
Respiration phases 12 Voxel resolution 2 mm
GTV size 9.40 cm3 Sinogram bin size 256× 64× 35
PTV size 153.90 cm3 Tracer uptake ratio 8 : 0.5: 1
Prostate PTV margin 6 mm Phantom size 256× 256× 39
Setup error 6 mm Voxel resolution 2 mm
GTV size 33.27 cm3 Sinogram bin size 256× 64× 39
PTV size 71.73 cm3 Tracer uptake ratio 8.5: 1
The LOR detection and dose delivery processes are separately simulated for conve-
nience. Both the activity and attenuation XCAT phantoms are input into the Geant4
Application for Tomographic Emission (GATE) package (see Appendix A.0.2). The
output coincidence data are stored in list-mode form. In this format, each recorded
coincidence event includes its timestamp and 3D coordinates of the two LOR end-
points. Note that these data contain both the scattered and random coincidence
events. Since the GATE simulation adopts the full ring geometry, the events that do
not intersect the actual PET detector arcs in the proposed system are discarded. The
filtered coincidence list forms the LOR queue for dose delivery.
Dose delivery estimation involves two processes: the determination of bMLC con-
figurations and subsequent Monte Carlo dose calculation. When dose delivery starts,
the Linac rotates around the circle and goes through different firing positions. At each
firing position, it scans through the current LOR queue and checks whether each in-
dividual LOR meets the three necessary criteria. If at least one LOR is determined to
be eligible for response, the EGRT modulation algorithms such as attenuation correc-
tion, incorporation of planning, or others may be enabled to determine its response
probability. The final probability is used as a coin-flip for each leaf opening. Once all
firing positions have been processed, the final set of bMLC configurations is obtained
and subsequently the voxel based Monte Carlo (VMC++) (see Appendix A.0.3) dose
calculation engine calculates the final dose map for evaluation.
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Figure 3.1: The simulation flow chart (starting from the shaded module). In an
EGRT treatment, there are two major processes to simulate: positron emission and
dose delivery. For simulation of the positron emission and detection process, the
4D XCAT phantom is input into the GATE package to obtain the LOR data for
dose delivery. The LOR data are used as input for the basic EGRT algorithm and
optional EGRT modulation algorithms such as attenuation correction and integrated
dose boost. The resultant set of bMLC configurations is used as inputs to the VMC++
dose calculation engine. The components that enable dynamic EGRT delivery are
collectively referred to as EGRT Engine, as labeled in the figure.
In the case of a moving phantom, the dose is first estimated separately for each
phase of motion. To calculate the total dose of a moving structure, dose maps of
different phases are registered to the same reference phase through rigid image reg-
istration. The multiple dose maps are then summed to produce a point-of-view map
relative to the moving structure. A detailed description of the dose evaluation scheme
for a moving phantom is shown in Figure 3.2.
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Figure 3.2: The dose evaluation scheme for a moving phantom. The periodic motion
curve is sampled into N phases. The number (i.e. 1, 2, · · · , N) in this figure indicates
the corresponding phase index.
The EGRT engine refers to our dynamic EGRT delivery algorithm used to deter-
mine the qualified LOR responses. The included components of the EGRT engine
are labeled in the simulation workflow (Figure 3.1). While the gantry and couch are
constantly moving in one direction, subsets of bMLC configurations are generated
continuously until the treatment ends. Note that these subsets of bMLC configura-
tions are phase-labeled, i.e. each subset belongs to a particular phase. To evaluate
the dose that has been accumulated in each phase during the whole treatment, the
set of bMLC configurations for each phase is obtained as a summation of subsets of
bMLC configurations that correspond to that particular phase. To evaluate the dose
accumulated for a specific moving structure (e.g. GTV) during the whole treatment,
rigid image registration is used.
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A summary of the main EGRT simulation parameters is shown in Table 3.21.
Table 3.2: Major EGRT and GATE simulation parameters
Category Parameter Value Parameter Value
EGRT Detector extent 2 cm iso leaf aperture(x-y) 0.5 cm
Detector coverage 180◦ arc iso leaf aperture (z) 1 cm
PET ring radius 50 cm EGRT spatial window ±0.5◦ arc
Rotating frequency 1 Hz EGRT time window 500 ms
Linac radius 60 cm Helical pitch 0.2
Background activity 3 kBq/cc Radiotracer FDG
Collimator radius 50 cm Firing positions 256
Collimator leaves 64
GATE Version V5.0.0.p01 Light decay time 40 ns
Coincidence window 10 ns Energy resolution 0.26
Scatter threshold(keV) 350,650 Coincidence policy TWG
Choices of parameters take into account typical engineering design considerations
and actual clinical uptake of the FDG radiotracer [19, 40]. For performance eval-
uation, we compare the proposed EGRT method and a conventional helical IMRT
method without optimized intensity modulation. Both simulations use nearly the
same system settings (i.e. the same MLC system, the same number of 256 firing
positions and the same firing geometry with a more suitable helical pitch). The main
difference is that EGRT opens the leaves that correspond to qualified LORs from
the tumor, while the conventional treatment opens the leaves that intersect the PTV
without tracking the tumor position.
3.1.2 Preliminary Study: Water Phantom
3.1.2.1 Simulation Details
The preliminary water phantom study is conducted for the very initial concept and
feasibility demonstration. In this study, both the hot source and the warm background
are modeled as water. Simulations included three cases: 1) No motion; 2) Target in-
plane (x) motion; 3) Target through-plane (z) motion. The simulated list-mode data
1TWG = takeWinnerofGoods.
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are input into the EGRT simulation framework, using a PTV corresponding to the
specific motion case. Table 3.3 outlines the parameters for the simulations.
Table 3.3: Simulation parameters for water phantom study.
Parameter No Motion X Motion Z Motion
Target diameter (cm) 3.7 3.7 3.7
Target activity (kBq) 24 24 24
Background diameter (cm) 20 20 20
Background activity (kBq) 3 3 3
Motion amplitude (cm) 0 1.0 0.65
Motion period (s) 0 3.7 4.84
PTV diam/axial extent (cm) 5/6 6/6 5/6
Rotation period (s) 1 1 1
PET axial coverage (cm) 2 2 2
PET circular coverage (%) 50 50 50
bMLC x/z leaf at iso (mm) 5/10 5/10 5/10
Firing positions 256 256 256
LOR angular threshold (◦) ±0.5 ±0.5 ±0.5
Lag threshold (ms) 500 500 500
Treatment time (s) 600 600 600
Table speed (cm/s) 0.01 0.01 0.01
As a comparison, the same cylindrical PTV in each case is uniformly irradiated
using a helical IMRT delivery scheme. The point-of-view dose maps for the EGRT
and IMRT methods are both normalized with the same integral dose to the phantom.
The dose volume histogram (DVH) is calculated based on the point-of-view dose maps
to compare the two methods for each of the motion cases.
3.1.2.2 Results
The GATE simulations resulted in 91677, 105669 and 91353 beamlet responses for
the no motion, x-motion and z-motion cases, respectively. After 600 s of treatment,
this translates to, on average, between 150 and 175 beamlet responses per second,
or in this case per rotation. Figure 3.3 depicts dose maps of three different phases
of motion for both of the simulated motion cases. Dose concentration in the moving
target can be seen in both the x-motion and z-motion scenarios.
Figures 3.4, 3.5, and 3.6 show GTV point-of-view dose maps assembled from all
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Figure 3.3: (Top) Axial dose maps for three different phases for the simulated x-
motion case. (Bottom) Coronal dose maps of three phases from the z-motion case.
The dashed black lines indicate the GTV position. Dashed white lines are overlaid
for positional reference.
12 simulated motion phases for each scenario, as well as the associated DVH curves
comparing EGRT with IMRT. In all cases, there is a peaking of dose in the center of
the GTV, discussed below. However, even with this inhomogeneity, there is a 17%,
21% and 17% relative increase in dose to 95% of the GTV for the static, x-motion
and z-motion scenarios, respectively, when comparing the EGRT and IMRT methods
normalized for the same integral dose to the phantom (denoted as healthy tissue).
EGRT IMRT 
Figure 3.4: (Left) Axial and coronal point-of-view dose maps for the GATE simulated
case with no motion comparing EGRT and IMRT methods. The dashed black lines
indicate the GTV position. (Right) Associated DVH curves.
3.1.3 Preliminary Study: Physical Phantom Experiments
3.1.3.1 Simulation Details
Phantom experiments are conducted using a GE Discovery PET/CT scanner (GE
Healthcare, Waukesha, WI). A cylindrical phantom and six spherical inserts (37, 28,
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EGRT IMRT 
Figure 3.5: (Left) Axial and coronal point-of-view dose maps for the GATE simulated
x-motion case comparing EGRT and IMRT methods. The dashed black lines indicate
the GTV position. (Right) Associated DVH curves.
EGRT IMRT 
Figure 3.6: (Left) Axial and coronal point-of-view dose maps for the GATE simulated
z-motion case comparing EGRT and IMRT methods. The dashed black lines indicate
the GTV position. (Right) Associated DVH curves.
22, 17, 13, and 10 mm in diameter) were filled with FDG for a target-to-background
ratio of 8:1 with activity level based on 10 mCi of injected activity for a 70 Kg subject.
The phantom is affixed to a motion stage and situated inside the scanner (Figure 3.7).
The motion stage used is the 4D Phantom that was developed at Washington
University as a quality assurance (QA) tool designed to position a radiological phan-
tom with sub-millimeter accuracy [62]. It consists of two parts. One part is a 3D
motion platform that can move a phantom independently along all axes to simulate
internal 3D motion of a target. The other part is a 1D motion stage that moves an
optimal marker vertically to simulate external abdominal respiratory motion. The
motion stage is programmed with breathing trajectories acquired from volunteers us-
ing the Varian RPM system. The RPM system employs an external optical marker
on the abdomen that is tracked by a camera. This system is used to acquire a
one-dimensional breathing trajectory from a volunteer who is instructed to breath
normally. We denote this as the free breathing scenario. For better comparison with
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Figure 3.7: FDG phantom experiment setup. (Left) GE Discovery
PET/CT system. (Middle) 4D Phantom (image from http://radonc.wustl.edu/–
md/pparikh/4dphantom.html). (Right) FDG phantom reconstruction. The dashed
line is a cylindrical planning target volume (PTV) which includes the motion trajec-
tory of the largest sphere.
the GATE simulations, a periodic motion trajectory was constructed based on the free
breathing motion path by calculating an average period and amplitude. We denote
this motion pattern as the periodic breathing scenario. The two motion trajectories
are depicted in Figure 3.8.
Figure 3.8: (Left) Free and (Right) Periodic breathing motion trajectories used
in the phantom experiments. Peak exhalation, which reflects the lowest point of
the abdominal marker during measurement, is defined to be positive in this case to
correlate with the positive z translation of the motion stage.
The recorded vertical motion from the RPM system is used to drive the motion
stage in a purely superior/inferior (z) direction. After FDG filling, the PET phantom
is secured to the 3D portion of the stage and the stage motion is either turned off
or programmed with the periodic or free breathing trajectories. The 1D portion of
the stage is also programmed with the corresponding scenario. The PET data are
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recorded in raw list-mode form so that the timestamp of each recorded LOR event
is known. The RPM system is used to track the 1D motion stage so that triggers
from the RPM system could be synchronized with the list-mode data from the PET
scanner. The raw LOR list-mode data are not corrected for scatter or randoms.
The list-mode data are used as input into the EGRT simulation framework described
above.
A cylindrical PTV is designated around the largest 37 mm sphere and fully con-
tains its motion trajectory in the z direction (see Table 3.4 for the experimental
parameters including PTV sizes).
Table 3.4: Simulation parameters for physical phantom experiments.
Parameter No Motion Periodic Z Free Z
Target diameter (cm) 3.7 3.7 3.7
Target activity (kBq) 41.44 41.44 41.44
Background diameter (cm) 20 20 20
Background activity (kBq) 5.18 5.18 5.18
Motion amplitude (cm) 0 0.65 0.875
Motion period (s) 0 4.84 N/A
PTV diam/axial extent (cm) 5/6 5/6 5/7
Rotation period (s) 1 1 1
PET axial coverage (cm) 2 2 2
PET circular coverage (%) 50 50 50
bMLC x/z leaf at iso (mm) 5/10 5/10 5/10
Firing positions 256 256 256
LOR angular threshold (◦) ±0.5 ±0.5 ±0.5
Lag threshold (ms) 500 500 500
Treatment time (s) 600 600 600
Table speed (cm/s) 0.01 0.01 0.01
The EGRT algorithm uses this PTV as a mask, rejecting all LOR events that
do not intersect the PTV. Uniform coverage of the same PTV is simulated for com-
parison. The VMC++ simulation of the EGRT system calculates the resultant dose
distribution in a cylindrical water phantom with the same dimensions as the PET
phantom. The point-of-view dose map is estimated by calculating 12 dose maps for
12 distinct motion phase bins that are based on displacement rather than time. 12
displacement-based bins in each of the free and periodic motion scenarios are spaced
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uniformly between the minimum and maximum trajectory displacements across the
full time course. The free breathing scenario has bins spanning 1.75 cm peak-to-peak,
while the bins for the periodic case span 1.3 cm peak-to-peak. The dose maps for
each bin are shifted based on their displacement relative to a reference bin and then
summed to produce a single point-of-view dose map. The associated DVH curves
are calculated based on the point-of-view dose maps for the target volume and full
phantom.
3.1.3.2 Results
The phantom experiments resulted in 154142, 184979 and 243842 beamlet responses
for the no motion, periodic and free-breathing scenarios, respectively. The differences
in the number of counts is likely due to the differences in the delay between FDG
filling and the starting of experiment for each scenario. After 600 s of treatment, this
translates to between 250 and 400 beamlet responses per rotation.
Figures 3.9, 3.10 and 3.11 depict the dose distributions for the EGRT and IMRT
(uniform PTV coverage) methods from the moving spherical target’s point of view,
with associated DVH curves. As in the simulation results, the dose peaks in the
center of the target for the EGRT method, which yields a 18%, 17%, and 23% relative
increase in dose to 95% of the target volume compared with uniform PTV coverage
IMRT method when both are normalized for the same integral dose to the phantom.
EGRT IMRT 
Figure 3.9: (Left) Point-of-view dose maps for the phantom study no-motion case
comparing EGRT and IMRT methods. The dashed black lines indicate the GTV
position. (Right) Associated DVH curves. The arrow indicates relatively higher dose
in the direction of the second largest sphere.
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EGRT IMRT 
Figure 3.10: (Left) Point-of-view dose maps for the phantom study periodic breath-
ing scenario comparing EGRT and IMRT methods. The dashed black lines indicate
the GTV position. (Right) Associated DVH curves.
EGRT IMRT 
Figure 3.11: (Left) Point-of-view dose maps for the phantom study free breathing
scenario comparing EGRT and IMRT methods. The dashed black lines indicate the
GTV position. (Right) Associated DVH curves.
3.1.4 Preliminary Study: Discussion
We have demonstrated a proof of principle for responding to individual PET emis-
sions with radiation beamlets along the emission paths. In this section we discuss
limitations of the current work, as well as areas of future work.
The observed dose peaking in the center of a uniformly avid target can be explained
by the backprojection effect. There are more LORs that intersect the center of the
GTV than the edge, as the detected LOR rate spatial profile is the projection of the
sphere onto the PET detector array. In filtered-backprojection image reconstruction,
the peaked projection is first filtered so that the backprojected image intensity of
the GTV is reflective of its original activity distribution. EGRT, however, results in
radiation backprojection (no filtering) along the LOR paths and therefore preserves
the peaking from the original projection.
Due to the dose peaking effect, one may think that a more fair comparison between
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the IMRT and EGRT methods would be to integrate a boost in the IMRT plan, as
is commonly done for stereotactic hypofractionated treatments. However, the same
deterministic boost can be applied to the EGRT plan. In other words, all planning
weights that are a result of IMRT planning should be incorporated into the EGRT
plan for a fair comparison. In the following example, the IMRT boost is implemented
by boosting a sub-volume in the PTV, which we denote as the Boost volume, that has
the same size as the GTV and receives twice the intensity as the non-Boost portion
of the PTV. We incorporate this same boost in the EGRT scheme by assigning a
probability to beamlet-responses based on their intersection with the PTV and Boost
volumes. Beamlets that intersect the Boost volume were delivered with twice the
probability as those that intersect the PTV volume but do not intersect the Boost
volume. Figure 3.12 depicts the dose maps and DVH curves comparing the IMRT-





Figure 3.12: (Left) Axial and coronal point-of-view dose maps for the GATE simu-
lated z-motion case comparing EGRT and IMRT methods with a simultaneous inte-
grated boost. The dashed black lines indicate the GTV position. (Right) Associated
DVH curves.
In this case, both scenarios have been normalized for the same absolute integral
dose to the phantom as the non-boost cases for a direct comparison. The IMRT-
Boost method achieves a 24% and 40% increase in dose to 95% and 50% of the
GTV volume, respectively, compared to the original IMRT method. The EGRT-
Boost method achieves a 32% and 76% increase in dose to the GTV compared to the
original IMRT method. The relative gain of EGRT over IMRT is not as high as in
the non-boost cases, likely due to the fact that the boost volume largely overlaps the
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GTV volume in all phases of motion and therefore the deterministic benefit of the
treatment plan is competing with EGRT’s stochastic benefit. Nonetheless, it can be
seen that IMRT planning weights can be employed within the EGRT framework to
take advantage of a priori information.
In all phantom experiments presented above, there is an increase in dose in the
direction from the largest sphere to the second largest sphere (indicated by the arrow
on Figure 3.9). This is due to radiation delivery along LOR paths that originated
from the second largest sphere but whose paths also intersect the PTV. As the EGRT
algorithm is blind to the origin of each LOR, all LORs that intersect the PTV can
be responded to, irrespective of their source. This effect can be mitigated in future
work through prior knowledge of the PET distribution of the subject.
An interesting effect can be seen in the free breathing scenario (Figure 3.11). A
ripple pattern of the dose distribution appears in the longitudinal (z) direction. At
first this was thought to be due to the reported thread effect of a helical delivery
system [16]. The thread effect is known to be strongly dependent on the pitch of the
treatment delivery, where the pitch is defined as the number of rotations per table
traversal of a slice-width. However, when the pitch was varied in the free breathing
scenario there was little change in the ripple pattern. It is hypothesized that the
observed ripple effect in this case is due to the erratic free breathing motion path.
The full analysis of this effect will be the subject of future work. Even in its presence,
the DVH curves for the free breathing scenario demonstrate a 23% relative increase
in dose to 95% of the target volume when compared with the IMRT approach.
Oncologic applications of PET continue to evolve as new radiotracers are devel-
oped that target various aspects of cancer biology and function. PET is a molecular
imaging modality that is able to detect and image a broad range of biological pro-
cesses. 18F-Fluorodeoxyglucose (FDG)-PET, which measures the metabolic activity
of glucose, is currently the gold standard in noninvasive cancer detection, with higher
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sensitivity and specificity than CT or MRI across a broad range of cancers [32]. In
addition to FDG for metabolic activity, other PET radiotracers have been used to im-
age cellular proliferation (18F-fluorothymidine [26]), hypoxia (18F-fluoromisonidazole
[71, 76]), and amino acid transport (18F-fluoroethyltyrosine [36], 18F-FACBC [84]).
These imaging applications can potentially translate into PET-based treatment where
EGRT becomes a tool to achieve biologically adaptive therapy.
3.1.5 Preliminary Study: Conclusions
The feasibility of emission guided radiation therapy has been demonstrated using
the principle of radiation backprojection along detected LOR emission paths. Dose
peaking in the center of a PET-avid volume is a consequence of the technique, and
a thread-like effect is observed in the free breathing scenario. However even in the
presence of these inhomogeneities the simulations and experiments performed in this
study have demonstrated at least 15% relative increase in dose to 95% of the target
volume when compared to uniform irradiation of the same planning target volume.
EGRT has the potential to enable true biologically guided and biologically adaptive
treatment.
3.1.6 Patient Model Study: 4D XCAT Phantom
Six simulation studies have been conducted to validate the feasibility of EGRT for
two clinical cases. Two typical disease sites are studied: a lung tumor scenario and a
prostate tumor scenario.
3.1.6.1 Simulations Details
• Lung tumor scenario
The lung tumor simulation includes both respiratory motion and heart motion,
with periods of 4.2 s and 1 s, respectively, sampled in 12 phases. The GTV is
modeled using an ellipsoid with a set of semi-axis lengths of 1.5, 1, 1.5 cm and
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placed in the right lung. The GTV motion path is based on an XCAT built-in
3D periodic tumor motion trajectory with typical lung motion behavior and
amplitude. The trajectory of the lung tumor motion is shown in Figure 3.13.
The PTV is modeled using a cylinder that contains the full range of GTV
motion with a total height of 7 cm and an ellipsoidal cross section whose set of
semi-axis lengths are 2 and 2.5 cm. Two cases, with and without attenuation
correction, are evaluated. 100 Gy is prescribed to 95% of the GTV volume.
For the case without attenuation correction, the EGRT treatment time is 300 s
with a table speed of 0.023 cm/s; for the case with attenuation correction, the
EGRT treatment time is 1000 s with a table speed of 0.007 cm/s. The mean of
12 phases of the XCAT attenuation phantom is used for the PTV attenuation
map calculation. The tumor, lung and background activity uptake ratio is
assumed to be 8:0.5:1. The phantom geometry can be seen in Figure 3.15.
Figure 3.13: The 3D lung tumor trajectory (first phase at the origin). The red and
blue markers depict each way of the tumor round trip respectively. The peak-to-peak
tumor motion amplitude is 16.6 mm, 3.5 mm and 0.02 mm for superior-inferior (SI),
anterior-posterior (AP), lateral-medial (LM) directions respectively.
• Prostate tumor scenario
To evaluate the feasibility of EGRT treatment in a different disease site, more
studies have been conducted for a prostate tumor case. In this work, four
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prostate cases are modeled: with and without setup error and with and without
an integrated boost. The GTV is modeled using the XCAT built-in prostate
profile with a size of 33.27 cm3. Since no motion is modeled in the prostate case,
the PTV is constructed with a 6 mm margin around the GTV in all directions,
resulting in a size of 71.73 cm3. Due to strong inhomogeneous attenuation, all
cases of prostate cancer have been simulated with the attenuation correction
EGRT modulation algorithm enabled. 6 mm setup error is simulated in the
lateral-medial direction. In order to make use of the same set of GATE data,
the setup error is simulated by shifting the PTV in the corresponding direction.
The boost region is set to be the GTV if there is no setup error and is shifted
with the PTV in the presence of setup error. 78 Gy is prescribed to 95%
of the GTV volume. When the integrated boost algorithm is enabled, the
same amount of dose is prescribed to the boost region. The treatment time is
1000 s for all cases, with a table translation speed of 0.007 cm/s. The XCAT
attenuation phantom is used for the PTV attenuation map calculation. The
tumor to background activity ratio is selected to be 8.5:1. The phantom setup
including the contouring of the GTV, PTV and important OARs can be found
in Figures 3.16 (b) and 3.17 (b).
3.1.6.2 Results
• Lung Results
The GATE simulation results in 39084 and 47925 beamlet responses in 300 s
and 1000 s of treatment for the cases without and with attenuation correction,
respectively. Figure 3.14 depicts the dose maps of all 12 simulated phases for the
EGRT algorithm in both coronal and sagittal views in the absence of attenuation
correction. Dose concentration in the moving target can be observed, which
indicates that the EGRT method is able to track the tumor’s motion.
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Figure 3.14: Dose maps of all 12 simulated phases in both (a) coronal and (b)
sagittal views. Red means high dose and blue means low dose. Dashed lines are
overlaid for positional reference. Each image is using a window of [min max] of itself.
Figure 3.15 shows the GTV point-of-view dose maps assembled from all 12
motion phases for each case, as well as the associated DVH curves comparing
the conventional method with EGRT in the cases with and without attenuation
correction. In both EGRT cases, there is a peaking of dose in the center of
the GTV, discussed below. However, even with this inhomogeneity, there is
a 31%, 41% relative increase in dose to 95% of the GTV and a 44%, 55%
relative increase in dose to 50% of the GTV for the cases without and with
attenuation correction, respectively, when comparing the EGRT methods with
the conventional method. All dose distributions were normalized for the same
integral dose to the lung.
The GTV dose relative increase is higher when attenuation correction is enabled
in the EGRT method. This is due to the fact that after attenuation correction,




Figure 3.15: Point-of-view dose maps and associated DVH for the lung case with
(a) EGRT, (b) conventional method and (c) EGRT with attenuation correction. The
GTV is contoured using a black solid line.
the dose distribution is normalized. In other words, the GTV dose increase is
achieved at the price of heart dose increase. This may be favored in the case
where the heart dose increase is still within the planning limit. This study also
demonstrates that EGRT modulation through customization of the response
probabilities can be used to optimize the dose distribution.
• Prostate Results
– Without Setup error
The GATE simulation results in 22231 and 19128 beamlet responses in
1000 s of treatment for the cases without and with the integrated boost,
respectively. The number of beamlet responses is reduced for the boost case
due to the probability scheme in EGRT modulation. Figure 3.16 depicts
the DVH and the dose distributions for all four scenarios comparing the
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original EGRT case, the boosted EGRT case, the conventional case and
the boosted conventional case in the absence of a setup error.
(a) Dose Distribution (b) Radiation Response
Figure 3.16: The dose distributions for (a) original EGRT, (b) conventional method,
(c) boosted EGRT and (d) boosted conventional method with the associated DVH.
The GTV is contoured with a black solid line in all scenarios. Contoured PTV (red),
bladder (magenta), and rectum (green) are shown only in (b) for simplicity. The
boost region is equivalent to the GTV in this case (without setup error).
Using the conventional method without boost as a basis for comparison,
the boosted conventional method resulted in a 8% and 20% relative dose
increase to 95% and 50% of the GTV, respectively. The EGRT method
yielded a 14% and 36% increase, while the boosted EGRT method resulted
in a 19% and 55% relative dose increase to 95% and 50% of the GTV,
respectively. All methods were normalized for the same integral dose to
the rectum.
– With Setup error
When setup error is simulated by shifting the PTV, the GATE simulation
results in 22172 and 18929 beamlet responses in 1000 s of treatment time
for the cases without and with integrated boost, respectively. Figure 3.17
depicts the DVH and the dose distributions for all four scenarios comparing
the EGRT case, the boosted EGRT case, the conventional case and the
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boosted conventional case in the presence of setup error.
(a) Dose Distribution (b) Radiation Response
Figure 3.17: The dose distribution for (a) original EGRT, (b) conventional method,
(c) boosted EGRT and (d) boosted conventional method with the associated DVH in
the presence of simulated setup error. The GTV is contoured with a black solid line
in all scenarios. Contoured PTV (red), bladder (magenta), rectum (green) and boost
region (yellow) are shown only in (b) for simplicity.
Compared with the conventional method, the boosted conventional method
results in a dose increase of 2% and 21% to 95% and 50% of the GTV,
respectively. The EGRT method yields a 19% and 35% and the boosted
EGRT yields a 21% and 52% relative dose increase to 95% and 50% of the
GTV, respectively. All methods are normalized for the same integral dose
to the rectum.
3.1.7 Patient Model Study: Discussion
In this work, we integrate positron emission into the process of radiation therapy
dose delivery for treatment guidance by directing radiation beamlets along detected
LOR paths in near real-time. Since PET imaging serves as the gold standard for
non-invasive cancer detection and staging [32], and is increasingly being used for
treatment planning [95, 21], this proposed biological targeting method may provide
a way to close the loop between detection and radiation treatment.
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In the current implementation of EGRT, a few items require further considera-
tion. First, we want to discuss several issues on the EGRT results. It should be noted
that the EGRT dose increase in the prostate case is smaller than that observed in
the lung case, which could be explained by the PTV-ITV ratio used. As EGRT is
able to concentrate the dose to the PET-avid region while the conventional method
irradiates the whole PTV, the larger the PTV-ITV ratio used, the larger the an-
ticipated advantage. The advantage of EGRT still exists when the boost scheme is
implemented, which indicates that the dose increase in EGRT is due to the inherent
tumor targeting.
Also, as indicated by the results, both the positron range uncertainty and angle
divergence in PET do not compromise the accuracy of emission guidance. There are
two possible reasons for this. One is that the uncertainty due to the positron range
and angle divergence is small compared to the treatment beam resolution. The other
is that the uncertainty has a zero-mean stochastic nature and while it may add a
small blurring component, there should be no bias in the tumor tracking accuracy.
Besides, the results take into account the decay of PET signals during treatment.
Given current simulation settings, treatment time can be generally controlled to be
less than 20 minutes. Most clinical PET tracers are 18F based, which has an approx-
imate half life of 110 min. Therefore, at the end of a 20 min treatment, the activity
remains 88% of the maximum, which have casted little effect on the treatment delivery
efficiency.
Furthermore, unlike in the conventional method, dose peaking is observed in the
center of a uniformly PET-avid target. This phenomenon is due to the backprojection
effect. There are more LORs that intersect the center of the GTV than the edge, as
the detected LOR rate spatial profile is the projection of the target onto the PET
detector array. Therefore, more beamlet responses will be directed towards the center
of the target. Due to the dose peaking effect, the results are presented in the form of
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dose escalation. Note that the EGRT dose benefits due to inherent tumor tracking
are generic and thus will not vanish if assessment criteria are changed. For example,
if the results are normalized to the target (GTV) dose, the benefit may be in the form
of reduced dose to critical structures. However, given the current EGRT algorithm
design, the benefits may not be in the form of some particular criteria such as target
dose uniformity without modification of the current algorithm.
Secondly, special care is needed in the practical implementation of EGRT for
cancer treatment. For example, EGRT performance is dependent on the target-to-
background activity uptake ratio. In the extreme case where there is no significant
difference between target and background activity, there would be no advantage of
EGRT over other methods. Also, although the attenuation correction EGRT modula-
tion algorithm can help to reduce the attenuation effect, a negative consequence is an
increase in treatment time if approximately the same number of beamlet responses is
to be maintained since many beamlet responses are suppressed. In addition, patient
and therapist are expected to receive similar levels of dose as in a standard clinical
PET exam. Studies have shown that a conventional whole-body 18F-FDG PET/CT
examination gives an average effective patient dose equivalent to 2.5 cGy [12]. This
dose should be taken into account when evaluating patient or therapist dose. It is
also worth noting that the selection of radioactive tracers for different tumor sites is
possible in EGRT. EGRT can benefit from new radiotracers that are developed to tar-
get various aspects of cancer biology and function. 18F-Fluorodeoxyglucose (FDG),
which measures the metabolic activity of glucose, is currently the gold standard in
noninvasive cancer detection, with higher sensitivity and specificity than CT or MRI
across a broad range of cancers. FDG is effective for many lung tumors. However,
for prostate cancer, 18F-Fluorocholine (FCH) and 18F-fluorocyclobutane-1-carboxylic
acid (FACBC) may be more effective [82, 84].
Finally, EGRT performance could be further improved by better engineering and
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algorithm designs in several aspects. For example, no attempt has been made to
compensate for both the scattered and random events from the raw PET coincidence
dataset. Although the PTV intersection requirement reduces the error that these
false events introduce, correction for scatter and random events should be imple-
mented to further improve EGRT performance. Moreover, simulation settings are
not optimized. Each beamlet response is assumed to have the same beam intensity
and duration. The patient couch also has a constant translation speed. To achieve
more degrees of freedom for a more optimized delivery or shorter treatment time, it
is viable to modulate the intensity or duration of each beamlet, or apply a variable
couch speed to allocate more treatment time for desired regions. Most of all, cur-
rent EGRT algorithm design does not incorporate a conventional treatment planning
component. The EGRT modulation simulations have demonstrated the feasibility of
dose modulation by making use of leaf opening probabilities. The overall leaf opening
probability distribution resembles the beamlet weighting distribution in conventional
inverse planning. In the future development of EGRT treatment planning where a
detailed plan is specified, the conventional weighting distribution may first be calcu-
lated using inverse optimization and then converted into a corresponding leaf opening
probability distribution. This future work will enable a fair comparison of planned
EGRT with current state-of-the-art conventional external beam therapy.
3.1.8 Patient Model Study: Conclusion
In the patient model study, we introduce EGRT as a new radiation therapy technique
to improve treatment performance. The feasibility of EGRT has been demonstrated
using the XCAT digital phantom as well as Monte Carlo simulations of PET acquisi-
tion and radiation delivery. An EGRT treatment scheme with attenuation correction
and boost algorithms are proposed as an implementation of the EGRT concept in
two clinical scenarios. The treatment scheme and associated algorithms are designed
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based on realistic hardware and software technology. Compared with a conventional
method, dose concentration is observed for both moving and static targets. EGRT has
the potential to enable true biological targeting and guidance in radiation delivery.
3.2 Simultaneous Tracking of Multiple Targets
3.2.1 Motivation
It is known that cancer cells tend to migrate from one organ or part to another non-
adjacent organ or part (called metastasis). This brings additional difficulty for cancer
treatments, which is usually much more than that of treating one single localized
tumor. Hence, besides tumor tracking, another major challenge in current RT is how
to efficiently and effectively treat multiple targets or metastases in a single patient.
When combined with the tumor tracking issue, i.e. in the situation where one or all
of these targets have significant intrafractional motion, treating multiple targets can
be even more challenging.
The need of an approach that can efficiently and simultaneously track multiple
targets has therefore become increasingly important. This is true especially under
the background that the death rates have been significantly reduced for patients with
single primary tumors (thanks to the development of advanced RT techniques such
as IMRT and IGRT), while they are still much higher for patients with metastatic
disease. For example, it is reported that brain metastases can develop in up to half
of all patients with cancer and therefore have become a serious health problem [74].
In addition, more than 100,000 patients are diagnosed to have solitary brain tumors
in the United States each year and even more patients have multiple metastases [52].
Such brain tumors are usually not amenable to surgical resection and it is concluded
that whole brain radiation therapy does not actually provide lasting and effective care
for most patients [52].
Being able to treat multiple targets in a single patient with ease is a great benefit
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of EGRT. This is because EGRT algorithms need no major modifications at all for
this type of treatment while conventional methods typically have to treat the targets
sequentially with multiple isocenters and plans, which can impact the overall time,
cost, and complexity of treatment. More importantly, tumor tracking problem can
potentially be inherently and simultaneously addressed for all the targets in EGRT.
The resultant target dose escalation can therefore provide great tumor control. In
this section, we investigate the feasibility of treating multiple targets using both the
4D XCAT phantom and clinical patient data.
3.2.2 Digital Patient Model
The same XCAT phantom as in previous tumor tracking section is used, except
that two additional targets have been added to the left lung for a multiple-target
simulation. Please refer to Figure 3.19 for an illustration of the phantom setup of all
three simulated targets. The identification number of each target (i.e. GTV1, GTV2,
and GTV3) is also labeled in this figure. Major motion directions for each target are
marked on the coronal view (the simulation is designed such that the major motion
of all targets can be observed in the same coronal image). The two added targets are
of similar size as the original GTV (specific sizes are not listed here for simplicity,
please refer to Table 3.1). Each PTV is made from the corresponding ITV with the
same amount of margin as in the original simulation. Note that due to the fact that
the two extra targets are close to each other, their PTVs are merged.
The same major EGRT and GATE simulation parameters are used. GATE sim-
ulations are conducted for the three targets with the same activity level. EGRT
simulation time is reduced to 15 min. Attenuation correction algorithm is applied
to correct for the corresponding effect. Exactly the same EGRT algorithms are im-
plemented except that the PTV intersection criterion has been extended due to the
increased number of PTVs: as long as the LOR intersects at least one of the PTVs,
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it is eligible for response. The same conventional algorithm as in the previous tumor
tracking section has been used for dose performance comparison.
Figure 3.18 shows the DVH comparison.
Figure 3.18: DVH comparison of EGRT and conventional treatments in the multiple-
target simulation.
Note that all dose distributions are normalized for the same mean dose to the lung.
The DVH comparison shows that compared to a conventional helical treatment, for
95% of the GTV, EGRT achieves a 16%, 22%, 18% relative increase in dose while for
50% of the GTV, EGRT achieves a 25%, 28%, 26% dose increase, for targets 1, 2,
and 3 respectively. Same level of dose increase is achieved for all three targets. This
is likely due to the fact that all GTVs have the same simulated activity level yielding
a similar number of emission counts for radiation response. This may not be true in
real EGRT treatments and the activity distribution for different targets are probably
different. Further algorithm work is needed to enable flexible control of the dose levels
of different targets given the prior knowledge of their activity distributions.
Figure 3.19 depicts the GTV point-of-view dose distribution comparison for target
1.
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Figure 3.19: GTV point-of-view dose distribution for target 1. The red arrows on
the coronal view point out the major motion direction for each of the three targets.
PTV and GTV are contoured using blue solid and black dashed lines, respectively.
Similarly, Figure 3.20 and 3.21 depict the GTV point-of-view dose distribution
comparison for target 2 and 3, respectively.
Figure 3.20: GTV point-of-view dose distribution for target 2. PTV and GTV are
contoured using blue solid and black dashed lines, respectively.
Figure 3.22 shows the dose tracking of all 12 motion phases from the coronal view.
It can be seen that tumor tracking is achieved simultaneously for all three targets.
3.2.3 Clinical Patient
EGRT’s capability of simultaneous tracking of multiple targets is further demon-
strated using clinical 4DCT and 4DPET data. Similarly like the XCAT phantom
scenario, the multiple-target simulation using the clinical patient data is almost the
same, in terms of major simulation parameters and processing of clinical PET and
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Figure 3.21: GTV point-of-view dose distribution for target 3. PTV and GTV are
contoured using blue solid and black dashed lines, respectively.
CT data, as the single-target simulation. Therefore, the simulation details using the
clinical patient data are not listed here for simplicity and can be found in Chapter 5.
This patient contains two moving breast cancer metastases in the lung region with
a moderate motion amplitude. The identification number of each target (i.e. GTV1,
GTV2) is labeled in Figure 3.24. Please refer to Figure 3.24 for an illustration of the
clinically delineated GTVs and PTVs. Major motion directions for each target are
marked on the coronal view of the same figure. Clinical delineated PTVs are used
for the evaluation of eligible beamlet responses. The same EGRT algorithms with
attenuation correction are applied. Preliminary results are presented below.
Figure 3.23 illustrates the DVH comparison of EGRT and conventional treatments.
Note that all dose distributions are normalized for the same dose to the lung. The
DVH comparison shows that compared to a conventional helical treatment, for 95%
of the GTV, EGRT achieves a 6%, 17% relative increase in dose and for 50% of the
GTV, EGRT achieves a 15%, 29% dose increase, for targets 1 and 2, respectively.
Different levels of dose increase are observed for the two targets. This is likely due
to the fact that the two GTVs have different actual activity levels. Another major
reason may be that one of the motion phases of target 2 is not fully tracked (to be
discussed below).
Figure 3.24 depicts the GTV point-of-view dose distribution comparison for target
1 of the clinical patient case.
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Figure 3.22: Dose maps of all 12 simulated phases in coronal view for both con-
ventional and EGRT treatments. Red means high dose and blue means low dose.
PTV and GTV are contoured using blue solid and black dashed lines respectively for
positional reference. The dose maps are displayed with the same window [0.2 0.8]
relative to the maximum GTV dose across all phases.
Similarly, Figure 3.25 depicts the GTV point-of-view dose distribution comparison
for target 2.
Figures 3.26 and 3.27 show the dose tracking of all 6 motion phases from the
coronal view for targets 1 and 2, respectively. Note that unlike the XCAT phantom
case where the tumor motion of all three targets is on the same coronal plane due
to the intentional simulation design, the central coronal views of the two targets in
patient case are not on the same plane and thus two motion tracking figures are
shown.
The tracking map shows that the last of the six motion phases of target 2 is not
tracked. Despite this fact, a dose increase is still achieved for target 2 although in a
smaller amount as compared to target 1. This is very likely due to the fact that these
two tumors were not imaged in the same PET scan bed position and the last motion
phase of target 2 happens to be located at the edge of two PET scan bed positions.
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Figure 3.23: DVH comparison of EGRT and conventional treatments in the multiple-
target simulation.
Figure 3.24: GTV point-of-view dose distribution for target 1. The red arrows on
the coronal view point out the major motion directions for both targets. PTV and
GTV are contoured using white and black dashed lines, respectively.
Hence, the emissions from this last phase have very low chance for detection due to
the limited field of view. This is a limitation of the sequential bed position acquisition
protocol for PET imaging, which would not be an issue for an EGRT system due to
the helical nature of PET emission data collection.
3.3 Treatment of a Non-PET-avid Target
One problem that interests the radiation oncologist is: can EGRT treat tumor areas
which do not have specific radiotracer uptake? This is of high interest clinically since
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Figure 3.25: GTV point-of-view dose distribution for target 2. PTV and GTV are
contoured using white and black dashed lines, respectively.
it is shown by many studies that microscopic disease can extend beyond the region
of FDG uptake that is easily visualized in PET. Therefore, it is crucial for EGRT to
be capable of delivering radiation to the GTV parts which have little to no avidity
in the PET scan. However so far, the proposed EGRT approach is only shown to be
able to treat PET-avid regions preferentially.
To address this issue, three methods are proposed, demonstrated, and presented
in this section, which are referred to as margin extension algorithms. The essential
principle of margin extension algorithms is to properly manipulate the LOR response
behavior or create/transform LORs such that the GTV parts which are not PET-avid
can be treated similarly as PET-avid parts. To explain these methods, please see
Figure 3.28. We assume a case where the distribution of the non-PET-avid volume
(referred to as margin in the following explanation) and GTV is shown as in the
following figure. We further assume that the margin motion is very similar to the
GTV motion.
Correspondingly, the three methods are named and listed below:
1. Copy: The first method is to copy the dose from the original GTV to the
margin part. This can be achieved by shifting all the LORs toward the margin
extension direction in an amount that is appropriate for the margin size in the
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Figure 3.26: Dose maps of all 6 simulated phases in coronal view for both conven-
tional and EGRT treatments for target 1. Red means high dose and blue means low
dose. PTV and GTV are contoured using white and black dashed lines, respectively
for positional reference. The dose maps are displayed with the same window [0.4 0.9]
relative to the maximum GTV dose across all phases.
case of interest. Note that original LORs are still kept. In our implementation,
for each LOR, we create a new LOR in addition to the original LOR as shown
in Figure 3.28 (a). The spatial coordinates of all created LORs are designed
such that the dose distribution deposited for the PET-avid GTV is copied to
the location of non-PET-avid margin.
2. Broaden: The second method is to broaden the GTV dose distribution to ex-
tend it to the margin portion. This can be achieved by opening adjacent bMLC
leaves toward the margin extension direction when the current beamlet-response
is substantially perpendicular to the direction of desired margin extension. In
our practical implementation, whenever a leaf is opened, the adjacent leaf that
extends dose toward the margin direction is opened with a probability. This
probability is angle dependent and it has a larger value if the original leaf is
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Figure 3.27: Dose maps of all 6 simulated phases in coronal views for both conven-
tional and EGRT treatments for target 2. Red means high dose and blue means low
dose. PTV and GTV are contoured using white and black dashed lines, respectively
for positional reference. The dose maps are displayed with the same window [0.4 0.9]
relative to the maximum GTV dose across all phases.
more perpendicular to the margin extension direction, and vice versa.
3. Shift and broaden: In this method, LORs are first shifted to the center of
mass of the original GTV and margin combination. Then adjacent leaves are
opened to broaden the original dose distribution in both directions (i.e. toward
or away from margin) to accomplish the treatment goal.
All algorithms have passed the simulation tests with varying PTV sizes and setup
errors in all major directions. This is to demonstrate the algorithms will work regard-
less of these two factors. Margin extension algorithms demonstrate that EGRT has a
lot of flexibility in manipulating the LORs and the behavior of beamlet response to
achieve a desired treatment or dose distribution even in the absence of specific guid-
ance from tracer uptake. Copy, broaden, and shift and broaden are three methods of
implementation of the margin extension concept. In all methods, prior information
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(a) Copy (b) Broaden (c) Shift and Broaden
Figure 3.28: Illustration of margin extension methods.
such as the margin extension direction and position relative to the original GTV are
needed as inputs.
The above methods generate similar EGRT dose performance and hence we present
the simulation setup and associated results just from the broaden method for simplic-
ity, as shown in Figure 3.29. The results indicate that the center of mass of the dose
distribution has been shifted toward the margin extension direction.
Figure 3.29: Simulation setup and GTV dose distribution for the margin extension
algorithm. The GTV is in dark gray and the margin extension is in white. They are
both contoured.
Figures 3.30 (a) and (b) show DVH results for EGRT simulations without and with
the margin extension algorithm, respectively. In both scenarios, EGRT is compared
to the same conventional helical treatment as in the previous tumor tracking section.
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(a) Without margin extension (b) With margin extension




THE IMPACT OF MAJOR TREATMENT PARAMETERS
In our previous simulations in Chapter 3, some major simulation parameters are se-
lected mainly based on current existing technologies. For example, part of the system
design simulates the current Tomotherapy (Accuray, Sunnyvale, CA) machine such
as the number of bMLC leaves, the system radius, or typical treatment time. When
determining the activity level to simulate the emission process, values commonly ob-
served in clinical PET imaging are used. For some other parameters which are more
related to the EGRT concept, we choose them appropriately by balancing between
the considerations of algorithm design and the constraints of hardware manufacturing.
For example, ideally the rotation needs to be as fast as possible to freeze the tumor
motion with small system latency for better tracking performance. However, the
faster the rotation, the more difficult the manufacturing of the machine. Therefore,
the rotation speed is chosen to be 1 second in previous simulations. Finally, for those
parameters which do not have counterparts in current RT practice, we choose them
based on our estimation and experience. For example, the number of firing points is
chosen to be 256 since we think this would yield a satisfactory EGRT performance.
It is desirable to know how the EGRT performance is dependent on the choices
of all major simulation parameters. For instance, if a rotation period of 2 s can yield
similar EGRT performance as 1 s, this is very beneficial information since the burden
for building the EGRT hardware can therefore be significantly reduced with slower
rotation. Also, the answer to whether treatment time can be reduced without the
sacrifice of treatment effectiveness is equally important.
In this chapter, we have carried out a large number of simulations to find out
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the dependence of EGRT performance on the following major simulation parameters:
number of firing points, PTV margin size used, treatment time, EGRT spatial win-
dow, EGRT time window, rotation speed, and a combination of rotation speed and
EGRT time window. Five to seven representative values within a reasonable range
have been selected and simulated for each parameter.
DVH plots, the GTV point-of-view and motion tracking dose maps, and statistics
on number of beamlet responses, response time as well as phase lag have been used to
analyze the performance dependence. The response time of an LOR refers to the time
interval between its detection and response. The response time statistics includes the
minimum (min), the mean, and the standard deviation (std) of response times for all
LORs which have received radiation backprojection during treatment. In addition
to statistics of response time, we have also recorded the phase lag information for
each simulation. One beamlet response with phase Lag N means that the phase of
LOR response is N phases behind its actual emission phase. In other words, Lag 0
means that the LOR is responded in the same phase of its detection, representing
accurate tumor tracking for this LOR. Due to the fact that the motion is periodic, the
maximum possible phase lag is half of the total number of phases used in simulation.
For simplicity, all simulations are based on the raw EGRT algorithm. In other
words, no modulation or planning algorithms have been applied. Conventional treat-
ments are not simulated either and comparisons are done between EGRT simulations.
Last, conclusions in this chapter are drawn to be as general as possible. It is
however worth emphasizing that all the conclusions are based on the XCAT simulation
scenario.
4.1 Number of Firing Points
In previous standard simulations, 256 firing points have been used to densely sample
the gantry circle so that EGRT could use emission guidance almost from any angle.
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However, this only allows a travel time of about 4 ms between firing positions (at 1 s
revolution period) and we assume the bMLC can switch to a new configuration within
this travel time to prepare for dose delivery. 4 ms is a very challenging requirement
for current bMLC hardware. Therefore, it would be desirable to find out whether the
number of firing points can be reduced without compromising EGRT performance.
Five simulations with different numbers of firing points of 64, 96, 128, 192, and
256 have been carried out. The number of beamlet responses and associated response
time statistics, as well as the statistics of phase lag are listed in Table 4.1 and 4.2.
Table 4.1: Comparison of outputs from simulations with different number of firing
points
Response time statistics
# of firing points # of responses Min Mean Std
64 24893 0.135803 0.255117 0.062073
96 37575 0.135986 0.255146 0.061482
128 49932 0.135803 0.254677 0.061572
192 74988 0.135539 0.254593 0.06162
256 99941 0.135681 0.254745 0.061666
Table 4.2: Statistics of lag counts(in hundreds)/ratio for Table 4.1
Lag 0 Lag 1 Lag 2 Lag 3 Lag 4 Lag 5 Lag 6
67/0.27 180/0.72 0/0.00 0/0 0/0 0/0 0/0
104/0.27 270/0.72 0/0.00 0/0 0/0 0/0 0/0
139/0.28 358/0.71 0/0.00 0/0 0/0 0/0 0/0
205/0.27 543/0.72 1/0.00 0/0 0/0 0/0 0/0
275/0.27 722/0.72 1/0.00 0/0 0/0 0/0 0/0
As expected, the number of beamlet responses increases as the number of firing
points increases, and with an almost linear relationship, indicated in Figure 4.1.
Response time statistics is almost the same for all simulations as shown in Ta-
ble 4.1. This is as expected since the number of firing points should have no influence
on the temporal aspects of the beamlet response. This is the same case for the statis-
tics of phase lag where the ratio of each Lag N keeps almost constant although the
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Figure 4.1: Linear relationship between number of firing points and number of beam-
let responses.
sheer counts of responses keep increasing with more firing points.
It is worth mentioning that in all simulations where the EGRT time window is
0.5 s and rotation period is twice this value, the mean response time is found to be
about 0.255 s, which is approximately half of the time window. This coincides with
our prediction in Chapter 2. The response time minimum is about 0.13 s, which
represents the minimum inherent EGRT system latency under a rotation frequency
of 1 Hz. The standard deviation of 0.06 s shows that the response times of most
LORs fall within a window of [0.2 0.3] s.
It is also found out that the percentage of correctly responded LORs (i.e. without
phase lag) is about 27% and almost all the remaining responded LORs have a lag of
just one phase. Almost none of the LORs has a lag of more than two phases. This
is reasonable given that the time interval of a single phase is simulated to be 0.35 s
(a motion period of 4.2 s divided into 12 phases). Therefore, it indicates that tumor
tracking can be achieved (see Figure 4.3 and 4.4) with a lag of one phase as long as
most LORs are responded within a delay time that is less than the time interval of a
single phase.
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Figure 4.2: DVH comparison of EGRT treatments with different numbers of firing
points. DVH curves are distinguished with increasing line width as the number of
firing points increases, and with alternating styles of solid and dashed lines (starting
from solid line style).
Figure 4.3: GTV point-of-view dose maps for EGRT treatments with different num-
bers of firing points: 64, 128, and 256 (from left to right).
Figure 4.2 illustrates the DVH comparison of five simulations which are all nor-
malized to have the same mean lung dose. DVH results show that the number of
firing points has little effect on the EGRT dose performance except that a smaller
number of firing points yields a smaller GTV minimum dose. This is very beneficial
for the development of the EGRT hardware since with a reduced number of firing
points, the requirement of fast bMLC switching speed can be relaxed.
Figure 4.3 depicts the GTV point-of-view dose distribution comparison for dif-
ferent numbers of firing points: 64, 128, and 256. The GTV dose maps confirm the
conclusion drawn from the DVH comparison.
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Figure 4.4: Motion tracking maps in coronal view for EGRT treatments with different
numbers of firing points: 64, 128, and 256 (from left to right).
Figure 4.4 shows the dose tracking of all 12 motion phases from the coronal view.
As shown in the figure, the dose map with the least number of firing points shows
the most noisy tracking due to the reduced number of beamlet responses. However,
accurate tumor tracking is preserved in all cases.
4.2 PTV Margin Size
The amount of margin to be used is a critical choice in RT treatments. With larger
margins, the tumor will be more likely covered all the time during treatment, at the
price of more irradiated healthy tissue. Therefore, it is a trade-off between the control
of treatment uncertainty and dose to OARs.
Five simulations have been carried out in this section to understand how PTV
margin size would affect EGRT performance. In all simulations, the PTV is defined
to be the ITV plus margin. Margins of 0, 2, 4, 6, and 8 mm are used while other
parameters are kept the same for all simulations.
The number of beamlet responses and associated response time statistics, as well
as the statistics of phase lag are listed in Table 4.3 and 4.4. The response time
statistics changes little with varying margin sizes since the temporal aspects of EGRT
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treatment are not related to the margin size used. The statistics of phase lag remains
similar across all simulations as shown in Table 4.12.
Table 4.3: Comparison of output from simulations with different margin sizes
Response time statistics
Margin size(mm) # of responses Min Mean Std
0 45079 0.135681 0.254141 0.061363
2 53483 0.135681 0.254318 0.061387
4 62669 0.135681 0.254572 0.061346
6 75194 0.135681 0.254822 0.061533
8 85580 0.135681 0.254852 0.061667
Table 4.4: Statistics of lag counts(in hundreds)/ratio for Table 4.3
Lag 0 Lag 1 Lag 2 Lag 3 Lag 4 Lag 5 Lag 6
123/0.27 326/0.72 0/0.00 0/0 0/0 0/0 0/0
146/0.27 387/0.72 0/0.00 0/0 0/0 0/0 0/0
172/0.27 453/0.72 1/0.00 0/0 0/0 0/0 0/0
206/0.27 544/0.72 1/0.00 0/0 0/0 0/0 0/0
234/0.27 620/0.72 1/0.00 0/0 0/0 0/0 0/0
As expected, the number of beamlet responses increases with the margin size
(which can be easily explained using the PTV intersection criterion), and with an
approximate linear relationship, indicated in Figure 4.5.
Figure 4.6 illustrates the DVH comparison of five simulations (i.e. 0, 2, 4, 6, 8 mm
margin) which are all normalized to have the same mean lung dose. The DVH shows
that the EGRT dose performance is very sensitive to the margin size used. It also
implies that the background signal plays a significant role for giving dose to healthy
tissue (since if there is no background signal, DVH curves should be very similar for
all cases). Therefore, for RT treatments with large uncertainty which entails the use
of a larger PTV margin, EGRT can achieve more dose benefits.
Figure 4.7 depicts the GTV point-of-view dose distribution comparing the above
simulations with different PTV margin sizes (0, 4, and 8 mm), which supports the
90
Figure 4.5: Linear relationship between margin size and number of beamlet re-
sponses.
DVH result. Note that the PTV contour is chosen from the 8 mm margin case for
reference purposes in this figure and Figure 4.8.
Figure 4.8 shows correspondingly the dose tracking of all 12 motion phases from
the coronal view. As shown in the figure, healthy tissue will be irradiated to the
extent determined by the PTV margin size used, which therefore affects the GTV
dose escalation level. However, accurate tumor tracking is preserved in all cases
regardless of margin size.
4.3 Treatment Time
Treatment time is a very important consideration for any type of radiation therapy
technique since it determines how many patients a hospital can treat each day. Ideally
the shorter the treatment time, the more likely it will be favored by the clinical users.
In our previous simulations, we simulate a treatment time of about 20 min of beam-on
time. In this section, five simulations with treatment time of 400, 800, 1200, 1600,
and 2000 s have been conducted to explore its influence on the EGRT treatment
performance.
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Figure 4.6: DVH comparison of EGRT treatments with different margin sizes. DVH
curves are distinguished with increasing line width as the margin size decreases, and
with alternating styles of solid and dashed lines (starting from dashed line style).
Figure 4.7: GTV point-of-view dose maps for EGRT treatments with different margin
sizes: 0, 4, and 8 mm (from left to right).
The number of beamlet responses and associated response time statistics are listed
in Table 4.5.
As expected, the number of beamlet responses increases with the treatment time,
and with an approximate linear relationship, indicated in Figure 4.9. The response
time statistics as well as statistics of phase lag changes little with varying treatment
time as shown in Table 4.5 and 4.6. This is due to the fact that different treatment
times result in different table speeds however the rotation speed and EGRT time
window are kept constant in all cases.
Figure 4.10 illustrates the DVH comparison of five simulations (i.e. treatment
time of 400, 800, 1200, 1600, and 2000 s) which are all normalized to have the same
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Figure 4.8: Motion tracking maps in coronal view for EGRT treatments with margin
sizes: 0, 4, and 8 mm (from left to right).
Table 4.5: Comparison of output from simulations with different treatment times
Response time statistics
Treatment time(s) # of responses Min Mean Std
400 21414 0.136292 0.255297 0.060674
800 42686 0.135986 0.253749 0.061446
1200 63798 0.135803 0.254283 0.061126
1600 85706 0.135864 0.255083 0.061351
2000 106214 0.135864 0.255073 0.061224
mean lung dose. DVH results show that the EGRT dose performance is not sensitive
to the treatment time within the range of 400 to 2000 s in this XCAT phantom case.
This implies for EGRT treatment, treatment time can be reduced while maintaining
dose distribution fidelity.
Figure 4.11 depicts the GTV point-of-view dose distribution comparison for the
simulations with treatment times of 400, 1200, and 2000 s.
Figure 4.12 shows the dose tracking of all 12 motion phases from the coronal
view correspondingly for Figure 4.11. As it is shown, an aspect of reduced treatment
time is nosier dose tracking maps. However, the point-of-view map reflects the true
distribution that the tumor sees and is maintained as can be seen from the DVH
plots.
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Table 4.6: Statistics of lag counts(in hundreds)/ratio for Table 4.5
Lag 0 Lag 1 Lag 2 Lag 3 Lag 4 Lag 5 Lag 6
59/0.27 154/0.72 0/0.00 0/0 0/0 0/0 0/0
117/0.27 308/0.72 0/0.00 0/0 0/0 0/0 0/0
175/0.27 461/0.72 1/0.00 0/0 0/0 0/0 0/0
234/0.27 620/0.72 1/0.00 0/0 0/0 0/0 0/0
291/0.27 768/0.72 2/0.00 0/0 0/0 0/0 0/0
Figure 4.9: Linear relationship between treatment time and number of beamlet
responses.
4.4 EGRT Spatial Window
The EGRT basic algorithm says that the LOR must intersect the Linac source within
an angle tolerance on the gantry circle specified by the EGRT spatial window. The
smaller the EGRT spatial window, the more accurate the beamlet response. Six
simulations with different spatial windows of ±0.25◦, ±0.5◦, ±0.75◦, ±1◦, ±2◦, ±5◦
have been carried out to understand how the EGRT spatial window would affect
EGRT performance.
The number of beamlet responses and associated response time statistics, as well
as the statistics of phase lag are listed in Table 4.7 and 4.8.
As one would expect, the number of beamlet responses increases as the spatial
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Figure 4.10: DVH comparison of EGRT treatments with different treatment times.
DVH curves are distinguished with increasing line width as the treatment time in-
creases, and with alternating styles of solid and dashed lines (starting from dashed
line style).
Figure 4.11: GTV point-of-view dose maps for EGRT treatments with different
treatment times: 400, 1200, and 2000 s (from left to right).
window increases, and with an almost linear relationship, indicated in Figure 4.13.
Since only the EGRT spatial window has been changed and this is not related to
the temporal aspects, the response time statistics is almost the same for all simulations
as shown in Table 4.7. This is the same case for the statistics of phase lag where the
ratio of each Lag N keeps almost constant although the sheer counts increase with a
wider spatial window.
Figure 4.14 illustrates the DVH comparison of six simulations which are all nor-
malized to have the same mean lung dose. The DVH shows that the larger the spatial
window, the worse the dose performance. However, within the range of [±0.25◦ ±1◦],
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Figure 4.12: Motion tracking maps in coronal view for EGRT treatments with dif-
ferent treatment times: 400, 1200, and 2000 s (from left to right).
Table 4.7: Comparison of outputs from simulations with different EGRT spatial
windows
Response time statistics
Spatial window # of responses Min Mean Std
±0.25◦ 67529 0.135986 0.255987 0.061526
±0.5◦ 133288 0.135681 0.25548 0.061614
±0.75◦ 196728 0.134583 0.254982 0.061511
±1◦ 258372 0.134583 0.254326 0.061477
±2◦ 487009 0.131287 0.252247 0.061529
±5◦ 1029183 0.122864 0.246043 0.061479
the difference in GTV dose is small.
Figure 4.15 depicts the GTV point-of-view dose distribution comparison for spatial
windows of ±0.25◦, ±1◦, and ±5◦.
Figure 4.16 shows the dose tracking of all 12 motion phases from the coronal view.
As shown in the figure, the smallest spatial window shows the most accurate tumor
tracking, with largest noise due to the reduced number of beamlet responses. For ±5◦
spatial window, no obvious lag in dose tracking is observed, although inferior dose
escalation is present due to the increase of spatial error.
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Table 4.8: Statistics of lag counts(in hundreds)/ratio for Table 4.7
Lag 0 Lag 1 Lag 2 Lag 3 Lag 4 Lag 5 Lag 6
183/0.27 490/0.72 1/0.00 0/0 0/0 0/0 0/0
365/0.27 965/0.72 2/0.00 0/0 0/0 0/0 0/0
538/0.27 1424/0.72 3/0.00 0/0 0/0 0/0 0/0
711/0.27 1868/0.72 4/0.00 0/0 0/0 0/0 0/0
1372/0.28 3488/0.71 8/0.00 0/0 0/0 0/0 0/0
3081/0.29 7193/0.69 16/0.00 0/0 0/0 0/0 0/0
Figure 4.13: Linear relationship between EGRT spatial window and number of beam-
let responses.
4.5 EGRT Time Window
The EGRT time window is the time interval in the past from which the Linac selects
LORs for radiation response when arriving at each firing point. Since this is the
parameter that directly relates to the temporal accuracy of tumor tracking, it needs
to be properly determined. To understand how the EGRT time window (given the
same rotation frequency of 1 Hz) would affect EGRT performance, the results of six
simulations with different EGRT time windows are obtained for comparison. These
six simulations are exactly the same except that the time windows are: 0.25, 0.5,
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Figure 4.14: DVH comparison of EGRT treatments with different spatial windows.
DVH curves are distinguished with increasing line width as the EGRT spatial window
increases, and with alternating styles of solid and dashed lines (starting from solid
line style).
Figure 4.15: GTV point-of-view dose maps for EGRT treatments with different
EGRT spatial windows: ±0.25◦, ±1◦, and ±5◦ (from left to right).
0.75, 1, 1.25, and 5 s.
The number of beamlet responses and associated response time statistics, as well
as the statistics of phase lag are listed in Table 4.9 and 4.10.
As expected, the number of beamlet responses increases as the EGRT time window
increases, and with an almost linear relationship, indicated in Figure 4.17.
The response time statistics in Table 4.9 shows that the fastest response to an
LOR is about 0.13 s after its detection, which is independent of the EGRT time
window used. With more LORs included as candidates for radiation response as
the time window increases, both the mean and standard deviation of response times
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Figure 4.16: Motion tracking maps in coronal view for EGRT treatments with dif-
ferent spatial windows: ±0.25◦, ±1◦, and ±5◦ (from left to right).
Table 4.9: Comparison of outputs from simulations with different EGRT time win-
dows
Response time statistics
Time window (s) # of responses Min Mean Std
0.25 63315 0.135681 0.200091 0.030148
0.5 133288 0.135681 0.25548 0.061614
0.75 192781 0.135681 0.39269 0.212331
1 258844 0.135681 0.497978 0.257312
1.25 314866 0.135681 0.622905 0.35595
5 1029948 0.135681 2.257822 1.425035
increase. Table 4.10 depicts the statistics of phase lag for all responded beamlets. As
indicated by the results, the smaller the window, the less the phase lag and hence
the better the tumor tracking. When the time window is 5 s (larger than the period
4.2 s), all possible phase lags happen. Also note that, the number of Lag 0 counts
stays the same for windows of 0.5, 0.75, 1, and 1.25 s. This is because this quantity
is saturated, which implies that any time window increase within this range is not
useful.
Figure 4.18 illustrates the DVH comparison of six simulations which are all nor-
malized to have the same mean lung dose. Figure 4.19 depicts the GTV point-of-view
dose distribution comparison for time windows of 0.25, 1, and 5 s.
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Figure 4.17: Linear relationship between EGRT time window and number of beamlet
responses.
Table 4.10: Statistics of lag counts(in hundreds)/ratio for Table 4.9
Lag 0 Lag 1 Lag 2 Lag 3 Lag 4 Lag 5 Lag 6
272/0.43 360/0.56 0/0 0/0 0/0 0/0 0/0
365/0.27 965/0.72 2/0.00 0/0 0/0 0/0 0/0
365/0.18 987/0.51 553/0.28 21/0.01 0/0 0/0 0/0
365/0.14 987/0.38 1016/0.39 219/0.08 0/0 0/0 0/0
365/0.11 987/0.31 1016/0.32 539/0.17 240/0.07 0/0 0/0
1030/0.10 2099/0.20 1988/0.19 1376/0.13 1577/0.15 1555/0.15 671/0.06
Figure 4.20 shows the dose tracking of all 12 motion phases from the coronal
view. As shown in the figure, the smallest time window shows the most accurate
tumor tracking. For a 5 s time window, both lag in dose tracking and inferior dose
escalation are observed.
4.6 Rotation Period
In our previous simulations, 1 s has been used as the rotation period. Such fast
rotation imposes engineering challenges to build the EGRT system. In this section,
we investigate how EGRT performance is related to the gantry rotation speed. Eight
simulations of different rotation periods (i.e. 1, 1.5, 2, 2.5, 3.5, 4, 6, 8 s) have been
100
Figure 4.18: DVH comparison of EGRT treatments with different EGRT time win-
dows. DVH curves are distinguished with increasing line width as the EGRT time
window increases, and with alternating styles of solid and dashed lines (starting from
solid line style).
Figure 4.19: GTV point-of-view dose maps for EGRT treatments with EGRT time
windows: 0.25, 1, and 5 s (from left to right).
conducted for this investigation. A 0.5 s time window has been kept constant for
all eight simulations. In this case, it is expected that when the rotation period gets
larger (i.e. rotation is slower), the total number of beamlet responses become smaller
and eventually reduces to zero after a certain value. This can be explained using
Figure 4.21.
Assume the Linac arrives at the firing position located at point G. Since in the
simulation each detector arc covers 90 degrees, the detector pair will be at positions




. To obtain a qualified LOR for response, the
algorithm will check the LOR detection history within an EGRT time window of 500
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Figure 4.20: Motion tracking maps in coronal view for EGRT treatments with dif-
ferent EGRT time windows: 0.25, 1, and 5 s (from left to right).
ms and with a spatial window of ±0.5◦. In other words, only LORs that have been
detected by the detector in the previous 500 ms and at the same time have almost
intersected the X-ray source will have a chance to be responded to. When the rotation
period is 4 seconds, 500 ms corresponds to a travel range of 45 degrees for the Linac,
i.e. Linac travels from Point H to G. Therefore, the only possible LOR that is eligible
for radiation response is line EOF in such a case. When the rotation period is larger
than 4 seconds, no LOR will be possibly detected and responded to at any firing
point. This coincides with our simulation results where there is no beamlet response
from simulations with rotation periods of 4, 6, and 8 s. Therefore, only the results
from simulations with rotation periods of 1, 1.5, 2, 2.5, and 3.5 s are shown.
The number of beamlet responses and associated response time statistics, as well
as the statistics of phase lag are listed in Table 4.11 and 4.12. The response time
statistics are different from previous sets of simulations. The minimum and mean of
response times keep increasing with slower rotation. This is because when rotation
period is long, the Linac responses tend to fall behind the LOR detections. Also due
to this reason, the standard deviation is decreasing under a fixed time window.
Since the EGRT time window is fixed to be 500 ms, no LOR with a lag more than
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Figure 4.21: EGRT geometry for the explanation of the general relationship between
number of beamlet responses and rotation speed.
Table 4.11: Comparison of output from simulations with different rotation periods
Response time statistics
Rotation period (s) # of responses Min Mean Std
1 133288 0.135681 0.25548 0.061614
1.5 115188 0.203888 0.36186 0.079402
2 62377 0.270874 0.399993 0.060645
2.5 29861 0.339874 0.4331 0.042979
3.5 1292 0.475403 0.49226 0.005545
500 ms will be responded to. Therefore, for all five listed simulations, the phase lag is
kept within 2 phases as shown in Table 4.12. Also note that with decreasing rotation
speed, the phase lag of beamlet responses tends to shift from Lag 0 to Lag 2.
As explained by Figure 4.21, the number of beamlet responses decreases as the
rotation period increases, and with an approximate linear relationship, indicated in
Figure 4.22
Figure 4.23 illustrates the DVH comparison of four simulations (i.e. 1, 1.5, 2, 2.5
s) which are all normalized to have the same mean lung dose. The result of 3.5 s
is not listed since the slow rotation results in a non-comparable dose distribution.
DVH shows that the EGRT dose performance has little to do with the rotation speed
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Table 4.12: Statistics of lag counts(in hundreds)/ratio for Table 4.11
Lag 0 Lag 1 Lag 2 Lag 3 Lag 4 Lag 5 Lag 6
365/0.27 965/0.72 2/0.00. 0/0 0/0 0/0 0/0
93/0.08 926/0.80 132/0.11 0/0 0/0 0/0 0/0
14/0.02 507/0.81 101/0.16 0/0 0/0 0/0 0/0
0/0.00 227/0.76 71/0.23 0/0 0/0 0/0 0/0
0/0 7/0.58 5/0.41 0/0 0/0 0/0 0/0
Figure 4.22: Linear relationship between rotation period and number of beamlet
responses.
within a range of [1 2.5] s, as long as the EGRT time window is constant. This is
beneficial for the manufacturing of the EGRT system since now the bMLC switching
speed can be reduced potentially by a factor of at least 2.5 (and potentially more
when combined with other parameter changes such as the reduction of firing points,
see section 4.1). A compromise is that the number of beamlet responses is decreasing
yielding potentially longer treatment times required to achieve a specific dose target.
Figure 4.24 depicts the GTV point-of-view dose distribution comparison for the
above three simulations with rotation periods of 1, 2, and 2.5 s.
Figure 4.25 shows the dose tracking of all 12 motion phases from the coronal view.
As shown in the figure, the dose map with largest rotation period shows the most
noisy tracking due to the reduced number of beamlet responses. However, accurate
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Figure 4.23: DVH comparison of EGRT treatments with different rotation periods.
DVH curves are distinguished with increasing line width as the rotation period in-
creases, and with alternating styles of solid and dashed lines (starting from solid line
style).
Figure 4.24: GTV point-of-view dose maps for EGRT treatments with rotation
periods: 1, 2, and 2.5 s (from left to right).
tumor tracking is preserved in all cases.
4.7 Combination of Rotation Period and Time Window
Due to the special detector placement in EGRT (one pair of symmetrically opposed
90◦ arcs), it is preferred that the EGRT time window is half of the rotation period.
This can be explained again using Figure 4.21. In this case, when the Linac arrives at
each firing point, it evaluates the LORs that have been detected within a time window
that is half of the rotation period for beamlet responses. Within this window, the
Linac always finishes traveling a 180◦ arc and the detector pair has a full coverage of
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Figure 4.25: Motion tracking maps in coronal view for EGRT treatments with dif-
ferent rotation periods: 1, 2, and 2.5 s (from left to right).
the gantry circle due to its paired structure. Therefore, this combination of rotation
period and time window ensures that the emission guidance will be fully utilized for
any firing point.
Five simulations with a rotation period/time window combination of 1/0.5, 2/1,
4/2, 6/3, and 8/4 s/s have been carried out to explore its influence on EGRT perfor-
mance. The number of beamlet responses and associated response time statistics are
listed in Table 4.13. The response time statistics change significantly with varying
rotation periods. The same conclusion holds true that the mean of response times
is approximately half of the EGRT time window for all simulations. The number of
beamlet responses slightly decreases with the reduced rotation speed.
Table 4.13: Comparison of output from simulations with different combinations of
rotation period and time window
Response time statistics
Combination (s/s) # of responses Min Mean Std
1/0.5 133288 0.135681 0.25548 0.061614
2/1 128542 0.270874 0.508004 0.122845
4/2 121251 0.541046 1.008661 0.245819
6/3 114433 0.812988 1.501988 0.367014
8/4 108229 1.08374 1.990673 0.489642
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The statistics of phase lag are listed in Table 4.14. It indicates that the phase lag
tends to shift from Lag 0 to Lag 6 (the maximum possible phase lag) as the rotation
period increases.
Table 4.14: Statistics of lag counts(in hundreds)/ratio for Table 4.13
Lag 0 Lag 1 Lag 2 Lag 3 Lag 4 Lag 5 Lag 6
365/0.27 965/0.72 2/0.00. 0/0 0/0 0/0 0/0
14/0.01 684/0.53 582/0.45 4/0.00 0/0 0/0 0/0
0/0 28/0.02 385/0.31 509/0.42 279/0.23 8/0.00 0/0
0/0 0/0 40/0.0357 273/0.2390 340/0.29 314/0.27 175/0.15
0/0 0/0 0/0 68/0.06 334/0.30 448/0.41 230/0.21
Figure 4.26 illustrates the DVH comparison of five simulations (i.e. 1, 2, 4, 6,
and 8 s rotation periods) which are all normalized to have the same mean lung dose.
The DVH shows that the EGRT dose performance decreases with slower rotation as
expected. However, the reduction of the DVH performance is not as significant as one
would expect. This is likely due to the fact that although tumor tracking contains
significant lag for large rotation periods (as shown in Figure 4.28), the mean GTV
position is always equivalently targeted as in this special XCAT phantom case.
Figure 4.27 depicts the GTV point-of-view dose distribution comparison for the
above three simulations with combinations of 1/0.5, 4/2, and 8/4 s/s.
Figure 4.28 shows the dose tracking of all 12 motion phases from the coronal view.
As shown, significant tracking lag is observed for the rotation period of 8 s.
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Figure 4.26: DVH comparison of EGRT treatments with different rotation periods
and time windows. The DVH curves are distinguished with increasing line width as
the rotation period increases, and with alternating styles of solid and dashed lines
(starting from solid line style).
Figure 4.27: GTV point-of-view dose maps for EGRT treatments with rotation
periods and time windows: 1/0.5, 4/2, and 8/4 s/s (from left to right).
Figure 4.28: Motion tracking maps in coronal view for EGRT treatments with dif-
ferent rotation periods and time windows: 1/0.5, 4/2, and 8/4 s/s (from left to right).
108
CHAPTER V
EGRT TREATMENT PLANNING SCHEME
Treatment planning is an essential component in RT, as stated in Chapter 2. Any
type of new radiation therapy modality should have an associated treatment planning
solution to provide the capability of achieving IMRT-type planning modulation as in
current conventional RT. The feasibility of tumor tracking and a primitive modula-
tion method to compensate for attenuation have been demonstrated for EGRT using
Monte Carlo (MC) simulations with a water phantom, physical phantom experiments,
and a 4D digital patient model in Chapter 3.
In this chapter, we develop a planning scheme for EGRT to accomplish sophisti-
cated intensity modulation based on an IMRT plan while preserving tumor tracking,
thereby improving upon the basic EGRT treatment with escalated GTV dose with-
out increasing dose to OARs. Both the XCAT phantom and clinical patient data
are used for demonstration. We first briefly describe the design of a complete EGRT
treatment with the proposed planning scheme. We then present the method of in-
corporating planning modulation into EGRT and associated evaluation studies with
results. Finally we discuss other considerations, benefits, and limitations of this pro-
posed EGRT planning scheme. Note that in this work, we assume EGRT is applied
as an implementation of the motion-encompassing method, i.e. the ITV approach.
5.1 Treatment Scheme
Figure 5.1 illustrates a summarized workflow of the proposed EGRT treatment scheme
which uses the proposed planning scheme.
The EGRT treatment scheme based on the ITV approach is composed of three
major steps: simulation, pre-treatment, and treatment using the EGRT algorithms.
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Figure 5.1: EGRT treatment scheme. The entire EGRT treatment is divided into
three distinct components. Simulation and pre-treatment include the sequential pro-
cedures of imaging, contouring, tracer injection, and patient setup via PET/MVCT
to update the planning map. The treatment component includes the two repeating
operations of LOR detection and radiation response, which relies on the pre-computed
planning map to provide the LOR response probabilities, i.e. leaf opening probabili-
ties.
In simulation, the patient first undergoes PET/CT imaging for contouring and form-
ing the initial treatment plan. Retrospective CT and/or breath-hold CT scans are
used to obtain the desired data for planning. The maximum intensity projection can
be determined from the 4DCT dataset to obtain the ITV encompassing the full extent
of target movement. Margins are added to the ITV to define the PTV to account
for patient setup error and residual motion uncertainty. The breath-hold CT image,
contours, PET image, and dose prescription are used to calculate a planning map
via EGRT’s planning scheme (discussed in section 5.2). On the treatment day, the
patient is first administered with a PET radiotracer and waits in a waiting room for
the optimal uptake time as in a standard PET imaging protocol. The patient is then
positioned on the treatment couch and a simultaneous PET/MVCT scan of short
duration (< 2 min) is acquired with the EGRT system for alignment and calibration,
and additionally to update the planning map (the tracer distribution change within
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the treatment fraction is assumed to be small). The treatment is composed of two
repeating operations: LOR detection and minimal-lag radiation response. The ba-
sic EGRT algorithm sifts out qualified LORs for responses. To achieve the desired
intensity modulation, the treatment relies on the planning map to specify the LOR
response probabilities and is described below.
5.2 The Proposed EGRT Planning Scheme
In this section, we develop a planning scheme for EGRT to achieve specific planning
constraints/goals as in conventional optimized treatments. Two types of constraints
are typically used in IMRT optimization: one for OARs which limits the maximum
dose to a certain percentage of each volume, and one for the PTV which requires the
delivery of a prescription dose with high dose conformality. We aim to demonstrate
that, as compared with other ITV approaches, the same planning constraints can
be met for OARs in EGRT based on the same IMRT plan. At the same time, the
GTV dose can be escalated due to inherent tracking, with the dose reduced for the
non-GTV portions within the PTV.
The proposed planning scheme is based on EGRT’s unique treatment geometry,
which involves the concept of sinogram space as described in section 2.5.2. Dose
modulation can therefore be achieved via applying an LOR response probability to a
particular sinogram bin which is used to decide whether to open the corresponding
bMLC leaf for a qualified LOR. We refer to the probability distribution across all
bins in sinogram space as the planning map.
5.2.1 The Overall Scheme
Under the geometric approximation of mapping LOR paths into sinogram space, the
delivered dose of EGRT can be written as
d = D ·Σ · b (6)
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where vector b has a length of the number of elements in sinogram space, and specifies
the total number of qualified LORs for each sinogram bin in the EGRT treatment.
Matrix D is a group of beamlet kernels. The jth column of D is the vectorized 3D
dose distribution resulting from a beamlet with unit intensity along the LOR path
specified by the jth element of the sinogram. Σ is the planning map in the form of a
diagonal matrix, whose jth diagonal element corresponds to the response probability
to be applied for the LORs that correspond to the jth sinogram bin. In other words,
Σ represents the intensity modulation applied in EGRT.
The planning map Σ can be further decomposed into three daughter modulation
maps as
Σ = Φ(ΣA ·ΣP ·ΣXm) (7)
where ΣA, ΣP , and ΣXm are all diagonal matrices whose diagonal elements represent
modulation accounting for different purposes and have a range of [0 1]. They are
referred to as the attenuation correction map, PET activity normalization map, and
modified IMRT plan map, respectively. Φ is an operator that normalizes the resultant
diagonal elements to have a maximum value of 1. The overall modulation contributed
by ΣA and ΣP aims to compensate for a non-uniform LOR distribution before any
other modulation is applied. Specifically, ΣA represents the modulation to remove
the attenuation effect and ΣP represents the component to correct for the effect of a
non-uniform PET activity distribution outside of the PTV. This can be due to non-
specific uptake in tissue surrounding the target (e.g. FDG-uptake in the heart, liver
and other organs, as well as uptake due to inflammation). ΣXm represents the main
intensity modulation to be applied in EGRT and is derived from the IMRT plan of a
conventional motion-encompassing treatment.
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5.2.2 PET Activity Normalization and Attenuation Correction
One distinct feature of EGRT is that the delivery of radiation is reactive since it relies
on detected LORs as the delivery medium. Therefore, if no modulation is applied
and beamlet intensity/duration is constant, the resultant EGRT dose distribution
essentially depends on the distribution of detected LORs, which can be non-uniform
due to an inhomogeneous PET activity distribution and the non-isotropic attenuation
of annihilation photons through the subject.
Non-specific and non-uniform uptake is commonly observed in conventional PET
imaging. It is part of the information that PET images convey and therefore no cor-
rection is performed during the diagnostic imaging process. However, non-specific and
non-uniform uptake in the background needs to be accounted for in EGRT treatments.
This is due to the fact the LOR response rates are proportional to the aggregate ac-
tivity along their response paths. Therefore, an inhomogeneous activity distribution
yields a non-uniform LOR response distribution. To correct for this effect, we cal-
culate a PET activity normalization map that is inversely proportional to the LOR
detection rates in sinogram space. Specifically, the line integrals of activity are first
efficiently pre-calculated using Siddon’s algorithm [90] from the reconstructed PET
images during pre-treatment for all sinogram bins. The PET activity inside the PTV
region is set to zero before projections are calculated to remove bias from uptake in or
near the moving GTV. We denote the minimum line integral of PET activity values
across all non-zero bins as vPmin. For sinogram bin j with associated line integral value






where superscript P indicates the correction for the PET activity effect.
The same issue arises with the non-isotropic attenuation of annihilation photons,
which also results in non-uniform LOR detection rates and therefore a non-uniform
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radiation response distribution. Likewise, the attenuation effect needs to be corrected
before any planning modulation is applied. Please refer to section 2.5.2.1 for a detailed
discussion on attenuation correction in EGRT and here we present a brief review.
Similarly as with the PET activity normalization map, the line integrals of at-
tenuation coefficients are first efficiently pre-calculated from the planning patient CT
images (and updated from the pre-treatment PET/MVCT scan) for all sinogram bins.
Let us denote the maximum line integral value across all bins as aAmax . For sinogram
bin j and a line integral value aAj , its leaf opening probability is given as:
pAj = e
−aAmax+aAj (9)
where the superscript A refers to attenuation effect correction. Both Eqns. 8 and 9
are determined heuristically and aim to remove their corresponding effects by com-
pensating for lower LOR detection likelihood with higher LOR response probability,
and vice versa.
5.2.3 Modified IMRT Plan
With the LOR response distribution made uniform through PET activity normaliza-
tion and attenuation correction, EGRT can now incorporate a traditional IMRT plan
to improve the dose performance. For the clinical patient case, we use the Pinnacle3
workstation (Philips Healthcare, Fitchburg, WI) as our optimization engine. For the
digital patient, this task is achieved using an optimization package called MOSEK
(http://www.mosek.com/) and a beamlet-based optimization algorithm which aims
to minimize the L2-norm of the difference between the calculated dose and the pre-




λi(Aix− di)T (Aix− di) (10)
subject to x > 0 (11)
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where the index i denotes different structures including PTV and OARs, λi is the
relative importance factor [109], each column of matrix Ai is the beamlet kernel
corresponding to the ith structure, x is a 1D vector that consists of row-wise con-
catenations of beamlet intensities for all fields, and di is the vectorized prescribed
dose of the ith structure. The traditional aperture constraint that stems from the
physical constraints of the MLC is not included since the EGRT delivery relies on a
probability scheme which is not limited by such a constraint.
To reduce the field complexity and the intensity difference between adjacent fields
(or firing points), which is also preferred in EGRT’s probability-based delivery scheme,





















subject to x > 0 (13)
where β1 is the penalty weight associated with the first regularization term which
aims to reduce the complexity within each field while β2 is the penalty weight of the
second regularization term aiming to reduce the complexity between adjacent fields,
Nf is the number of fields and Nu is the number of beamlets within a field. After
intensity optimization based on formula 12, the resultant fluence map is converted
into the IMRT plan map.
The IMRT plan map is optimized for conventional external beam radiation ther-
apy. It is sub-optimal for EGRT since it does not take into account the GTV dose
peaking effect in EGRT treatment. Therefore, dose to nearby OARs may be increased
relative to the IMRT planning value, unless a modification to the original IMRT plan
115
is employed. To achieve the same planning constraints for OARs, we modify the orig-
inal transformed IMRT plan map, which is implemented by multiplying an additional
probability for sinogram bins whose corresponding spatial orientations intersect the
OARs of interest. The specific probabilities are empirically chosen for different OARs
with a typical range of [0.5 1], depending on their proximities to the GTV.
5.2.4 Workflow of EGRT’s Planning Scheme
Figure 5.2: Calculation of the planning map. To obtain the final planning map,
three daughter modulation maps need to be calculated first: a modified IMRT plan
map, attenuation correction map, and PET normalization map. The final planning
map is obtained as the product of these three maps with a subsequent normalization.
Figure 5.2 shows a workflow for calculating the EGRT planning map. The plan-
ning map is calculated as a multiplication of the modified IMRT plan map, attenua-
tion correction map, and PET activity normalization map followed by normalization.
These three maps are built in the same sinogram space of dose delivery and contain
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the LOR response probability values to account for the corresponding types of mod-
ulation discussed above. To obtain the modified IMRT plan map, the stack of fluence
maps are first calculated through conventional inverse planning optimization using
simulation CT imaging as described above. The fluence maps are then interpolated
and reshaped into sinogram space, and subsequently modified to further suppress
dose to nearby OARs. The attenuation correction map is converted from the forward
projected CT image based on Eqn. 9. A 511 keV CT image is used in this process,
which can be transformed from the pre-treatment MVCT scan. Similarly, the PET
activity normalization map is calculated from the projection of the pre-treatment
PET scan, excluding the PTV region, based on Eqn. 8. For the clinical patient case,
the reconstructed PET images are used as the estimate of the actual PET activity
map.
5.2.5 EGRT Simulation Workflow
Simulation studies are performed with both a digital and a clinical patient with mov-
ing tumors in the lung region to investigate the performance of the proposed EGRT
treatment. The same digital patient as in Chapter 3 is used. To simulate realistic
emission data from the digital patient, the same GATE package is used. In the clinical
patient case, raw list mode data from a PET/CT Discovery system (GE Healthcare,
Waukesha, WI) are retrospectively used for the study, under an institutional review
board (IRB) protocol. Both raw PET list mode data and reconstructed, binned
4DPET datasets are used in the simulation. The simulation of Linac dose delivery
uses the same VMC++. Both VMC++ and GATE have been validated against well
established MC codes and commercial PET systems, respectively.
To simulate a dynamic EGRT treatment as a complete motion management
scheme, the simulation workflow for the clinical patient scenario is shown in Fig-
ure 5.3.
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Figure 5.3: EGRT simulation workflow for the clinical patient case (starting from the
shaded module on the top left). The workflow is divided into four major segments:
imaging, planning, EGRT delivery, and dose evaluation. The first three segments de-
scribe a complete radiation therapy chain for moving tumors and the dose evaluation
segment is designed to evaluate the dose performance of the treatment.
The entire workflow is segmented into four major sequential steps. The simulation
starts from the imaging step where datasets of PET list mode, 4DCT and breath-
hold CT images are acquired. PET list mode and 4DCT projection data are collected
at the same time using a GE Discovery PET/CT scanner. The CT projection data
are sorted based on the phases of the breathing trajectory obtained using the Varian
RPM system. The PET list mode data are then synchronized with CT phases using
the same breathing trajectory, referred to as phase-labeled PET list mode data. The
imaging data are input into the planning step for the generation of the planning map
to be fed into the EGRT delivery segment. The IMRT treatment plan with typical
beam and field setup parameters is optimized using the Pinnacle3 workstation. The
final planning map is then calculated based on the proposed planning scheme.
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The EGRT delivery step is used mainly to simulate the dynamic aspect of the
EGRT treatment where tumor tracking and planning modulation are achieved. The
EGRT delivery segment starts with the conversion of the phase-labeled raw PET
list mode data into the LOR queue where each entry includes its timestamp, 3D
Cartesian coordinates of the two LOR end-points, and phase number. When the
dose delivery starts, the Linac goes through all firing points sequentially along the
whole treatment helix. At each firing point, it scans through the LOR queue that
can be detected by the 2-cm PET detectors at its current position and then checks
whether each individual LOR meets the basic EGRT algorithm criteria (The PTV
intersection criterion is implicitly implemented in the planning scheme). If one LOR
is determined to be eligible for response, it will be decided to be responded to or
not based on its response probability determined by the planning map according to
its location in sinogram space. The consequent bMLC opening will be added to the
list of bMLC openings. Once all firing points have been processed, the entire list of
bMLC openings will be output, which specifies the complete set of information that
defines the beamlet responses during the treatment including the spatial coordinates
of the firing points, the leaf numbers that are opened, and the phase number of the
4DCT dataset at the time a leaf is opened.
Each entry of the list of bMLC openings will be matched with the 4DCT dataset
based on its phase for subsequent VMC++ calculation in the dose evaluation step.
The dose for each phase is obtained via summation of all the beamlet responses for the
same phase. To calculate the total dose of a moving structure, dose maps of different
phases are registered to the same reference phase through rigid image registration.
The multiple dose maps are then summed to produce a point-of-view map relative
to the moving structure, resulting in its accumulated total dose during the entire
treatment.
The above workflow is different from that for the digital XCAT patient in the
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imaging and planning steps. In the imaging step, the emission data are simulated
using GATE and the phase information is known a priori. In the planning step,
the IMRT plan is optimized using MOSEK and the inverse-planning algorithms as
discussed in section 5.2.3.
5.2.6 Performance Evaluation
For performance evaluation, conventional 3D IMRT treatments are first designed for
both the digital and clinical patient cases. In the digital XCAT case, the PTV is
designed as the ITV plus 6 mm uniform margin added to account for patient setup
and other uncertainties. In the patient case, the clinically defined PTV which con-
tains the GTV motion is used. The OAR planning limits are based on the values
recommended by the Quantitative Analysis of Normal Tissue Effects in the Clinic
(QUANTEC) [65] and Radiation Therapy Oncology Group 0236 [96] for digital and
clinical patients respectively. 256 fields are used to correspond with the EGRT treat-
ment geometry. The resultant optimized fluence maps are then used to simulate a
3D divergent dose distribution. Conventional helical IMRT (hIMRT) treatments are
also simulated as comparisons to both 3D IMRT and EGRT treatments. On one
hand, hIMRT treatments intend to replicate the 3D IMRT treatment in the helical
treatment geometry with a different source-to-axis-distance (SAD) by interpolating
and reshaping the same IMRT plans. On the other hand, the hIMRT treatments use
nearly the same system settings (i.e. the same bMLC system, the same number of
firing positions, the same SAD, and the same firing geometry with a more suitable he-
lical pitch) as EGRT treatments. The main difference is that EGRT opens the leaves
according to the probability scheme using LOR-based guidance, while the hIMRT
treatments deliver the dose with deterministic plan intensities as the 3D IMRT treat-
ments. The purpose of including hIMRT in the current study is to understand if any
of the performance benefits of EGRT over 3D IMRT are due to the helical geometry
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of EGRT. The evaluation details pertaining to the individual studies are discussed
below.
• Digital XCAT patient
In the XCAT patient case, respiratory motion and heart motion are modeled
with periods of 4.2 and 1 s, respectively, sampled in 12 phases. The GTV is
modeled using an ellipsoid with a set of semi-axis lengths of 1.5, 1, 1.5 cm
and placed in the right lung. The GTV motion path is based on the XCAT
built-in 3D periodic tumor motion trajectory with typical lung motion behavior
and peak-to-peak amplitudes of 16.6, 3.5, and 0.02 mm for SI, AP, and LM
directions, respectively. Structures are contoured based on the phantom masks.
The ITV volume is calculated as the union set of all GTV voxels. The PTV is
designed as a 6 mm uniform extension of the ITV. The IMRT plan is optimized
with a prescription of 70 Gy to 95% of the PTV. The table position covers a
treatment range of 7 cm containing the whole PTV. The treatment time is 1200
s, resulting in a table speed of approximately 0.006 cm/s. The first phase of the
generated 511-keV attenuation phantom, 110-keV attenuation phantom, and
PET activity phantom are used for the calculation of the attenuation correction
map, IMRT plan map, and PET normalization map, respectively. The tumor,
lung, and background activity uptake ratio is set to be 8:0.5:1 with the base
background activity set to be 3 kBq/cc. The phantom geometry can be seen in
Figure 5.6.
• Clinical patient
The clinical patient datasets of 4DCT, 4DPET, and breath-hold CT are ret-
rospectively collected at the Stanford Cancer Institute under an IRB protocol.
The tumor is staged as a metastasis of breast cancer in the left lung region,
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with a GTV size of 3.33 cm3 averaged over all six motion phases. The tu-
mor motion has estimated peak-to-peak amplitudes of 8.5, 4.5, and 2.5 mm
for SI, AP, and LM directions, respectively. The raw PET-list mode data
is corrected with a 1.02 cm systematic shift in the longitudinal direction af-
ter manual registration of the 4DPET and 4DCT volume using RT Image
(http://rtimage.sourceforge.net/). Structure contours are made by a designated
specialist on the breath-hold CT, which is used for the IMRT plan modulation
map calculation with the help of the Pinnacle3 workstation. In observation of
the spine’s proximity to the GTV, the IMRT plan is optimized with a prescrip-
tion of 54 Gy to 95% of the PTV. Optimized fluence maps are output without
any modifications for the feasibility of delivery. The breath-hold CT is converted
into a 511 keV CT volume for the attenuation correction map calculation. To
obtain the PET activity normalization map, the first phase of the reconstructed
4DPET volume is interpolated to coincide with the breath-hold CT volume in
terms of resolution and position. The table position covers a treatment range
of 9 cm and the treatment time is 1200 s, resulting in a table speed of 0.0075
cm/s. Since only 5 minutes of PET data are acquired per bed position, PET-list
mode data are looped with simulated FDG decay for re-use. GTV is manually
registered to each 4DCT phase similarly using RT Image to evaluate its accu-
mulated dose during the entire treatment. The phantom geometry can be seen
in Figure 5.9.
Figure 5.4 illustrates an example of the fluence maps output from Pinnacle3 and
the IMRT plan map converted from the fluence maps.
A summary of major treatment as well as GATE, and phantom simulation pa-
rameters for performance evaluation is shown in Table 5.1 and 5.2, respectively1.
1TWG. = takeWinnerofGoods, Bg. = Background, Sino. = Sinogram, resol. = resolution,
ITV/PTV = ITV to PTV
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Figure 5.4: Calculation of the IMRT plan map using Pinnacle3. (a) Pinnacle3 inter-
face for inverse planning. (b) 256-field fluence maps. (c) The central sinogram of the
IMRT plan map.
Table 5.1: Major treatment and GATE simulation parameters
Category Parameter Value Parameter Value
EGRT Detector extent 2 cm iso Leaf aperture(x-y) 0.5 cm
Detector coverage 2× 90◦ arc iso Leaf aperture (z) 0.5 cm
PET ring radius 50 cm EGRT spatial window ±0.5◦ arc
Rotating frequency 1 Hz EGRT time window 500 ms
Linac radius 60 cm hIMRT pitch 0.2
Collimator radius 50 cm Radiotracer FDG
Collimator leaves 64 Firing positions 256
3DIMRT SAD 100 cm Field number 256
GATE Version V5.0.0.p01 Light decay time 40 ns
Coincidence window 10 ns Energy resolution 0.26
Scatter threshold(keV) 350,650 Coincidence policy TWG.
5.3 Results
5.3.1 Digital XCAT Patient
Figure 5.5 shows the dose distribution and DVH comparison of 3D IMRT and hIMRT
treatment using the same treatment plan. Motion is not simulated in this case. The
dose distribution is normalized to have the same mean lung dose. The slightly infe-
rior performance of hIMRT, when compared to 3D IMRT, is likely due to delivering a
divergent IMRT optimized plan in a helical geometry. The SAD difference also con-
tributes to this difference but the influence is small. Overall, the dose performance
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Table 5.2: Major phantom and patient simulation parameters
Category Parameter Value Parameter Value
XCAT Respiration period 4.2 s Phantom size 256× 256× 35
Respiration phases 12 Voxel resolution 2× 2× 2 mm3
Couch travel range 7 cm Dose grid size 4× 4× 4 mm3
GTV size 9.40 cm3 Sinogram bin size 256× 64× 35
ITV size 17.01 cm3 Uptake ratio 8 : 0.5: 1
ITV/PTV margin 6 mm Bg. activity 3 kBq/cc
Treatment time 1200 s IMRT field size 5× 2 mm2
Prescription dose 70 Gy
Patient Respiration phases 6 Phantom size 512× 512× 40
Aver. GTV size 3.33 cm3 4D-CT resol. 0.98× 0.98× 2.5 mm3
Couch travel range 9 cm Breathhold resol. 0.98× 0.98× 1.25 mm3
ITV size 5.97 cm3 Dose grid size 3.92× 3.92× 2.5 mm3
Treatment time 1200 s Sino. bin size 256× 64× 40
IMRT field size 5× 2.5 mm2 Uptake SUV 6 (GTV), 1(Bg.)
PTV size 16.8 cm3 Prescription dose 54 Gy
of 3D IMRT and hIMRT is similar for both GTV and OARs. Since hIMRT treat-
ment uses exactly the same treatment geometry as EGRT, differences in performance
between 3D IMRT and EGRT should be largely independent of the change from a
divergent to helical geometry.
Figure 5.6 illustrates the GTV point-of-view dose maps assembled from all 12
motion phases for 3D IMRT, raw EGRT, and EGRT with the planning scheme, as
well as the associated DVH curves. The dose distribution is normalized to have the
same mean lung dose. 133,288 and 17,818 beamlet responses have been generated for
the two EGRT treatments, respectively. Note that the dose increase to nearby OARs
due to the EGRT dose peaking effect is not accounted for by modifying the IMRT
plan in both EGRT treatments. Without the proper planning scheme implemented,
raw EGRT cannot outperform 3D IMRT due to the fact that dose is distributed more
toward the lung rather than the heart. EGRT with the planning scheme is able to
deliver a better dose distribution to the target, although at the price of increased




Figure 5.5: Dose distribution and associated DVH comparison of 3D IMRT and
hIMRT. The PTV and GTV are contoured using solid lines in the dose distributions.
In the DVH plot, 3D IMRT and hIMRT are represented as solid lines and dashed-
dotted lines, respectively.
Figure 5.7 shows the comparison of 3D IMRT, and planning scheme-implemented
EGRT without or with modification for additional modulation to the heart and spine.
When additional modulation is enabled, the number of beamlet responses is reduced
from 17,818 to 15,805. Heart dose is suppressed with additional modulation (see
arrow-pointed dose distribution). Compared with the 3D IMRT treatment, EGRT
achieves a 15.1% relative increase in dose to 95% of the gross tumor volume (GTV)
and a 31.8% increase to 50% of the GTV while the OAR doses are kept similar or
lower for EGRT. This comparison shows that dose increases to nearby OARs can be
suppressed with additional modification to the original IMRT map with minor dose
degradation to the target.




Figure 5.6: Comparison of 3D IMRT (thin solid line), raw EGRT (dashed-dotted
line), and EGRT with the planning scheme that does not include modification for
additional OARs modulation (thick solid line).
planning scheme (i.e. Figure 5.7(c)) in both coronal and sagittal views. The results
indicate that in spite of the dose noise introduced due to the reduced number of
beamlet responses, tumor tracking is largely preserved.
5.3.2 Clinical Patient
Figure 5.9 shows the comparison of 3D IMRT and planning scheme implemented
EGRT with additional modulation on spine, heart and esophagus. 32,086 beamlet
responses have been generated for the EGRT treatment. Compared with the 3D
IMRT treatment, EGRT yields a 15.2% relative increase in dose to 95% of the GTV
and a 20.7% increase to 50% of the GTV while OAR doses are kept similar or lower
for EGRT. Note that the challenging sparing of spine achieved in 3D IMRT is retained
in EGRT with the proposed planning scheme.




Figure 5.7: Comparison of 3D IMRT (thin solid line), EGRT with planning scheme
that does not include (dashed-dotted line) and includes (thick solid line) additional
OAR modulation.
in both coronal and sagittal views. Unlike the XCAT patient case in which PET
data and CT phases are ideally matched a priori, such matching in the patient case
is not guaranteed due to motion and breathing changes in the sequential PET/CT
scan and the uncertainties in PET and CT phase sorting based on external surrogate
tracking. Nevertheless, the results still show that tumor tracking is preserved when
the planning scheme is incorporated.
5.4 Discussion
In this work, we implement the EGRT concept as a complete motion management
scheme that is able to incorporate IMRT plan modulation. Due to the inherent
tracking capability of EGRT, the proposed treatment can significantly improve the
dose performance of the conventional ITV approach while still preserving its ease of
implementation in each step of the imaging, planning, and delivery therapy chain.
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Figure 5.8: Tumor tracking of EGRT with the planning scheme. Both PTV and GTV
are contoured to show the dose tracking. The dose map of each phase is displayed
with an individually optimized window.
In the current implementation of EGRT, a few items require further consideration
and discussion. The planning scheme entails the discarding of a portion of beamlet
responses. Dose maps showing the tumor tracking of each phase can therefore be
noisy as shown in the XCAT patient case. This effect is less pronounced with a
smaller number of phases and higher overall activity levels as in the clinical patient
case. In either case, the point-of-view dose map is representative of the effective dose
for each structure and this is what is used to calculate the DVH curves.
In the evaluation studies, a 256-field IMRT plan is used rather than a conventional
plan which typically has 7-12 fields. This is due to the fact that EGRT favors a
plan that spans all angles to make full use of LOR data. The helical geometry
provides more degrees of freedom than a conventional geometry due to the large
number of fields used [10]. Therefore, compared with a conventional step-and-shoot
IMRT treatment, EGRT possesses increased flexibility in planning a treatment. The




Figure 5.9: Comparison of 3D IMRT (dashed-dotted line) and EGRT with planning
scheme (solid line) for the clinical patient case.
for EGRT delivery can be used to improve EGRT’s performance. Additionally, the
intensity/duration of the beamlet responses can also be modulated to give further
flexibility for EGRT’s capability to incorporate planning modulation. Also note that
the IMRT plans used in this study were optimized for a divergent geometry. Future
work will involve development of a treatment planning system optimized for EGRT’s
helical geometry.
The proposed planning scheme provides the insight and basis for the future devel-
opment of a fully characterized EGRT planning system. In order to achieve desired
intensity dose modulation without interference, corrections for attenuation and non-
uniform PET activity are necessary. Moreover, in spite of the fact that the EGRT
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Figure 5.10: Tumor tracking of a breast cancer lung metastasis under EGRT with
the planning scheme. The PTV and GTV are contoured for positional reference and
target motion delineation, respectively. The dose maps are displayed with the same
window [0.5 0.85] relative to the maximum GTV dose across all phases.
delivery relies on the statistical detection of LORs, a deterministic intensity modu-
lation can be approximately achieved. Modifications to the IMRT plan ensure that
clinical constraints for OARs can be met. The achievement of dose conformality to
the GTV remains an issue for EGRT. The dose peaking effect is a natural result of
the radiation backprojection principle in EGRT. This technique may be well suited
to situations in which an integrated boost dose is desirable [23].
The current proposed planning scheme illustrates a general way to incorporate
intensity modulation into EGRT. Although it is evaluated within the context of
motion-encompassing methods, the planning scheme can be applied for other applica-
tions including gating and tracking methods without major modification to similarly
achieve GTV dose escalation. This is due to the fact that the plan intensity weights
that would have been delivered to the margins are effectively reduced in EGRT. The
planning scheme also accounts for uncertainties beyond tumor motion. For example,
the tumor may shrink during the treatment course and this is not accounted for in the
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conventional ITV approach unless a patient is re-imaged and re-planned. However,
since the planning scheme allows EGRT to concentrate the dose to just the GTV,
normal tissue sparing will likely be better if the GTV size is reduced, or equivalently
the dose to the GTV can be further increased.
Finally, it should be noted that in the evaluation scheme, it is implicitly assumed
that the motion can be or should be divided into phases. However in fact, tumor
motion can be quite irregular, even for a lung tumor. Therefore, any 4D tracking
based methods with the phase division assumption is subject to the challenges of
motion irregularity during the imaging or delivery process. In contrast, the tumor
tracking and proposed planning scheme in the EGRT treatment is not limited by
the phase theory. EGRT therefore provides a potential solution to deal with the
different types of motion, periodic or random, encountered over all treatment sites.
Also note that in the simulation study presented in this work, 4DCT is only acquired
for evaluation purposes. In an actual EGRT treatment, a slow CT can be used to
obtain the ITV instead, thereby avoiding the increased dose and complexity of 4DCT
imaging. In fact, each step of imaging, planning, and delivery of the proposed EGRT
treatment can essentially be regarded as 3D, with the tumor tracking taken care of
automatically. The complexities and uncertainties associated with 4D imaging and
delivery can be significantly reduced or in some cases eliminated.
5.5 Conclusion
In this work, we design a planning method for EGRT to achieve intensity modula-
tion with the capability of incorporating a conventional IMRT treatment plan. We
proposed a detailed treatment scheme based on this planning method and evaluate it
within the context of the motion management strategy where the tumor motion un-
certainty is managed by an encompassing volume. Simulation studies are performed
on both digital and clinical patients. Emission data from both MC simulation and
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a commercial PET/CT scanner has been used for validation. Compared to the ITV
approach, EGRT outperforms with a dose increase of more than 15% to the moving
target while the dose levels of OARs are kept similar or reduced. With the capabilities
of achieving both tumor tracking and intensity modulation, EGRT has the potential






As mentioned in Chapter 2, the concept of EGRT is broad and thus not limited
to any specific type of dose delivery method or geometry. The work presented in
previous chapters has primarily focused on demonstrating feasibility and applications
of LOR-based EGRT using a helical dose delivery geometry. To illustrate other
possible EGRT implementations, this section will discuss the design and geometry of
image-based EGRT.
As previously stated, image-based EGRT aims to reconstruct a PET image based
on LOR data generated through subsecond acquisition and then applying a tumor
localization algorithm to identify and delineate tumor location using the resulting
image for conventional on-board treatment guidance. Figure 6.1 illustrates two similar
system designs modified from the conventional Linac for image-based EGRT.
The current conventional Linac system has an on-board x-ray imager (OBI). Two
different designs are therefore proposed with and without the OBI. As indicated in
Figure 6.1, θ1 and θ2 are denoted as the angular coverage of one PET detector arc
in the two arrangements. Due to the incomplete data coverage in the sinogram, the
two designs have different strengths and drawbacks. The system without OBI has a
total angular coverage of 2θ1. Each PET detector has a large effective field of view
(FOV) and may show advantages in treating peripheral tumors. The system with
OBI has a total angular coverage of 4θ2, which is more evenly distributed around
the patient. With the same total data coverage, the system with OBI is expected
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(a) EGRT system without OBI (b) EGRT system with OBI
Figure 6.1: The proposed image-based EGRT system design.
to obtain PET images with fewer artifacts and therefore demonstrate higher tumor
localization accuracy.
A preliminary study based on a prostate tumor case and the system design without
OBI (a similar design as LOR-based EGRT) is conducted to test the potential use of
image-based EGRT for tumor tracking purposes. The prostate phantom used here is
the same as in Chapter 3. The preliminary results are shown in Figure 6.2 and 6.3.
Figure 6.2: 3D PET reconstructed images (imaging time: 1, 2, ..., 10 s) using 3D
parallel non-filtered back-projection reconstruction algorithm. Shown is the tumor’s
central slice from an axial view.
The results indicate that image-based EGRT is very promising for the application
of tumor tracking. Note that the reconstruction technique used here is a simple 3D
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(a) Localization accuracy (b) Standard deviation
Figure 6.3: Localization accuracy and standard deviation for Figure 6.2. SI local-
ization has the highest accuracy and precision, since the reconstruction resolution in
the SI direction is 2 mm while the recon resolution in the AP and LM directions is
about 7.8 mm. In the LM and SI directions, SI localization converges to the highest
accuracy and precision when the acquisition time is greater than 8 seconds. In the AP
direction, the localization accuracy has a bias and it is likely due to signal attenuation
in the LM direction (due to long body axis and bone attenuation).
parallel backprojection algorithm. Other researchers have proposed more advanced
iterative reconstruction algorithms which have shown improved tracking accuracy for
subsecond timescales [112].
Figure 6.4 shows the proposed treatment scheme of image-based EGRT in a fixed
gantry IMRT system. Before the treatment fraction starts, the FDG radiotracer is
administrated to the patient. For each treatment field, PET images are first gener-
ated from the incomplete LOR data and compared with the planning CT image to
determine the tumor location. The treatment plan is then modified accordingly to
compensate for patient setup error and the prescribed dose is delivered. In the case of
significant patient motion, the EGRT method is able to provide near real-time tumor
tracking. During treatment, the PET detectors continuously detect LORs and the
PET images are updated at short time intervals. The dose is delivered based on the
phase of tumor motion as in a conventional gating method.
The performance of image-based EGRT therefore mainly depends on the success
of two major components: accurate tumor localization and improved dose delivery
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Figure 6.4: EGRT treatment scheme in fixed gantry IMRT.
with a modified treatment plan based on the updated tumor location. In the local-
ization step, a major challenge arises due to inaccurate PET reconstruction from the
incomplete LOR data measurement. PET images reconstructed from incomplete data
contain strong streak artifacts, and they do not accurately depict the tumor distribu-
tion. Nevertheless, in EGRT, the on-board PET images are used only to determine
the tumor transformation from the planned position, while the tumor distribution
can be obtained from the planning CT images. As such, accurate tumor localization
is still achievable in spite of the low quality of on-board PET images, as shown in Fig-
ure 6.2 and 6.3. Moreover, iterative algorithms which are not sensitive to truncation
of projection data can be applied in this case. With reconstructed images which typ-
ically have higher intensity for tumor volumes, a convolution-based cross correlation
algorithm can be used to localize the tumor, as is the case for the previous preliminary
study. The second challenge arises when the tumor localization step determines that
there is indeed a change in tumor location. If the location change is small and the
beamlet kernel is assumed to remain unchanged, the change can be accounted for by
modifying the treatment plan accordingly via a mathematical transform.
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6.1.2 Other Considerations
Important discussions on EGRT’s limitations, benefits, and future work have been
presented and can be found in section 3.1.4, 3.1.7, and 5.4. In this section, we provide
supporting evidence or further discussion for three important issues which have not
been fully discussed in the planning scheme study.
6.1.2.1 9-field IMRT Plan
The first issue is the reason why we compare EGRT with a 256-field IMRT in Chap-
ter 5. We explained this is due to the fact EGRT favors a plan that spans all angles
to make full use of LOR data. One may then wonder why not use VMAT plan for
comparison in this case. In fact, a comparison with the VMAT plan seems more
appropriate. However, while a comparison with VMAT is useful, the 256-field IMRT
plan presented in this work serves as a good approximation [77]. In addition, the
256-field IMRT plan corresponds well with EGRT’s 256-firing-position geometry en-
abling a direct comparison for implementation. Additional concerns may arise from
the fact that we did not compare EGRT with a typical 7-field or 9-field IMRT. Here
we present a comparison of 9-field and 256-field IMRT treatments below (Figure 6.5)
for further clarification.
These two plans are optimized for the same dose prescription using the Pinnacle
system. As shown in Figure 6.5, for similar dose performance to the target, the 256-
field plan does a better job than the 9-field plan when evaluating the performance
using the maximum dose delivered to OARs as the criterion (Note that during op-
timization, the planning constraints for OARs are also specified using the form of
maximum dose). The result is as expected since a 256-field IMRT plan generally
achieves better or at least as good performance as a conventional 7-9 field plan due to
the increased degrees of freedom for optimization. Therefore, this comparison demon-




Figure 6.5: Comparison of 9-field (dash-dotted line) and 256-field (solid lines) IMRT
treatment based on the same planning goals.
conclusion as in Chapter 5.
6.1.2.2 Uniformity Constraint in IMRT Optimization
The second issue comes from the fact that uniformity and maximum target dose
constraints are used in the IMRT optimization. Due to the nature of the EGRT
delivery there are no such constraints. One may be concerned if the IMRT plans are
re-optimized with only a minimum dose constraint not worrying about uniformity or
maximum dose, the GTV DVH of the IMRT treatment will look more like the EGRT.
In addition, dose to OARs may be reduced in IMRT when the uniformity penalization
is removed so that the central claim of EGRT’s dose escalation may no longer hold
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true.
In fact, the comparison of IMRT and EGRT is fair and the claims in this work are
valid based on the following reasons. First, the study aims to demonstrate the pro-
posed planning scheme for EGRT as an implementation of the motion-encompassing
method, i.e. ITV approach, in a realistic clinical scenario. Therefore, the IMRT
method for comparison is designed in the same way as it would be in the clinical
ITV approach. The uniformity constraint is necessary since a uniform prescription
coverage of the PTV is considered optimal in the conventional ITV approach where
tumor tracking is absent.
Secondly, in the original comparison, EGRT is implemented based on the IMRT
plan that is optimized with a uniformity constraint. Therefore, the effect of a uni-
formity constraint is also translated to EGRT performance. The fact that EGRT
delivers more dose to the tumor with similar OAR sparing is mainly because of the
dose delivery mechanism used. EGRT tracks each positron emission LOR and se-
lectively responds. Such a physics-based approach naturally results in more dose
concentration inside the tumor. If a different IMRT plan (e.g. without the unifor-
mity constraint) is used as an input to EGRT, then further dose concentration can
be achieved.
To support our argument, we design studies for further clarification. Using patient
data, we re-optimize an IMRT plan using the Pinnacle optimization engine with no
maximum and uniformity dose constraints. To achieve the best possible performance
of IMRT, the dose distribution is simulated using this IMRT plan assuming no tumor
motion and setup error (except the registration error between the planned CT and
4DCT), referred to as ideal tumor tracking in our results presented below. We then
implement the EGRT treatment using the new IMRT plan and the proposed scheme
as described in Chapter 5. Tumor motion is still simulated in the EGRT treatment.
Figure 6.6 shows the dose distribution and DVH comparison of IMRT and EGRT
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treatment using the new optimization. Two important observations can be made: (a)
EGRT achieves GTV dose escalation over IMRT treatment with ideal tumor tracking
without increasing dose to the OARs; (b) more importantly Conclusion (a) is true
despite the fact that a non-uniform IMRT plan is used. Note the reason that the dose
increase is not as large as that in Chapter 5 is because there is no tumor tracking




Figure 6.6: Dose distribution and DVH comparison of IMRT treatment with ideal
tracking and non-uniform plan (dash-dot lines) and EGRT treatment based on the
same plan with EGRT-tracking (solid lines).
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6.1.2.3 Tumor Dynamic Changes
The third issue is raised in considering dynamic tumor changes during the course of
RT. For example, researchers have reported significant reduction in the tumor uptake
of radiotracers during the entire treatment course. Complete degradation of PET
tracer uptake in the tumor or conversely, high tracer uptake in the normal tissue
directly adjacent to the GTV due to inflammation have also been observed. One
might be concerned that EGRT cannot address dynamic changes since the EGRT
method relies on PET signal for the radiation delivery.
It should be noted that in the current design of an EGRT treatment, a tumor-
to-background uptake ratio of >1 is required to achieve dose benefits. It is correct
that the EGRT performance degrades if the tumor uptake decreases during the treat-
ment course. In previous studies, we implicitly assume that EGRT is primarily used
for hypofractionated radiation therapy such as SBRT, where safe dose escalation is
achieved by EGRT due to its excellent tumor tracking capability. Studies have shown
that within the time frame of several treatment fractions, the maximum standard
uptake value (SUVmax) inside the tumor volume either decreases by a small amount
or in some cases even increases due to suspected hypoxic changes [40, 100]. As such,
we are confident that sufficient emissions from the tumor volume are present when
EGRT is used in a hypofractionated scenario.
It is true that tumor uptake may considerably change during the long treatment
course of conventional fractionated radiation therapy. This change is largely patient
specific [100]. In these scenarios, we will require multiple PET scans on different days
of radiation therapy to monitor the variation of tumor uptake. As a matter of fact,
PET has played an increasingly important role in monitoring radiation therapy [5, 41].
We can use the PET images to customize EGRT plans for better treatment perfor-
mance. For example, instead of applying a constant fraction dose (e.g. 2 Gy) in a
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treatment course, a theoretically more reasonable fraction dose scheme can be de-
signed based on the tumor’s unique radiation response (e.g. small/medium fraction
dose for tumors showing complete/partial metabolic response, and a large fraction
dose for stable or progressive metabolic disease). In rare cases, if PET tracer concen-
tration in the tumor completely degrades and a radiation oncologist concludes that
further therapy is necessary, treatment can be switched from EGRT to conventional
therapy.
In Chapter 5, we focus on the engineering and algorithmic aspects of our EGRT
technique. A detailed investigation on the above issues is beyond the scope of this
dissertation, but of high interest in our next-phase research of EGRT.
6.2 Concluding Remarks
The advent of MLC, IMRT, IGRT, and increased computer processing power for
advanced, image-based treatment planning methods, have greatly advanced the tech-
niques for delivering modern radiation therapy. However, the sub-millimeter precision
of these delivery systems is compromised by treatment uncertainties which may arise
from many factors. The main uncertainties include intrafractional and interfractional
tumor motion, patient setup error, tumor volume delineation, and unpredictable tu-
mor volume change in response to radiation. They constitute the major challenges of
current RT treatment limiting treatment effectiveness.
To realize the full potential of radiation treatment that is constrained by such
uncertainties, many methods have been proposed to alleviate the problem and have
shown success to a certain extent. However, even state-of-the-art tumor tracking
methods have significant disadvantages that are essentially unavoidable. To eliminate
treatment uncertainties, the invisible tumor needs to shine brightly during radiation
therapy. If tumors could directly signal their location during treatment, radiation
can be delivered with the highest confidence and the best treatment outcome can be
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achieved.
To accomplish the above treatment goal, inherent fusion of imaging and therapy
during treatment is required. With this thought in mind and inspired by the phys-
ical principle of emission imaging for cancer diagnosis, this work therefore proposes
EGRT, which naturally integrates emission guidance into therapy. With the tumor
targeted accurately and directly by the emission guidance, clinicians will no longer
be operating in the dark. The feasibility of accurate tumor tracking in EGRT has
been demonstrated using extensive evaluation studies. To establish EGRT as an inde-
pendent modality for cancer treatment, a complete planning scheme is proposed and
has been demonstrated to work as well. Many therapeutic benefits can be derived
from the proposed EGRT treatment. The most direct benefit is GTV dose escalation
as compared to conventional methods. Other benefits such as the effectiveness of
treating multiple metastases are also compelling.
This dissertation has answered the two most important questions for EGRT in-
cluding the feasibility of tumor tracking and the capability of dose planning. However,
the development of EGRT is still at its early stage. Many aspects require further in-
vestigation to fully explore the vast possibilities of EGRT treatment. For example, the
current planning scheme does not fully account for biological information and tracer
distribution. However, tumor radiobiology is extremely relevant to cancer treatment
and such information is readily available in EGRT. If appropriately made use of, such
information can substantially improve treatment effectiveness through dose painting
based on the real-time PET-guided delivery. We hence look forward to future research





Part of this appendix is adapted from our previous work on EGRT [29] and listed
here for the reader’s reference. Modifications have been made.
A.0.1 Overview
Simulation is a good approach to validate the proposed EGRT concept without build-
ing an actual system. To make realistic and productive simulations, several effective
simulation tools are needed. One is needed to simulate the positron emission process
for the acquisition of LOR data. Another tool is needed to simulate the process of dose
delivery according to the dynamically determined beamlet responses. Two dedicated
Monte Carlo tools (i.e. GATE and VMC++) are finally selected. Due to the intensive
computation involved in Monte Carlo simulation, an online cloud-computing applica-
tion (i.e. CliQr) is employed to speed up simulations. In the planning scheme study,
IMRT treatment plans need to be optimized. A commercial optimization package
(i.e. MOSEK) and treatment planning system (i.e. Pinnacle workstation) are used.
To validate the EGRT concept, a binary application (i.e. EGRT engine) is built for
efficient investigations.
A.0.2 GATE
GATE, short for Geant4 Application for Tomographic Emission, is a PET/SPECT
dedicated Monte Carlo simulation platform based on Geant4, an opensource package
developed by the international OpenGATE collaboration [94, 44, 83]. GATE can be
installed in multiple operating systems including Windows and Linux. In this work,
we run GATE in Ubuntu 10.04.
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Since GATE is an application built on top of Geant4, simulations can be ini-
tiated, designed, and controlled by using simple scripts. Sample scripts of various
PET systems are available in the installation package so that users can customize
their simulations by modifying on them. Therefore, since highly sophisticated exper-
imental settings can be easily configured, GATE now plays a key role in the design
of new medical imaging devices, in the optimization of acquisition protocols, and in
the development and assessment of image reconstruction algorithms and correction
techniques [94].
In order to understand how GATE works, a summary of steps to write a compre-
hensive GATE script is given below:
1. Define the scanner geometry
2. Define the phantom geometry
3. Set up the physics process
4. Initialize the simulation
5. Set up the detector model (digitizer)
6. Define the sources
7. Specify the data output format
8. Start the data acquisition
GATE is able to not only construct a user-defined phantom, but also read in a
voxelized phantom such as the XCAT phantom. An illustration of a GATE simulation
system with a voxelized phantom is shown in Figure A.1.
GATE can directly output the coincidence events in list-mode format specifying
the 3D coordinates of the two endpoints for each recorded LOR as well as time
information. These outputs are then used as inputs for our EGRT algorithms.
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Figure A.1: Illustration of GATE simulation system. The whole system is defined
in a cubic volume called world. Calculation is done only for particles in the world
volume. The ring detector system is placed around the isocenter of the world volume.
The voxelized phantom can be read in with its isocenter coincided with that of the
world volume.
A.0.3 VMC++
VMC++ (National Research Council, Canada), short for voxel based Monte Carlo
package, is a highly efficient Monte Carlo dose calculation engine for radiation therapy
treatment planning [47, 46]. It has been validated against well established codes [101].
VMC++ can be easily installed and operated under both Windows and Linux sys-
tems. Based on the characteristics of VMC++ (discussed below), it is a perfect fit for
the simulation of the Linac dose delivery. The main command of running VMC++
is shown below (in a Windows system):
vmc.exe input_file_name
In order to run the VMC++ for customized simulation, the main task is therefore
to write an input file which includes the following information:
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• The information of the input phantom such as image values and voxel resolution
• Source position and beamlet edge coordinates
• Source spectrum to be used
• Monte Carlo simulation parameters
One input file can only include one point source, thereby simulating dose distri-
bution for only one beamlet response for EGRT. Therefore, an EGRT simulation will
need thousands of input files, depending on how many beamlet responses are gener-
ated. For each input file, VMC++ simulates the Monte Carlo dose deposited in the
phantom according to the beamlet information specified in the input file and then
outputs the corresponding 3D dose distribution as a single binary file.
As an example, Figure A.2 shows the VMC++ calculation after a progression of
beamlet responses from simulated PET list-mode events for the preliminary water
phantom study (see section 3.1.2). The upper left image depicts the dose distribu-
tion after only 10 beamlets were delivered, each corresponding to a single previously
detected LOR. The bottom right image is the dose distribution after 50,000 beamlets
were delivered over a period of 300 s.
A.0.4 CliQr
A major computation in EGRT simulations is the dose distribution calculation of
each beamlet response with VMC++ using a MC algorithm. The calculation of one
beamlet response is relatively fast which takes about several seconds. However, an
EGRT simulation generally results in 10 to 100 thousand beamlet responses. This may
take days or even weeks to finish if we simulate all responses sequentially. Considering
the need to run many EGRT simulations to test the algorithms or even for debugging










Figure A.2: (Top) Map of bMLC leaf opening counts. Vertical direction is leaf
number, horizontal direction is firing position. (Bottom) Dose map progression over
logarithmic time scale. Upper left 10 beamlets. Lower right 50,000 beamlets after
300 s. The dose maps are self-normalized to the maximum dose within each case.
Since we do not want to build significant internal hardware infrastructure, the
cloud and its almost infinite resources on-demand seemed to be the perfect answer.
CliQr (www.cliqr.com) offers a solution that enables us to store our application on
the cloud, get on the cloud quickly to start any number of simulations we want, and
move from cloud to cloud to get the best performance possible, all without having to
change our application or simulation programs in any way. To make full use of cloud
resources, we have add the functionality of dividing our beamlet sequence file into
many nodes (e.g. 30) so that the simulation time can be shortened to be 1/30 of the
original one.
A.0.5 MOSEK
MOSEK is an optimization package to generate IMRT treatment plans for XCAT
phantom case in this work. The MOSEK optimization package can be used to solve
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large-scale mathematical optimization problems [4]. MOSEK provides fast and effi-
cient specialized solvers for a lot of types of optimization problems including linear
problems, quadratic problems, general convex problems, and mixed integer problems.
This package can be used with various interfaces including C/C++, .NET, Java, and
Python. In this work, MOSEK MATLAB optimization toolbox is called to run the
optimization codes.
A.0.6 Pinnacle
To fully demonstrate the feasibility of the EGRT concept, clinical patient data have
been collected. Each set of patient data contains gated 4DCT images, gated 4DPET
images, raw PET list-mode data, Varian RPM trace data, and breath-hold CT images
with planning information such as contours of structures. A commercial Pinnacle
treatment planning workstation (Philips Healthcare, Fitchburg, WI) has been used
to import all these patient data conveniently together with all clinically contoured
structure sets. More importantly, it can be used for customized treatment planning
of the patient data and has been very useful during our development of the EGRT
planning scheme. Figure A.3 illustrates the Pinnacle interface for customized EGRT
planning.
A.0.7 EGRT Engine
After the simulated GATE data or commercial PET scan data are obtained, the
subsequent EGRT simulations include a wide variety of simulation tasks that are
computation intensive. These include, for example, the process of reading in various
input files (e.g. coincidence list mode data, 4DCT images with associate structure
files) based on the desired simulation parameters, the implementation of the EGRT
basic algorithm on each individual LOR according to the specific EGRT treatment
geometry, and consequent Monte Carlo simulations of all resultant beamlet responses
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Figure A.3: The Pinnacle interface for customized EGRT planning.
as well as the final dose distribution and DVH calculation which requires image reg-
istration.
In addition, the above tasks need to be repeated many times during the early
investigation stage of the work. Therefore, it is very desirable to build an application
that can perform those resource-consuming jobs efficiently and comprehensively. We
used C++ code and algorithms developed by RefleXion Medical (Burlingame, CA),
to simulate the EGRT system. RefleXion Medical is a company that is currently
developing the first EGRT system.
To run an EGRT simulation, one needs to prepare an appropriate configure file,
and then run the following command in any Ubuntu terminal.
EGRTSim config.txt
where EGRTSim is the name of the EGRT engine binary and the config.txt is the
name of the configure file.
A sample configure file is attached in Appendix B for the reader’s reference.
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APPENDIX B
A SAMPLE CONFIGURE FILE
1 % ExecutionMask [Optional , string , 0000000 ... 1111111]
%
3 % ExecuteIMRT is true if (ExecutionMask & 000000001 > 0)
% ExecuteEGRT is true if (ExecutionMask & 000000010 > 0)
5 % ExecuteDVH is true if (ExecutionMask & 000000100 > 0)
% ExecuteFullVMC is true if (ExecutionMask & 000001000 > 0)
7 % ExecuteQuickVMC is true if (ExecutionMask & 000010000 > 0)
% Execute3DIMRT is true if (ExecutionMask & 000100000 > 0)
9 % ExecuteSinoRecon is true if (ExecutionMask & 001000000 > 0)
% WriteCoincidenceToDisk is true if (ExecutionMask & 010000000 > 0)
11 % VisualizeVolumes is true if (ExecutionMask & 100000000 > 0)
%
13 ExecutionMask 000010010
15 % CoincidenceDataFile [Optional , <Valid String >, NULL]
% Specifies the processed coincidence data file (assumes a fixed EGRT geometry)
17 CoincidenceDataFile /home/smazin/HEAD/Code/PETSim/test_pcoin.dat
19 % CalibrationCoincidenceDataFile [Optional , <Valid String >, NULL]
% Specifies the processed calibration coincidence data file
21 CalibrationCoincidenceDataFile /home/smazin/HEAD/Code/PETSim/test_cal_pcoin.dat
23 % AttenuationMapPath [optional , <Valid string > [<positive float >], NULL , -1]
% Path to attenuation map for attenuation correction
25 % Second argument is water value for CT image. If specified then the map
% will be converted to 511 keV.
27 AttenuationMapPath /data/attenuationmap511keV.dat 0.018
29 % AttenuationNormCutoffPercentage [optional , float [0..1] , 1]
% Percent of max value in atten. map to use as cutoff for taking average of
31 % for probability normalization.
AttenuationNormCutoffPercentage 1
33
% PETMapPath [optional , <Valid string >, NULL]
35 % Path to PET map for PET map correction
PETMapPath /data/PETMap.dat
37
% PlanningModulationMapPath [optional , <Valid string >, NULL]
39 % Path to a Planning Modulation map to incorporate IMRT planning into EGRT
% EnforceVolumeFilter OR IgnoreVolumeFilter will specify whether or not
41 % to use the planning mod map only or in conjunction with the PTV filter
PlanningModulationMapPath /data/PlanModMap.dat IgnoreVolumeFilter
43
% BatchVMCSize [Optional , positive integer , 200]
45 % Note that for IMRT and IMRT3D , BatchSize is interally force to ’1’, to
% overcome deficiencies in the libvmcpp.so interface/API
47 BatchVMCSize 200
49 % LogSeverity [Optional , Debug|Error , Error]
% Debug: More verbose comments are output and intermediate files are not deleted.
51 LogSeverity Error
53 % OutputFilePrefix [Mandatory , <Valid string >, NULL]
% Specifies the prefix used to name the output files storing the
55 OutputFilePrefix Output/Run1
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57 % GATEDataFile [Optional , <Valid filename >, NULL]
% If specified , PET event data will be generated from GATE coincidence data
59 GATEDataFile /home/qfan/HEAD/GateSims/gateCoincidences.dat
61 % GATEConfigFilePath [Optional , <Valid string >, NULL]
% Specifies the path to the GATE config file (needed to read params for dose mapping)
63 GATEConfigFilePath ../../ GateSims/sim7_300s_z2 .0 cm_motionXYZ/phantom.mac
65 % GATETableMotion [Optional , true|false , false]
% Specifies whether Table Motion was simulated in the GATE simulation.
67 GATETableMotion false
69 % GEListModeNumDataFiles [Optional , <positive integer >, 0]
% If GEListModeNumDataFiles is specified , PET event data will be generated from
71 % a set of GE list mode data files
% Each GE list mode data file entry should be specified as follows:
73 % (Filename [string ]) (Z-offset [float]) (T-overlap [float (0..1) , 0.5])
% (VarianRPMLag [<optional >, float , -10])
75 GEListModeNumDataFiles 1
~/ fromJaeWon /07 _06_2010/LM_static 0.0 0.5 -10
77
% VarianRPMFile [Optional , <Valid string >, <Valid string >, NULL , NULL]
79 % Specifies the path to the Varian RPM data file to bin list -mode PET/CT data
% Second string should read "BinByPhase" if the motion binning is to be phase -based
81 VarianRPMFile Motion.vxp
83 % VarianRPMMinPos [Optional , float , 0]
% Specifies the minimum position for binning using the VarianRPM motion trajectory.
85 VarianRPMMinPos 0
87 % VarianRPMMaxPos [Optional , float , 0]
% Specifies the maximum position for binning using the VarianRPM motion trajectory.
89 VarianRPMMaxPos 0
91 % VarianRPMZOffset [Optional , float , 0]
% Specifies the Zoffset for binning using the VarianRPM motion trajectory.
93 VarianRPMZOffset 0
95 % VarianRPMMinTriggers [Optional , int , 12] (must be >= 2)
% The number of triggers that will be checked to determine VarianRPMLag
97 VarianRPMMinTriggers 12
99 % CenterOfMassFile [Optional , <valid string >, NULL]
% Specifies filename to use for Center Of Mass text file (Motion Estimator)
101 CenterOfMassFile /data/fromJaeWon /11 _05_2010/LM_Vol -7/ Avrg_COM.txt
103 % PlanningVolumes [Optional , positive integer (Number of volumes )]
% Each volume configured as (data_type=Analytical|Voxelized), (label=[ string]),
105 % (planning_type=PTV|GTV|OAR|BOOST|PTV3DIMRT|NORMVMIN|NORMVMEAN|
% NORMVMAX|NORMVXX|NORMDXX|RX|PET),
107 % (motion=static|periodic|VarianRPM), egrt -probability [0..1] , plotDVH (0 or 1)
PlanningVolumes 1
109 Voxelized Tumor GTV static 1.0 1 /home/ananduri/mask 01001
Analytical PTV PTV static 1.0 1 0 0 0 2 2 2 0 0 0 0
111 Analytical Lung OAR static 0.01 1 3 3 3 1 1 1 0 0 0 0
113 % RXDoseLevel [Optional , positive float , 100]
% Dose [Gy] that will be prescribed to the RX Volume
115 RXDoseLevel 100
117 % TimeStep [Optional , positive double , 0.0001]
% EndCalibrationTime [Optional , positive double , -1];






125 % PETDetExtent [Optional , positive double , 2.0]
% PET detector extent in z [cm]
127 PETDetExtent 2.0
129 % PETRingRadius [Optional , positive double , 50.0]
% PET arc radius of curvature [cm]
131 PETRingRadius 50.0
133 % PETDetWidth [Optional , positive double , 0.1]
% PET detector width [cm]
135 PETDetWidth 0.1
137 % Arcs [Mandatory , positive integer (number of arcs), 0]




143 % RingRotationPeriod [Optional , positive double , 1.0]
% Rotation period of gantry [s]
145 RingRotationPeriod 1
147 % RingCount [Optional , positive integer , 1]
% Number of PET rings
149 RingCount 1
151 % RingZOffset [Optional , double , -0.5]
% Offset (units of PETDetExtent) in the Z-direction , where first ring is situated
153 RingZOffset -0.5
155 % TableStartPosZ [Optional , positive double , 0.0]
% Table start position in z (in cm)
157 TableStartPosZ 0.0
159 % TableEndPosZ [Optional , positive double , 0.0]
% Table end position in z (in cm)
161 TableEndPosZ 0.0
163 % PETRandomAngleAmount [Optional , positive double , 0]
% PET random angle amount to add to second ray [deg]
165 PETRandomAngleAmount 0
167 % IsotopeHalfLife [Optional , positive double , 0]
% Halflife (in minutes) of the radioisotope in the PET tracer (e.g. F18 is 109.771)
169 % determines how much decay will happen when looping occurs
IsotopeHalfLife 0
171
% LinacPosition [Optional , positive double between [0,360), 90]
173 % Location in degrees of the linac
LinacPosition 90
175
% LinacRadius [Optional , positive double , 60]
177 % Distance (in cm) from linac to center of PET ring
LinacRadius 60
179
% LinacPower [Optional , positive double , 8.5/60]
181 % Linac power output (in Gy/s)
LinacPower 0.141666667
183
% LeafApertureISO [Optional , positive double , 0.5]
185 % Leaf aperture width at isocenter (cm)
LeafApertureISO 0.5
187
% LeafApertureISO_Z [Optional , positive double , 0.5]
189 % Leaf aperture width (in the z-direction) at isocenter (cm)
LeafApertureISO_Z 0.5
191
% CollimatorAngleSpread [Optional , positive double between [1.0, 60.0) , 10.0]
153
193 % Angular spread of the collimator in degrees
CollimatorAngleSpread 10
195
% CollimatorLeaves [Optional , positive integer between [0,1024) , 64]
197 % Number of leaves on the MLC
CollimatorLeaves 64
199
% Collimator Radius [Optional , positive double , 50]
201 % Distance (in cm) from collimator to isocenter
CollimatorRadius 50
203
% RotateGantryClockwise [Optional , positive boolean , false]
205 % Specifies whether the gantry (PET detectors and linac) rotates counterclockwise
RotateGantryCounterClockwise false
207
% EGRTTimeWindow [Optional , positive double , 0.50]
209 % Time window (in seconds) for valid PET events
EGRTTimeWindow 0.50
211
% EGRTAngularSpread [Optional , positive double , 0.5]
213 % Spread (in degrees) between the linac and a valid PET event (at any given time)
EGRTAngularSpread 0.5
215
% EGRTZWindow [Optional , positive double , 2.0]
217 % Z-tolerance for an LOR to be responded to
EGRTZWindow 2.0
219
% EGRTFiringPoints [Optional , positive integer , 256]
221 % Number of discrete firing points (along the linac -circle) used by EGRT
EGRTFiringPoints 256
223
% EGRTGammaTarget [Optional , positive float [0,1], 0]
225 EGRTGammaTarget 0
227 % IMRTHelicalPitch [Optional , positive float , 0.2]
% The helical pitch for IMRT treatment (number of rotations per slice traversed)
229 IMRTHelicalPitch 0.2
231 % SinogramPhiLines [Optional , positive integer , 210]
% SinogramDistLines [Optional , positive integer , 249]
233 % Specifies the dimensions of the Sinogram
SinogramPhiLines 210
235 SinogramDistLines 249
237 % ReconSizeXYZ [Optional , positive integer , (VMC Phantom Size)]
% BackProjectOffsetXYZ [Optional , positive double , (VMC Phantom Offset )]
239 % Specifically used by QuickVMC and SinoRecon
ReconSizeXYZ 512 512 1
241 BackProjectOffsetXYZ 0.0 0.0 0.0
243 % BackProjectorFOV [Optional , positive double , 50.0]
% Back -projection FOV
245 BackProjectFOV 50.0
247 % BackProjectorFOVz [Optional , positive double , 5.0]
% Back -projection FOV in z
249 BackProjectFOVz 5.0
251 % BackProjectorOSFactor [Optional , positive integer , 8]
% Back -projection oversampling factor
253 BackProjectOSFactor 8
255 % NumPhasesEGRT [Optional , positive integer , 1]
% Number of phases for EGRT simulation
257 NumPhasesEGRT 1
259 % NumPhasesIMRT [Optional , positive integer , 1]
% Number of phases for IMRT simulation
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261 NumPhasesIMRT 1
263 % MotionPeriod [Optional , positive double , 0.0]
% Period for motion model (for Periodic , if static or VXP this is ignored)
265 MotionPeriod 0
267 % DICOMPhaseDir [Optional , <Valid string >, NULL]
% Use to list multiple dicom directories , one per phase
269 % DICOM files for each directory will be converted to a VMC++ .CT 3D phantom file




% GenerateRTStructROIMask [Optional , <string , string , integer array >, NULL]
275 % Use to convert RTStruct ROI ’s into 8-bit masks
% First string: RTStruct file , second string: DICOM ref image directory
277 GenerateRTStructROIMask /data/rtstruct.dcm /data/dicomCT 0 3 5
279 % VMCPhantomFilePath [Optional , <Valid string >, NULL]
% Specifies the path to the VMC phantom file.
281 % NOTE can either specify DICOMPhaseDir or VMCPhantomFilePath/Prefix but not both
VMCPhantomFilePath /data/VMCPhantoms/NCATphantom_256x256x35_2mm.CT
283
% VMCPhantomFilePathPrefix [Optional , <Valid string >, NULL]
285 % Specifies the prefix -path to the VMC phantom file for multiple phases.
VMCPhantomFilePathPrefix /data/VMCPhantoms/NCATphantom_256x256x35_2mm
287
% TruncVMCNewFilePath [Optional , string , NULL]
289 % If truncating VMC file , this specifies path to output new truncated VMC file
% If not defined the default is the output directory
291 TruncVMCNewFilePath /mnt/vmc++/ phantoms/tempVMC.CT
293 % TruncVMCNewFilePathPrefix [Optional , string , NULL]
% If truncating VMC file , this specifies path to output new truncated VMC file prefix
295 % If not defined the default is the output directory
TruncVMCNewFilePathPrefix /mnt/vmc++/ phantoms/tempVMC
297
% VMCPhantomTruncateSlices [Optional , int , int , 0, 1000]
299 % Specifies the slices to truncate to for the VMC .CT file
% Used to speed up processing time by ignoring slices that receive little to zero dose
301 % Note if this is used one cannot also specify VMCPhantomTruncateWithZBuffer
VMCPhantomTruncateSlices 0 1000
303
% VMCNcasePerBeamlet [Optional , positive integer , 10000]
305 % Specifies the value of VMC ncase per beamlet parameter
VMCNcasePerBeamlet 10000
307
% VMCNumExecThreads [Optional , integer , 1]
309 VMCNumExecThreads 1
311 % QuickVMCMultiplyPhantom [Optional , boolean , false]
% Specifies whether to multiply the VMC phantom by the QuickVMC dose map
313 QuickVMCMultiplyPhantom false
315 % DVHLegend [Optional , string , float , string (’all ’, 12, ’bold ’)]
% Usage: DVHLegend <show > <fontsize > <fontweight >
317 DVHLegend all 12 bold
319 % DVHPlotDoseMap
% Usage: DVHPlotDoseMap <doseprefix > <numphases > <AlgName > <LineWidth > <LineStyle >
321 DVHPlotDoseMap ./ simxxx_vmc_Alg01_Phase 1 IMRT 4.0 --
DVHPlotDoseMap ./ simxxx_vmc_Alg00_Phase 6 EGRT 4.0 -
323
% DVHReportDXX [Optional , float , float , ... (0.95 , 0.5)]
325 % Reports the DXX values for the volumes to be plotted.
% Usage: DVHReportDXX <val1 > <val2 > etc.




% GenImagesTruncate [Optional , true/false , (false)]
331 % Specifies whether generated image overlays should be truncated
GenImagesTruncate false
333
% GenImagesDosePhaseLimits [Optional , float , float (0.2 0.8)]
335 % Low and High multiplicatve values for dose phase overlay images
GenImagesDosePhaseLimits 0.2 0.8
337
% GenImagesColorMap [Optional , string , "jet"]
339 % ColorMap to display dose images in (and contours)
GenImagesColorMap jet
341
% GenImagesContours [Optional , float , float , float , ...]
343 % Contour levels on the POV dose map images [Gy].
GenImagesContours 50 100 200
345
% GenImagesContourParams [Optional , float , string , float , float , float]
347 % <Linewidth >, <Linestyle > and <RGB color > when plotting contours.
GenImagesContourParams 2.0 - -1 -1 -1
349
% GenImagesDrawVolume [Optional , string , float , string , float , float , float]
351 % Usage: GenImagesDrawVolume <VolLabel > <linewidth > <linestyle > <Red Green Blue >
GenImagesDrawVolume Vol1 2.0 -- 0 0 0
353 GenImagesDrawVolume Vol2 2.0 -- 0 1 0
355 % Pinnacle Settings
% Fluence file / start angle (deg) / CW (-1) or CCW (1)
357 % / IsocenterZ (cm) / Num Fields / First Field
% / Last Field / FieldSizeX / FieldSizeZ / FieldDX (cm) / FieldDZ (cm)
359 % / ColWidthX (cm) / ColWidthZ (cm) / SAD (cm)
PinnacleSettings ~/ Public /1_16.img 90 -1 0.0 16 0 15 101 101 0.5 0.5 0.5 0.5 100
361
% PinnacleFluenceIsoShift [Optional , float , float , 0.5, 0.5]
363 % Specifies isocenter location in Pinnacle fluence map
% relative to the central pixel in units of pixels
365 PinnacleFluenceIsoShift 0.5 0.5
367 % PinnacleMultiSource [Optional , boolean , false]
% Specifies whether to turn on multi -source 3DIMRT (i.e. non -Z-divergent delivery)
369 PinnacleMultiSource false
371 % PinnacleGenerateDoseKernels [Optional , boolean , false]
% Specifies whether to generate the dose kernels for all beamlets in the given field
373 PinnacleGenerateDoseKernels false
Listing B.1: EGRT configure file.
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